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1.1 Ovarian cancer 
 Introduction 
The ovaries are the most important part of the female reproductive system 1. Each ovary is divided 
into an outer cortex and an inner medulla 1. The surface of the ovary is covered by a single layer of 
cuboidal epithelium, called germinal epithelium1.  
Ovarian cancer is a type of cancer that begins in the ovaries and often goes undetected until it has 
spread within the pelvis and abdomen 2. It is ninth most common cause of cancer death among 
women in the United States. According to the Cancer Facts & Figures published by the American 
cancer society (ACS), 21, 290 (12.1 per 100,000 women per year) new cases and 14,180 deaths 
(7.7 per 100,000 women per year) due to ovarian cancer were registered in 2015 in the United 
States. Five year survival rate was 45.6% (Figure 1.1) 3. Broadly, tumors of the ovaries are 
classified into three major categories, i) Ovarian epithelial cancer, ii) Ovarian germ cell tumor and 
iii) Ovarian low malignant potential tumor. 
Epithelial ovarian cancer (EOC) is one of the most common gynecological malignancies and the 
fifth leading cause of cancer death among women in the United States (6% of cancer deaths) 4. 
About 9 out of 10 tumors of the ovary diagnosed (90%) are of this type. EOC occur primarily in 
middle aged or older women while it is rare in young adults, especially before puberty 5.  The 
standard treatment for patients with advanced disease is initial debulking surgery followed by 
carboplatin-paclitaxel combination chemotherapy. Five-year overall survival (OS) remains around 
44.2%, suggesting there is a wide inter-patient variation in response 6.                                        
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Figure 1.1 a) Incidence of ovarian cancer in the US, 1992-2012. b) New cases, 2008-2012, All Races, Females (NCI SEER cancer 
statistics)
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 Risk factors  
Factors like genetic mutations, hormonal therapy, age, nulliparity, obesity, and fertility drugs are 
associated with increased risk of ovarian cancer. Whereas oral contraceptives, multiple 
pregnancies, breast feeding and tubular ligation are associated with decreased risk of ovarian 
cancer. 
a) Genetic factors: Approximately 20% of ovarian cancer is familial and linked with BRCA1 
or BRCA2 gene mutation 7, 8. Germline deleterious mutations in the BRCA1/BRCA2 genes 
are associated with 15% to 40% lifetime risk of ovarian cancer 9, 10. Loss of BRCA1 or 
BRCA2 protein expression is more common in ovarian cancer 11. Prophylactic measure for 
this mutation is bilateral oophorectomy and it is beneficial in certain cases 12. Other gene 
like TP53, PTEN/MMAC1, STK11 and mismatch repair genes MLH1, MSH2, MSH6, and 
PMS2, have been associated with an increased risk of ovarian cancer (NCI). 
b) Hormonal therapy: Women using more than 10 years of hormonal therapy including 
estrogen only, progestagen only, estrogen-progestagen combinations and tibolone are in 
increased risk of ovarian cancer. The relative risk (RR) of hormone therapy current users 
verses never users of hormone therapy was 1.20 (95% confidence interval [CI], 1.09–1.32). 
Risk increases with increasing duration of use 13. A population-based case-control study of 
exclusively estrogen-only therapy for at least 5 years showed odds ratio [OR], 1.6; 95% CI 
.A cohort study showed that use of ERT(estrogen replacement therapy)/ET (estrogen 
therapy) and ERT/ET followed by EPRT (estrogen –progesterone replacement therapy)  
more than 20 years are associated with increased risk of ovarian cancer (RR=relative risk 
3.2 95%CI, 1.7-5.7) 14.  
c) Age and Nulliparity: Risk of developing ovarian cancer increases linearly from age 30 to 
50 years of age and continues to increase further with age thereafter 15. Women over 55 are 
most commonly diagnosed with ovarian cancer. About half of the women who are 
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diagnosed with ovarian cancer are 63 years or older 2. Furthermore, there is increased risk 
of ovarian cancer in older woman who have never been pregnant 16, 17. 
d) Body Mass Index (BMI), Diet and Obesity: BMI (= (the weight in kgs)/ (square of height 
in meters)) is associated with increased mortality rate from ovarian cancer. A prospective 
study on more than 900,000 U.S. adults (404,576 men and 495,477 women) showed 
individuals with BMI ≥ 40 had higher death rates from cancers (52% for men; 62% for 
women) compared to ‘normal’ BMI (18.5 to 24.9) 18. Some studies also support the 
association between increased risk of cancer with height and diet, along with BMI  19-21.  
e) Oral contraceptives: Interestingly, use of Oral contraceptive is associated with reduced risk 
of ovarian cancer. 10%-20% reduction in ovarian cancer risk is associated with one year 
use of oral contraceptive, where as 50% reduce risk associated with five years use of oral 
contraceptive among women 22, 23. Case-control (24) and cohort studies published since 
2000 observed risk reduction with use of oral contraceptive more than 1 year 24. A 
multicenter study with 330 cases and 982 matched controls, showed a statistically 
significant decreased risk of ovarian cancer associated with Progestational contraceptives 
(depot-medroxyprogesterone acetate [DMPA]) use 25. 
f) Tubular ligation: Decreased risk of ovarian cancer associated with tubal ligation 26, 27. 
Population-based case-control studies (13) showed tubal ligation is associated with a 29% 
reduction in ovarian cancer risk (OR, 0.71; 95% CI, 0.66–0.77) 28. 
g) Breast feeding: Case control studies (30) showed breast-feeding is associated with a 
decreased risk of ovarian cancer (RR, 0.76; 95% CI, 0.69–0.83) 29. 
h) Smoking: A meta-analysis from 51 studies with 28,114 ovarian cancer patient found a very 
small increased risk of ovarian cancer among current smokers compared with nonsmoker 
(RR, 1.06; 95% CI, 1.01–1.11) 13. 
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i) Use of Talc: A meta-analysis of 16 studies observed an increased risk with the use of talc 
(RR, 1.33; 95% CI, 1.16–1.45) 30. A case-control study that included 8,525 cases and 9,859 
controls have proven increased risk of epithelial ovarian cancer associated with genital 
powder use (OR, 1.24; 95% CI, 1.15–1.33) 31. 
 Prognosis of Ovarian cancer 
Women with low risk cancers defined as stage IA, IB, grade 1 or 2, nonclear-cell histologies do not 
need further adjuvant therapy. Survival of early-stage disease is significantly higher (20% to 30%) 
than advanced stage ovarian cancers 32. Five-year disease-specific survival is 84% for stage I 
compared to stage II disease, which is 76% 32. Interestingly younger women are more likely to be 
diagnosed with a lower-stage along with more well-differentiated tumors and have an improved 
outcome compared with older women. In addition, patients with a significant component of 
transitional cell carcinoma have a better prognosis 33-35. Case control studies suggest that BRCA1 
and BRCA2 mutation carriers show better response compared to sporadic EOC patients 36. Patients 
with high-risk early-stage epithelial ovarian cancer defined as stage I, grade 3; stage IC, stage II, 
clear-cell cancers and they require postsurgical adjuvant treatment. Additionally, late diagnosis is 
a major problem for ovarian cancer. Lack of awareness of patients and physicians about occurrence 
of nonspecific symptoms like abdominal pain and swelling, gastrointestinal symptoms and pelvic 
pain is another major concern. The ovarian cancer-associated biomarker CA-125 is more significant 
at the time of disease progression after 1-2 chemotherapy cycle in stage III and satge IV, instead of 
time of early stage of diagnosis 37. 
 Treatment of Ovarian epithelial cancer 
There are various therapies available for EOC which are selected based upon stage and tumor types. 
Platinum based chemotherapy is the standard-of-care for 75% of ovarian cancer patients. The 
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treatment of EOC is divided into three groups- Early stage, advanced stage and recurrent or 
persistence (as shown in Figure 1.2). 
Standard chemotherapy worldwide for epithelial ovarian cancer are platinum agents cisplatin or 
carboplatin either alone or combination with cyclophosphamide or paclitaxel 38-42. This regimen 
was evaluated and established by several clinical trials by GOG (Gynecology Oncology Group), 
MRC (Medical Research Council) 43-48. However, approximately 80% ovarian epithelial cancer 
patients relapse after first line platinum and taxane based chemotherapy. If CA-125 increases after 
first line treatment is completed, then relapse is usually suspected. 49. Patients with recurrent disease 
are therefore subdivided as: i) Platinum - sensitive recurrent and ii) Platinum - refractory/resistance 
recurrent  49.  
Carboplatin was approved by FDA in 1987 for ovarian cancer patient who are recurrent after 
cisplatin therapy 50. Currently, the most commonly used regimens for the Platinum-sensitive 
recurrent subtype are cisplatin or carboplatin + paclitaxel, carboplatin+ Gemcitabine, carboplatin 
+ pegylated lyposomal doxorubicin 51-56. Other regimens include carboplatin + epirubicin, Cisplatin 
+ doxorubicin + cyclophosphamide, PEGylated liposomal doxorubin + trabectedin 57. 58. 
If recurrence occurs within six months of completion of platinum containing therapy, it is referred 
to as Platinum-Refractory or Platinum-resistant Recurrence ovarian cancer. Anthracyclines (PLD), 
taxanes, topotecan, and gemcitabine are used as single agents for these recurrences, which are 
primarily contributed by platinum-resistant subsets 59-65. Paclitaxel is also commonly used in front-
line induction regimens 64. Furthermore, adverse effects of platinum-based chemotherapy in 
ovarian cancer as a single agent or in combinations are myelosuppression, nausea, vomiting, 
alopecia, and asthenia for this therapy. The most common toxicities are neutropenia, and 
gastrointestinal (GI) toxicity. 
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 Ovarian cancer clinical trials using Platinum/Paclitaxel chemotherapy 
Platinum drugs such as cisplatin plus paclitaxel combination therapy have been widely adopted as 
standard treatment for advanced ovarian cancer. A number of Phase I/II/ III clinical trials have 
evaluated the combination of carboplatin/paclitaxel chemotherapy and shown improvements in 
treatment outcomes in ovarian cancer patients following administration of platinating agents as 
chemotherapeutic agents and the use of paclitaxel as combination treatment, as summarized in 
Table 1.1. 
 Evidently, despite these treatment interventions, drug resistance, disease recurrence, and toxicities 
are major challenges for platinum-based therapy in ovarian cancer. The clinical trials presented 
here report that there is considerable variation in response to therapy which is a major challenge 
for platinum based therapy in ovarian cancer patients. 
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Table 1.1 Details of clinical trials evaluating platinum drugs/paclitaxel combination  therapy in ovarian cancer. 
Patient details Drug response/outcome Drug Toxicity Pubmed ID 
German Arbeitsgemeinschaft 
Gynäkologische Onkologie (AGO) patients 
(n=518) 
Overall response rate=75%; 
Complete responses rate= 
41%; Partial response=34%. 
Hematologic toxicity occurred more 
frequently than non-hematologic toxicity 
9346222 
Stage IV ovarian cancer patients (n=34) Complete response rate=82%; 
Partial rate=95%; 1-year 
survival rate=94% 
Nausea and vomiting grade 2=30%; 
Grade 2-3 gastrointestinal toxicity=20%; 
Grade 3-4 hematological toxicity=73% 
11695811 
International Federation of Gynecology 
and Obstetrics study on stage II to IV 
epithelial ovarian cancer patients (n=59) 
Response rate (complete 
response + partial 
response)=72% 
Quality-of-life scores improved 
significantly during therapy due to 
modest amount of toxicities.  
11324769 
Prospective randomized trials (phase I/II 
trials) by the Gynecologic Oncology Group 
and the European Organization for 
Research and Treatment of Cancer 
No differences in efficacy for 
carboplatin/paclitaxel 
compared to 
cisplatin/paclitaxel arm 
Reduce toxicity for carboplatin/paclitaxel 
compared to cisplatin/paclitaxel arm. 
10190787 
Advanced stage EOC patients (n=50) Response rate=72%; 
Recurrence or progression of  
disease=68% 
 9514799 
International Federation of Gynecology 
and Obstetrics study on Advanced 
epithelial ovarian cancer stages IIC, III, and 
IV (n=90) 
patients receiving 
carboplatin/cisplatin + 
paclitaxel had a high overall 
response (82%).  
Grade 3 and 4 neutropenia=20%; Grade 
3 and 4 thrombocytopenia=4% for 
carboplatin group. 
Grade 3 and 4 neutropenia=32%; Grade 
3 and 4 thrombocytopenia=7%, for the 
cisplatin arm  
9346224 
GINECO, a French cooperative clinical trials 
group for gynaecological cancer research 
(multicenter phase II 
carboplatin/paclitaxel study): (n=50). 
Overall response rate=43%. Grades 3 and 4 neutropenia=30%; 
Transitory peripheral neuropathy=45%. 
9346219 
Phase I study of carboplatin/paclitaxel in 
patients with stage IIC to IV ovarian 
cancer: (n=30) 
Overall response rate=57%. Grades 1 and 2 peripheral 
neurotoxicity=53%; patients developed 
Grade 4 neutropenia=31%. 
9045330 
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Figure 1.2 Overall treatment strategies for epithelial ovarian cancer (EOC) 
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1.2 Lung cancer: Non-small cell lung cancer (NSCLC) 
 Introduction 
In addition to ovarian cancer, platinum agents and paclitaxel are also used to treat patients 
diagnosed with lung cancers. This section is a brief overview of non-small cell lung cancer 
(NSCLC). 
Lung carcinoma is the most common malignancy worldwide, and the leading cause of cancer 
deaths. According to the most recent estimates, the global incidence of lung cancer is more than 
1.6 million cases/year, resulting in more than 1.3 million deaths/year (>18% of all cancer deaths) 
74. In the USA, the incidence of lung cancer was estimated to be 221,200 cases in 2013, leading to 
nearly 158,040 deaths (27.5% of all cancer deaths) 3. Five-year relative survival with for lung 
cancer patient was 15.7% (from 1995 to 2001) 75. Lung cancer can either arise directly from lung 
tissue or as a result of metastasis from other parts of the body. Broadly, there are two main types 
of primary tumor described as either small-cell or non-small-cell lung carcinomas (Figure 1.3).  
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer constituting around 
80% of lung cancers. It is histologically heterogeneous and constitutes squamous cell carcinoma, 
large cell carcinoma and adenocarcinoma (based on data obtained from National Cancer Institute- 
Non-small cell lung cancer treatment). NSCLC are therefore classified by the World Health 
Organization (WHO)/International Association Lung Cancer (IASLC) based on histology. There 
are three main subtypes, i) squamous cell carcinoma (25% of lung cancers), ii) adenocarcinoma 
(40% of lung cancers) and iii) large cell carcinoma (10% of lung cancers). Squamous cell carcinoma 
is located centrally, in the larger bronchi of the lung and strongly related with smoking. Squamous 
cell carcinoma is further subdivided into papillary, clear cell, small cell and basaloid tumor based 
upon histology of tumor. Similarly, adenocarcinoma is also subdivided into acinar, papillary tumor, 
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solid adenocarcinoma with mucin, adenocarcinoma with mixed subtypes and bronchioloalveolar 
carcinoma. Adenocarcinoma has the frequent histologic heterogeneity.  
The 5-year relative survival of patients with advanced NSCLC remains approximately 4 % 76. One 
major drawback of lung cancer is that the majority of lung cancer patients are diagnosed in 
advanced stages based on small biopsy and cytology 77. Determination of stage is very important 
for prognosis and selection of therapy. NSCLC staging is based on histology of tumor, resection 
margins (surgical margin) of it and also lymph node involvement (status and location of lymph 
node). Based upon these NSCLC stage is determine by TNM classification according to American 
Joint Committee on Cancer (AJCC) 2010, whereas T = size and extension of tumor, N = lymph 
node involvement and M = extension of metastasis 78.  
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Figure 1.3 Incidence and Mortality of lung cancer; Non-small cell lung cancer (NSCLC) (NCI SEER cancer statistics). 
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 Risk Factors 
Several risk factors are associated with development of lung cancer. Major risk factors include 
cigarette, pipe, or cigar smoking. The risk for lung cancer is on average tenfold higher in smokers 
compare to nonsmokers. The risk increases with the quantity of cigarettes, duration of smoking, 
and starting age 79. Exposure to second-hand smoke, radon, arsenic, asbestos, chromates, 
chloromethyl ethers, nickel, polycyclic aromatic hydrocarbons, radon and air pollution are also 
considered as potential risk factor of lung cancer 80.  
 Symptoms and Diagnosis 
The most common symptom is worsening cough or chest pain. Other presenting symptoms are 
hemoptysis (coughing up blood), malais (discomfort, illness), weight loss, dyspnea/ breathlessness, 
hoarseness (abnormal voice change). Symptoms from distant metastases can show neurological 
defect or personality changes from brain metastases or pain from bone metastases. Physical 
examination also shows supraclavicular lymphadenopathy, pleural effusion or lobar collapse, 
unresolved pneumonia, chronic obstructive pulmonary disease or pulmonary fibrosis 81.  
 Prognostic factors 
Prognosis of disease depends on current physical status, current disease status with stage, and prior 
physical status. Depending on these three prognostic factors alone, median survival varies between 
6 weeks and over a year. Additionally, other factors such as tumor size, histologic type, and cell 
type, age and sex appeared to be important when considered alone. Adverse prognosis is related 
with large tumor size >3 cm, histology-nonsquamous, vascular invasion and if tumor metastasize 
in lymph nodes. Prognosis is adversely affected by poor performance status and weight loss of 
more than 10% in inoperable condition patients 82-87. 
Biomarkers including genetic mutations and gene expression are important prognostic factors for 
lung cancer or Non-Small Cell Lung Cancer. These include identification of significant mutations 
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in patient groups and strategies to molecular targeted therapy are therefore important in improving 
the survival of these subsets of patients 88. Relevant genes include epidermal growth factor receptor 
(EGFR), Kirstein rat sarcoma viral oncogene (KRAS), Human epidermal growth factor receptor2 
(HER2), V-raf murine sarcoma viral oncogene homolog B1 (BRAF), PI3K catalytic protein alpha 
(PI3KCA), gene rearrangements in anaplastic lymphoma kinase (ALK) as well as somatic 
mutations and gene duplications in MAP2K1/MEK, a hepatocyte growth factor receptor, 89-91. 
 Treatment of Non-Small cell lung cancer (NSCLC) 
Treatment of NSCLCs depends on staging (as shown in Figure 1.4).  Standard treatment options 
are surgery, chemotherapy and radiation therapy. Platinum-based chemotherapy is the standard for 
NSCLC 92. Commonly use drug regimens are cisplatin/etoposide (EP5050) or weekly 
carboplatin/paclitaxel 93-95. Additionally, paclitaxel is also used as combination with cisplatin or 
carboplatin 92, 96, 96, 97, 97-110.  Platinum-based radiation chemotherapy (Platinum + etoposide or 
cisplatin + mitomycin + vindesine) is also used as a treatment option and may improve survival of 
patients with locally advanced NSCLC. However, toxicity is also high for combination therapy 
than single therapy 100, 111-115. Many clinical trials have shown Cisplatin-based combinations plus 
radiation therapy shows 10% reduction in the risk of death compared with radiation therapy alone 
116-119. Maintenance therapy with single agent or initial chemotherapy is recommended for patients 
with stable or responding disease after four cycles of platinum-based combination chemotherapy 
101, 120, 121. 
In spite of these treatment options, 5-year survival rate of NSCLC is very poor (3% to 7%) for 
majority of patients 122, 123. 
 NSCLC clinical trials using Platinum/Paclitaxel combination therapy 
Carboplatin (PC) plus paclitaxel (Taxol) is a standard treatment of advanced non-small-cell lung 
cancer (NSCLC). In Table 1.2 we evaluate the results from clinical trials performed on non-small-
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cell lung cancer (NSCLC) patients using combination of paclitaxel (Taxanes) and carboplatin 
Chemotherapy. Similar to our observation regarding clinical trials in ovarian cancers, variations in 
drug response and drug-related toxicities are major cause of concerns for patients diagnosed with 
NSCLC undergoing platinum/paclitaxel-based combination chemotherapy. Understanding the 
genomics and transcriptomics governing these inter-individual variations in treatment outcome 
may provide tools to guide treatment and tailor therapies specific to each patient with the goal of 
achieving maximum therapeutic effects. 
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Table 1.2 Summary of clinical trials of carboplatin/paclitaxel combination therapy in NSCLC. 
Patient details Drug response/outcome Drug Toxicity PubMed ID 
Patients with stage IIIb-stage IV NSCLC 
(n=90) 
Overall response=40%. 
One-year survival=50.7%  
Grades 3/4 leukopenia=13.3%,; anemia=15.5%; 
thrombocytopenia= 11.1%. 
11863090 
Stage IIIB or IV NSCLC (n=100) 
patients. 
Objective response=36%,. Grade 3/4 peripheral neuropathy=18%. 9007133 
Advanced stage NSCLC patients 
(n=33). 
Complete responses=41%; 
partial responses=41%. 
Grade 3/4 esophagitis=51%. 9007133 
Phase II trial at the the Fox Chase 
Cancer Center and its network on 
patients with advanced NSCLC  
 
Response rate =55%; 
median event-free 
survival=24 weeks; median 
survival=47 weeks, 
Peripheral sensory neuropathy=75%; 
myelosuppression=44% (grade 4 
granulocytopenia 38% and grade >=3 
thrombocytopenia 50%-70%). 
9331128 
Phase II trial conducted by the Eastern 
Cooperative Oncology Group with 
stage IV non-small cell lung cancer 
(NSCLC). 
Overall response 
rate=27%. Median 
survival=38 weeks; Survival 
rate at 1-year=32%  
Grade 3 or 4 granulocytopenia=47%; 
Thrombocytopenia=3%. Most common non-
hematologic toxicities were nausea, emesis, 
neuropathy, arthralgia and myalgia.  
9007120 
Phase II trial in patients with advanced 
NSCLC (n=54)  
Response rate= 50%. Myelosuppression was observed as principal 
toxicity.  Grade 3 or 4 granulocytopenia=70%; 
thrombocytopenia=13%; anemia=9%; 
fatigue=9%; hemorrhagic cystitis=1% after the 
first cycle.  
7543559 
Multi-center study of two dose levels 
of paclitaxel and carboplatin in locally 
advanced and metastatic non-small 
cell lung cancer (NSCLC) (n=130, 99 in 
the high dose (HD) and 31 in the low 
dose (LD) cohort)  
Overall best clinical 
response rate =23.8%; one 
complete (CR); 30 partial 
responses (PR). One-year 
survival=34%. 
Myelosuppression was the most prominent 
side-effect for both cohorts. Grade 3-4 
leucopenia =HD 34.4% and LD 19.3%; 
neutropenia (HD 59.2, LD51.6%. The most 
prominent non-hematologic toxicities were 
alopecia and polyneuropathy.   
 
11396237 
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Figure 1.4 NSCLC Treatment Summary by Stage (NCCN guidelines; Version 1.2016). 
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1.3 Platinum drugs 
 Introduction 
This section provides discussion of the key agents that are the focus of this thesis. Platinum drugs 
are currently used to treat various types of cancers including ovarian, non-small cell lung cancer 
(NSCLC), testicular cancer, lymphomas and myelomas. Figure 1.5 shows the major members of 
this class of platinating agents. 
 
Figure 1.5 Chemical structure of Platinum drugs 
Cisplatin was the first platinum drug to be approved by FDA. Therapeutic potential of cisplatin was 
discovered by Barnett Rosenberg in 1969130. Unfortunately, cisplatin chemotherapy has dose-
limiting side effects including nephrotoxicity, ototoxicity, myelosuppression and neurotoxicity 131. 
To overcome cisplatin toxicity, the second generation platinating agent carboplatin (Diammine[1,1-
cyclobutanedicarboxylato(2-) -O,O’] platinum(II); Empirical formula: C6H12N2O4Pt; Molar mass: 
371.249 g/mol; Trade name: Paraplatin) was developed and approved by the FDA in 1989 for the 
treatment of advanced ovarian cancer 132.  Additionally, to reduce toxicity carboplatin is 
administrated by a 30-minute intravenous infusion of 300 to 500 mg/m2 based on a patient renal 
function according to Calvert Formula: 
[Total Dose (mg) = (target AUC) x (GFR + 25)]. 
Neurologic toxicity due to carboplatin based therapy is low/very rare (~ 5%).   
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However, although carboplatin is routinely used for treatment of ovarian and other cancers, one of 
the biggest challenges faced by clinicians is the variation in clinical response, 133, 134 and toxicities 
including myelosuppression (Thrombocytopenia ~ 25%,Neutropenia ~ 16%, leukopenia ~ 16%, 
Anemia ~ 71%), gastrointestinal toxicity (vomiting, nausea and diarrhea ~ 65%,) 133 as well as 
development of drug resistance 134.  Therefore, a large number of the cancer patients relapse after 
first line based chemotherapy due to wide inter-patient variation 131, 135.  
Differential expression and/or activity of genes involved in the platinum drug pathway due to 
presence of single nucleotide polymorphisms (SNPs) may have an impact on treatment outcome 
and toxicity in cancer patients being treated with platinum compound. Here we discuss the most 
relevant genetic variations in the genes involved in the platinum-drug pathway and to evaluate their 
association with chemotherapy. 
 Mechanism of action of Platinum drugs 
Platinum drugs are highly polar hydrophilic molecules. They do not easily diffuse across 
hydrophobic/lipophilic lipid membranes.  Therefore, following intravenous administration of 
carboplatin or cisplatin, they remain inactive in their native form in the high chloride environment 
of plasma 131. Upon transport of platinating agents by ion pumps and transporters, they enter the 
cell where, owing to a much lower concentration, the carboxyl ligands are slowly displaced by 
water (aquation), at the rate of 1013 molecules/sec, leading to the development of aqua ligands. The 
positively charged aqua ligands are then displaced and the platinum atom binds to purine bases on 
DNA forming DNA adducts as mono adducts, 1,2-intrastrand DNA cross-links (1-2GpG, 1-3GpG, 
1-2GpA) and inter-strand crosslinks. These DNA crosslinks are attributed to the formation of DNA 
helix-distorting adducts that result in strand breakage activating DNA repair mechanisms that 
interfere with cell division, which ultimately results in apoptosis 131. The mechanism of action of 
platinum drugs is shown in Figure 1.6. 
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Figure 1.6 Mechanism of action of platinum drugs. 
Upon entering the cell platinum drugs lose chloride or oxalate ions, and gains two water molecules. The platinum atom binds to N7 
of purine in the DNA forming DNA adducts as mon-adducts and through 1,2-intra-strand (involving adjacent guanines on the same 
strand) and inter-strand (involving binding to guanines on opposite DNA strands). 
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 Metabolic pathway of platinum drugs 
1.3.3.1 Genes of importance in drug pharmacokinetics (PK) 
Figure 1.7 shows detailed metabolic pathway of platinum drugs including the pharmacokinetics 
(PK) and the pharmacodynamics (PD).  
Platinum drugs enter the cell as a “passenger” along with normal copper transport by binding to the 
N- terminus of Copper Transporter 1 (CTR1) followed by CTR1 monomer crosslinks without 
blocking copper binding 136, 137. The Copper Transporter 1 (CTR1), encoded by the gene Solute 
Carrier Family 31(SLC31), thus plays an important role in the influx of platinum drugs into the cell 
138-140. It is a 28kDa protein consisting of 190 amino acids. It has 3 trans-membrane domains. 
Mammals and yeasts lacking CTR1 have been shown to have lower accumulation of platinum 
inside the cell. A study demonstrated that the loss of CTR1 function is associated with 10-15% 
decrease in cisplatin entering the cell resulting in a two fold increase in cell survival 141. Low or 
reduced expression of CTR1 has been correlated with resistance to carboplatin and cisplatin and 
overexpression has been associated with increased carboplatin and cisplatin uptake 142-146. 
Furthermore, studies have also shown that CTR1-knockout results in resistance to platinum drugs. 
CTR1 lacking cells accumulates 50% less cisplatin and eightfold higher resistance compare to the 
CTR1+ cells 147. CTR1-/- tumor xenografts in mouse models also are not responsive to platinum 
drugs. Loss of CTR1 decreases the platinum drug binding to the transporter and reduces influx of 
cisplatin by 81%, oxaliplatin 68% and for carboplatin almost complete elimination of 148influx 
(Larson et al. 2009). However, once inside the cell, platinum drug also initiates the rapid 
degradation of CTR1 ion through ubiquitination and proteosomal action mediated by copper 
chaperone antioxidant protein (ATOX1). Proteasome inhibitors like bortezomib have been shown 
to block this process of CTR1 degradation which leads to increase in the uptake and transport of 
platinum-containing drugs. The molecular mechanisms of platinum compound involved 
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endocytosis of CTR1is not completely clear yet 148, 149. Some evidences show that CTR2 is involved 
in platinum compound/drug accumulation and that its expression correlates with the sensitivity of 
ovarian carcinoma cell lines to cisplatin 139, 150. Additionally SLC21A8 expression was significantly 
associated with 3 platinumbased chemotherapeutics agents such as cisplatin, carboplatin, and 
(trans-l-1,2-diaminocyclo-hexane)platinum-II (DACH-Pt), which is structurally related to the 
another platinating agent oxaliplatin (p= 0.025) 151.  
Copper transporting ATPase (ATP7A and ATP7B) provides efflux and resistance to platinum 
containing drugs along with copper transport 152-155. Cisplatin and other platinum drugs like 
carboplatin and oxaliplatin molecules bind to the first four metal N-terminal binding sites of 
ATPase copper transporter beta (ATP7B) transporter and stimulate catalytic phosphorylation of 
ATP7B, which eventually facilitated drug efflux 140, 155-157. ATP7B transfection in human 
epidermoid carcinoma cell line KB-3-1 resulted in resistance to both cisplatin and carboplatin 158, 
159.  In vivo studies in breast carcinoma 160 and ovarian cancer cell lines 161, 162 have shown 
association of expression of these genes with cisplatin and/or carboplatin resistance. ATP7B is the 
primary candidate for platinum drug resistance where ATPase copper transporter alpha (ATP7A) 
play minor role. ATP7B knockdown ovarian cells show increase cisplatin sensitivity and increased 
efficacy with cisplatin therapy. However, the mechanism between this association is not completely 
clear. High ATP7B gene expression is significantly associated with cisplatin resistance in ovarian 
carcinoma cell lines. In 2008/MNK ovarian cancer cell lines, increased ATP7A expression is 
predictive of poor survival (p<0.00057) to the cisplatin, carboplatin and Oxaliplatin 154. 
Additionally, in ovarian cancer cell line model ATP7B genes were expressed at higher levels in 
platinum-resistant cells compared with sensitive cells. ATP7B silencing showed 2.5-fold reduction 
of cisplatin IC50, increased DNA adduct formation and reducing tumor growth along with  
increased tumor cell apoptosis, and reduced angiogenesis 152. However, overexpression of ATP7A 
and ATP7B in Me32a fibroblast resulted in increased resistance to cisplatin but not to carboplatin 
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163. Homologous transporters ATP7A and B are 160-170-KDa membrane proteins with eight 
transmembrane and several cytosolic domains. The n-terminal cytosolic domain contain six copper 
binding sites where as ATP binding domain is located between transmembrane domain six and 
seven 164, 165. ATP7A and ATP7B are primarily involved in the copper transport from cytoplasm 
into trans-Golgi network. As the copper content of the cell increases, ATP7A moves from trans-
Golgi network to the plasma membrane while ATP7B relocates to intracellular vesicular 
compartments, to facilitate the export pathway 166, 167.  
ATP-Binding Cassette (ABC) transporter superfamily of proteins with 48 members are among most 
ancient and largest protein families since they have been found present in all living organisms, from 
prokaryotes to humans. Classification of proteins as ABC transporters is based on the sequence and 
organization of their ATP-binding cassette (ABC) domains 168-170. Glutathione conjugates of 
platinum compound can be excreted from the cells by members of the ABCC transporter family 
171. Therefore, the most important ABC transporters studied in context of transport of platinum-
containing drugs are ABCC2 and ABCG2 – which are very frequently associated with resistance 
of cancer cell to multiple drugs, also known as multidrug resistance (MDR) 172. ABCC2 - ATP-
Binding Cassette, Sub-Family C (CFTR), Member 2 or Multidrug Resistance- Protein 2 (MRP2) 
and ABCG2 - ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 are members of ATP-
binding cassette (ABC) transporter superfamily that regulate secretion of organic anions and efflux 
of platinum compounds 138. Cytotoxicity of cisplatin, carboplatin and oxaliplatin was significantly 
lowered in MDCKII cells transfected with ABCG2 transporter. The IC(50) values in MDCKII-
ABCG2 were 25.7 for cisplatin, 164 for carboplatin and 165 micro M for oxaliplatin whereas 
IC(50) for MDCKII cells were 15.4 for cisplatin, 133 for carboplatin and 50.3 micro M for 
oxaliplatin 173. Cisplatin-resistant melanoma cells showed a distinct overexpression of 
MRP2/ABCC2 on mRNA and protein level 174. Platinum drug resistance Ovarian carcinoma line 
A2780RCIS, the adrenocortical carcinoma line D43/86RCIS and the melanoma line MeWoCIS1 
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overexpressed of MRP2/ABCC2. The level of DNA platination corresponded inversely to the level 
of MRP2 expression in these cell lines. Therefore, functional inhibition of MRP2 might be a 
promising treatment strategy for resistance to platinum-based anticancer drugs 175. Multidrug 
resistance-associated protein 1 (MRP1) is a protein which is encoded by the ABCC1 gene and it 
play an interesting role in platinum drug resistance through the GS-X pump. The GS-X pump 
actively effluxes the glutathione S-platinum (GS-Pt) complex to detoxifying cells 176. Additionally, 
ABCC4 overexpression significantly associated with decreased cisplatin sensitivity in lung cancer 
patients 138, 171.  
Several genes, such as Myeloperoxidase (MPO), Superoxide Dismutase 1 (SOD1), GSTM1, 
NAD(P)H Quinone Dehydrogenase 1 (NQO1), GSTP1, and MT are responsible for lowering the 
intracellular concentration of platinum drugs. Increased concentrations of Glutathione (GSH), 
Metallothioneins (MT) induce resistance against cisplatin. Cytosolic glutathione S-transferase 
(GST) supergene family includes genes belonging to the subfamilies [alpha] (GSTA), µ (GSTM), 
[pi] (GSTP) and [theta] (GSTT).  GSTs are phase II metabolic isozymes involved in detoxification 
of many xenobiotic agents like anticancer drugs and carcinogens through conjugation with reduced 
glutathione (GSH) 177. This class of enzymes detoxifies carcinogens, therapeutic drugs, and 
environmental toxins by conjugation with glutathione. Genetic variations in GST genes can affect 
toxicity and efficacy of drugs. In ovarian tumor cell lines Glutathione S-transferase P1 knockdown 
showed 2.3- and 4.83-fold change in cisplatin and carboplatin chemosensitivity (IC50) respectively 
178-180. On the other hand, Glutathione S-transferase P1 knockdown in mesothelioma cells exhibited 
a decrease in GST enzyme activity and GSTπ protein levels along with an increase in both 
glutathione levels and sensitivity to cisplatin and oxaliplatin 181. Similarly, GST-pi mRNA was 
significantly increased in cisplatin resistant gastric cancer and bladder cancer cells 182, 183. SOD is 
involved in superoxide generation and plays an important role in Platinum drugs detoxification in 
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cell.    Inhibition of the SOD1 activity has been shown to enhanced the cisplatin sensitivity in the 
ovarian cancer resistant cells 184. 
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Figure 1.7 Metabolic pathway of Platinum drugs
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1.3.3.2 Genes of importance in drug pharmacodynamics (PD) 
1.3.3.2.1 Pt-adduct repair pathway 
Upon entering the cell, platinum drug binds to DNA and forms adducts 185. High mobility group 
(HMG) proteins recognize and bind to DNA intra-strand crosslinks and prevent replicative bypass 
repair and nucleotide excision repair (NER) leading to initiation of apoptosis 131, 186. HMGB1 thus 
inhibits DNA repair and causes more cisplatin DNA damage in murine model. Knocking out 
HMGB1 in cell lines showed increased DNA repair (187. Expression levels of HMGB1 have also 
been significantly associated with the potency of cisplatin and carboplatin in cancer cells 188. 
Binding of HMGB1 to DNA-Pt adducts is very specific and the amount of binding is correlated 
with cytotoxicity of platinum compounds  185. HMGB2 have been shown to enhance the cisplatin 
sensitivity of cells by inhibiting repair of the DNA lesion caused by cisplatin. Additionally, 
Polymerase 1 (PARP1) is a protein that also recognizes DNA lesions and plays an important role 
in the activation of the Base excision repair (BER) pathway 189-193. 
1.3.3.2.2 Mismatch repair pathway 
Single stranded DNA damage due to Pt-DNA adducts are recognized and repaired by the DNA 
mismatch repair pathway (Figure 1.8) 194. Genes involved in the mismatch repair pathway include 
MutS Homolog 2 (MSH2), MutS Homolog 3 (MSH3), MutS Homolog 6(MSH6), MutL Homolog 
1(MLH1), MutL Homolog 3 (MLH3), Postmeiotic Segregation Increased 2 (PMS2), Exonuclease1 
and PCNA. Lack of detection of Pt-DNA adducts by the mismatch repair genes MSH, MLH and 
PMS2 (MSH2, MSH3, MSH6, MLH1, MLH3, PMS1 and PMS2) may fail to trigger apoptosis 
which result in resistance to the platinum drugs 194, 195. A number of in vitro studies have suggested 
that MMR gene expression deficiency is a cause of platinum resistance. Furthermore, loss of 
hMLH1 in ovarian tumor cells was found to be correlated with cisplatin resistance 196. The human 
colon cancer cell line HCT116+ch2 showed 2.1-fold resistance to cisplatin and 1.3-fold resistance 
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to carboplatin compared to the subline expressing a wild-type copy of hMLH1. Concurrently, 
human endometrial cancer cell line HECS9 deficient in hMSH2 showed 1.8-fold resistance to 
cisplatin and 1.5-fold resistance to carboplatin when compared to a subline with wild-type hMSH2 
197. Another study reported that hMLH1 mRNA and protein expression levels were significantly 
decreased in the cisplatin-resistant head and neck squamous cell carcinoma cell lines compared 
with a cisplatin-sensitive cell line 198. Furthermore, dMSH2 knockout embryonic stem cell line was 
2.1-fold more resistant to cisplatin and 1.7-fold more resistant to carboplatin when compared with 
wild-type wt-2 cell line while the PMS2-/- mouse fibroblasts were 1.9-fold more resistant to 
cisplatin and 1.5-fold more resistant to carboplatin when compared to the isogenic PMS2+/+ 
fibroblasts 199. MSH3 deficiency increase sensitivity to both cisplatin and oxaliplatin at clinically 
relevant doses. MSH3 deficiency contributes to the cytotoxicity of platinum drugs through deficient 
DSB repair 200. Another study reported that, loss of MLH1, MLH2, MSH2, MSH3, MSH6 in 
isogenic strains of Saccharomyces cerevisiae led to increased resistance to cisplatin and 
carboplatin. Loss of PMS2 gene was found to be associated with an increased sensitivity, ranging 
from 2-6-fold to platinum compounds cisplatin and oxaliplatin in another study 201.   
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Figure 1.8 Mismatch repair (MMR) pathway. 
The MMR pathway recognizes and repairs single stranded DNA damage due to Pt-DNA adducts. 
Major genes involved in this pathway include the MutS and MutL Homolog genes, PMS2, 
Exonuclease1 and PCNA. 
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1.3.3.2.3 Nucleotide excision repair pathway 
The nucleoside excision repair (NER) pathway genes Xeroderma pigmentosum group (XPA), 
XPC, XPB/ Excision repair cross-complementing group 1 (ERCC3), XPD (ERCC2), XPG 
(ERCC5), XPF (ERCC4), ERCC1, DNA polymerases and DNA ligases are primarily involved in 
the identification and repair of platinum-DNA adducts (1, 2-intrastrand DNA cross-links) 202 
(Figure 1.9). The human platinum-resistant ovarian carcinoma cell line SKOV3/DDP showed 
expression levels of ERCC1 were significantly suppressed after stably transfecting with shERCC1-
recombinant plasmid, whereas increased sensitivity to cisplatin (p<0.01). In another study siRNA-
mediated ERCC1 silencing in the MCF-7, HeLa S3 and HCT116 cells showed both the ERCC1 
mRNA and protein expression were significantly inhibited, which led to a decrease in repair activity 
of cisplatin-induced DNA damage along with cell viability against platinum-based drugs such as 
cisplatin, carboplatin, and oxaliplatin 203.  On the other hand, ovarian cancer, which is frequently 
more resistant to cisplatin, shows increased expression of NER proteins including ERCC1 and XPC 
204. XPA promotes resistance in tumor cells to platinum based chemotherapeutic drugs. XPA was 
expressed at higher levels in cisplatin-resistant melanoma cells than in cisplatin-sensitive ones. 
Furthermore, the knockdown of XPA not only increased cellular apoptosis and also inhibited 
cisplatin-induced autophagy, which increase cisplatin sensitivity. XPA promoted cell-protective 
autophagy by polymerase 1 (PARP1) activation in a DNA repair-independent manner and cell 
became cisplatin resistance 205. Additionally, expression of XPA was higher in NSCLC tissues than 
that in normal lung tissues. Furthermore, silencing XPA gene increased the apoptosis and cisplatin 
sensitivity 206.  
XPB mRNAs have been observed to be expressed >2-fold higher in clear cell epithelial ovarian 
tumors 207. Higher mRNA levels of XPB were observed in clinically resistant tumor to platinum-
based chemotherapy. In a cohort of 27 patients, mRNA levels of XPB was 5-fold higher in 
platinum-resistant tumors (P = 0.001). Furthermore, these platinum-resistant tumors also show 
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higher mRNA levels of ERCC1 and XPA 208. ERCC1 is an excision nuclease within the nucleotide 
excision repair pathway that forms a heterodimer with XPF. ERCC1-XPF complex inhibitor 
reduced the level of this protein in ovarian cancer cells, inhibited Nucleotide Excision Repair and 
sensitized cells to cisplatin 209. Non-small cell lung cancer, ovarian and breast cancer cell lines 
showed increased cisplatin cytotoxicity and efficacy when ERCC1/XPF was down-regulated by 
RNAi 210. The expression of XPF was upregulated in cisplatin resistance KB carcinoma cells (KCP-
4) 211. Osteosarcoma cells (U2OS) by XPF and XPG knockdown exhibited increased sensitivity to 
platinum drugs compared to the parental cells up to fivefold 212. XPF is also required for the repair 
of DNA lesions through the Nucleotide Excision Repair and Interstrand Crosslink Repair pathways. 
Xeroderma pigmentosum D (XPD) protein expression levels may also influence response to 
platinum-based chemotherapy in epithelial ovarian cancer (EOC). In resistance group of serous 
ovarian cancer, XPD protein expression levels were significantly higher than sensitivity group. 
Upregulation of ERCC1 and XPD protein expression was associated with resistance process to 
platinum-based chemotherapy in advanced EOC 213. XPD expression was significantly related to 
resistance to platinum-containing treatment (p = 0.043) 214.  
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Figure 1.9 Nucleotide excision repair (NER) pathway 
The NER pathway is involved in the identification and repair of platinum-DNA adducts (1, 2-
intrastrand DNA cross-links). Major genes involved in this pathway include the Xeroderma 
pigmentosum group genes A-G, DNA polymerases and DNA ligases. 
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1.3.3.2.4 Homologous recombination and non-homologous end joining  
Homologous recombination and non-homologous end joining (NHEJ) DNA repair processes are 
also involved in the repair of double-stranded breaks due to DNA-Pt adducts (Thacker and 
Zdzienicka. 2004). The genes XPF and ERCC1 gene are involved in homologous recombination 
while X-ray repair cross complementing group/ X-Ray Repair Complementing Defective Repair in 
Chinese Hamster Cells 1 (XRCC1), XRCC2, XRCC3, XRCC4, XRCC5, XRCC6 and XRCC7 are 
involved in non-homologous end joining process 215. Protein expression of XRCC1 was 
significantly increased in cisplatin-resistant gastric cancer cells and caused cisplatin resistance to 
the cells. Furthermore, Inhibition of XRCC1 expression increased sensitivity of resistant cells to 
cisplatin 216. High XRCC1 expression was found to be associated with platinum resistance (p < 
0.0001) in ovarian cancer 217. 
1.3.3.2.5 Translesional bypass replication repair 
Finally, when all DNA repair mechanisms fail, translesional bypass replication or SOS repair 
pathway is activated to overhaul the DNA damages by pt-DNA adducts. Several genes including 
Polymerase (DNA Directed), Beta or POLB (DNA pol β), POLH (DNA pol η), POLK, POLM, 
DNA polymerase zeta, REV1, REV3 and REV7 are involved in this pathway 218. DNA pol β and 
DNA pol η Overexpression lead to cisplatin resistance. Polymorphism of these genes also 
associated with clinical response to the platinum drugs in cancer patients. REV3 is an essential 
component for of Polζ and both play an important role in SOS repair mechanism. Reduced levels 
of Rev3 exhibited sensitivity to cisplatin and significantly associated with better OS of platinum 
drug treated mice 219. Expression of hRev3 mRNA in the cisplatin resistant head and neck squamous 
cell carcinoma cell line was approximately 1.4-fold higher than in the sensitive cells. Furthermore, 
hRev3 knockdown with siRNAs increases sensitivity to cisplatin in this cell line 198. Reduced 
expression of the DNA polymerase zeta (catalytic subunit REV3) made fibroblasts more sensitive 
to cisplatin 218, 220. 
35 
 
 Pharmacogenomics of platinum drug pathway genes  
Pharmacogenomics is a field of research that combines pharmacology and genomics to study the 
effect of genes and genetic variations on the response to drugs with an ultimate goal of developing 
safe and efficacious ‘best-fit’ medications based on an individual’s genetic make-up 221.  
We performed a comprehensive review of the research on pharmacogenomics of platinum drug 
pathway genes conducted through a systematic search of papers reporting association between gene 
expression and/or genetic polymorphisms in Platinum drug pathway genes and clinical response to 
platinum-drug based therapy. The genes included in the ensuing review are the most important 
genes that have been reported to be involved in the transport (influx and efflux), DNA adducts 
repair, detoxification/xenometabolism (PK) and PD of platinum-based drugs. The criteria for 
identifying the genes to be selected for the study was based on the information available from the 
resources providing information on key pathways, e.g. KEGG (Kyoto Encyclopedia of Genes and 
Genomes), GO (NCBI’s Gene Ontology database), PharmGKB (The Pharmacogenomics 
Knowledgebase) and PGRN’s (Pharmacogenomics Research Network) drug-specific pathway 
information. Care was taken to ensure uniformity with respect to gene names and SNP IDs based 
on scientifically accepted notations and nomenclatures. The following sections will be divided into 
studies conducted on genetic variations within genes involved in platinum drug pharmacokinetics 
(transporters, drug metabolizing enzymes) and pharmacodynamics including a summary of the 
major studies and the conflicting evidences, if any. 
1.3.4.1 Genes involved in transport and metabolism of platinating agents (PK genes) 
1.3.4.1.1 Drug efflux and influx Transporter 
CTR1/SLC31 (Chromosomal location 9q32; length 42965bp; 5 exons) is a predictor of platinum-
based chemotherapy response and also plays a role as prognostic factor in NSCLC 222, 223. Ctr1 is 
predictor of platinum-based chemotherapy response and also plays a role as prognostic factor in 
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NSCLC 223. On the other hand, high SLC31A1/CTR1 expression of was associated with poor 
survival of (HNSCC) head and neck squamous cell carcinoma patients 224. In African Americans 
CTR1 expression is significantly reduced (P=0.001) along with tissue platinum concentrations 
(P=0.009) and tumor shrinkage (P=0.016) compared to Caucasians 225. Additionally, CTR1 
expression is a predictive/prognostic factor for a good outcome in stage III endometrial cancer 
patients treated with adjuvant carboplatin based combination chemotherapy. The patients with 
tumors showing high expression levels of CTR1 associated with longer DFS (P = 0.058) and 
significantly longer OS (P = 0.003) 226. Another recent study showed CTR1 expression was 
significantly associated with improved chemotherapeutic responses. The median survival time was 
15 months in patients with low CTR1 expression, but >66 months in patients with high CTR1 
expression (P<0.001)227.  
Table 1.3 summarizes genotype-phenotype associations between polymorphisms within platinum 
drug influx and efflux transporter genes and treatment outcome of platinating agent-containing 
cancer chemotherapy. 
The CTR1 SNP rs10981694 A>C was associated with cisplatin ototoxicity in NSCLC patients. C- 
Variants are poor tolerance to ototoxicity (p, 0.05) 228. Genetic polymorphisms rs7851395 A>G and 
rs12686377 T>G were significantly associated with platinum resistance in NSCLC patients treated 
with platinum-based anticancer drugs. Patients with a GT haplotype showed increased 
susceptibility to platinum resistance (P < 0.05), whereas an AG haplotype contributed to longer 
survival (P < 0.05) in Chinese NSCLC patients {{}}. Further, deletion of the CTR2 gene leads to 
increased cisplatin and carboplatin accumulation in cells 150.  
Genomic Location for ATP7A gene is Chromosome Xq21.1 and it is 139,740 bases long with 23 
exons and 3 splice variants. ATP7B is located at chromosome 13q14.3. This gene is 121,014 bases 
in length with 34 exons. ATP7A and ATP7B play important roles in platinum drugs efflux.  
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Resistance cell line to carboplatin, nedaplatin and oxaliplatin showed up-regulated expression of 
ATP7A, ATP7B transporter 229. In NSCLC patient’s low ATP7A expression was associated with 
an improved prognosis. The median survival time was 20 months in patients possessing tumors 
with high ATP7A expression, but >66 months in patients possessing tumors with low ATP7A 
expression (P<0.001). ATP7B expression was also significantly associated with tumor cell 
differentiation 227. ATP7B mRNA and protein expression in colorectal tumors is associated with 
clinical outcome to oxaliplatin/5FU. Patients with the lowest ATP7B expression significantly 
associated with longer time to progression (p = 0.0009) and increased risk of progression (p = 
0.002) along with the maximum benefit from platinum based therapy 153. ATP7A-positive patients 
NSCLC patient showed significantly poorer histological grade (p = 0.039) and poorer response to 
platinum-based chemotherapy (p = 0.001) compared with ATP7A-negative patients. Therefore, 
ATP7A expression may be used as an independent prognostic factor for OS (p = 0.045) for NSCLC 
patients treated with platinum based therapy 230. In a recent gene profiling study (Taqman low-
density array-TLDA) on cisplatin sensitive cell lines showed ATP7B gene expression was 
decreased 1.95-fold (p=0.03) but there was no change in gene expression of ATP7A or SLC31A1 
231.  
Only one study so far has investigated the association of ATP7a and ATP7B transporter SNPs with 
platinum drug response by sequencing of these genes in Japanese cancer patients treated with 
oxaliplatin/5-fluorouracil/leucovorin and paclitaxel/carboplatin. 38 genetic variations, including 30 
novel ones (seven nonsynonymous) in ATP7A and 28 novel and 33 known genetic variations 
(including 13 nonsynonymous SNPs) in ATP7B were detected These SNPs possibly influence the 
efficacy and toxicities of oxaliplatin and carboplatin treatment by changing the drug concentrations 
within tumor cells 232. 
The ABCC2 gene is located on chromosome 10 (10q24.2) and it is 69,979 bases long. This gene 
has 34 exons with 3 splice variants; whereas ABCG2 or Breast cancer resistance protein (BCPR) 
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is located on chromosome 4 (4q22.1) and 141,154 bases long with 19 exons and 4 splice variants. 
ABCC2 and ABCG2 are involved in carboplatin efflux  138, 233. Multiple studies have shown 
association of these transporters with survival in ovarian cancer patients. Low ABCC2 gene 
expression in tumor tissues from patients with ovarian cancer was associated with prolonged 
Progression Free Survival (PFS)233. Additionally, localization of ABCC2 in the nuclear membrane 
was associated with cisplatin resistance and clinical outcome in ovarian carcinoma and 
overexpression of ABCC2 at mRNA and protein levels was shown to be associated with decreased 
formation of intra-strand DNA cross-links and resistance to cisplatin in melanoma cells 234. In 
gastric cancer ABCG2 over-expression was shown associated with longer OS for platinum-
containing chemotherapy for 235. In HNSCC (head and neck squamous cell carcinoma) patient’s 
expression of ABCC2, and ABCG2 indicates poor survival of patients treated with platinum based 
therapy.  High ABCB1, ABCC1 expression was associated with both favorable progression-free 
survival (PFS, p = 0.0357, p = 0.0183) and OS (p = 0.0535. p = 0.038) 224.  
The non-synonymous polymorphisms rs2273697 (1249G>A/Val417Ile) in ABCC2 and rs2231142 
(C421A/Gln141Lys) in ABCG2 were correlated with treatment response and survival in ovarian 
cancer patients treated with platinum-based chemotherapy. SNP rs2231142 was associated with 
longer median PFS 236. Another study reported, polymorphism ABCG2 rs2231142 (C421A/ 
Q141K) significantly associated with worse OS for lung cancer patients treated with platinum-
based drugs (HR: 1.60; 95% CI 1.04-2.47; n = 256) 237. ABCG2 SNPs rs2725264 and rs4148149 
were associated with OS (P=0.041, P= 0,014) in 129 NSCLC patients treated with first-line 
platinum-based chemotherapy. The median survival duration for the rs2725264 T/T, T/C, and C/C 
genotypes was 35.75 , 34.25 and 14.89 respectively238. The ABCC2 polymorphism, rs8187710 
(4544G>A), is associated with OS (p=0.036) in advanced NSCLC patients treated with platinum-
based therapy. Allele A was associated with adverse OS (p=0.009) of IV NSCLC patients 239. 
Polymorphisms in ABCC2 rs717620 (C-24T) and rs3740066 (C3972T) was associated with 
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treatment response. Homozygotes of -24C was associated with a better treatment response 
(P=0.032). Whereas patients with 3972T had increased risk of severe thrombocytopenia toxicity 
with female patient group (P=0.034), with overall toxicity (P=0.02) and hematologic toxicity 
(P=0.002) among platinum-treated non-small cell lung cancer patients 240, 241.  
ATP-Binding Cassette, Sub-Family B (MDR/TAP) Member 1 (MDR1/ABCB1) is a 209,691 bases 
long gene located at chromosome 7q21.12. The MDR1/ABCB1 synonymous coding polymorphism 
rs1045642 (C3435T/Ile1145Ile) was associated with platinum-based chemotherapy response in 
lung cancer where the C/C genotype was more sensitive to platinum-based chemotherapy than 
patients with C/T and T/T. Frequency of this SNP is highest in Asian and Caucasians populations 
and the lowest in African populations 242-246. rs2032582 (G2677T) is a nonsynonymous SNP located 
in exon 21 of the ABCB1 gene. ABCB1 2677G>T/A polymorphism were significantly associated 
with grade 3 or 4 hematological and gastrointestinal toxicities in epithelial ovarian cancer patients 
and in non-small-cell lung cancer patients treated with platinum and taxen compounds 247, 248. 
Variant allele (T) of the ABCB1 SNP rs1128503 was associated with the risk of anemia in ovarian 
cancer patients treated with platinum compound. (C > T; p = 0.023, OR = 1.71, 95% CI = 1.07-2.71) 
249. 
ABCC1 gene is located at chromosome 16p13.11 (length: 193,498 bases) and ABCC4 is located at 
chromosome 13q32.1 (length: 281,618 bases).  Higher mRNA expression of ABCC1 significantly 
correlate with short period of progression free survival in advanced ovarian carcinoma patients 
treated with platinum based chemotherapy 250. rs1729786, a tagSNP in the gene ABCC4 was found 
significantly associated (OR=0.68; 95% CI=0.50–0.92; unadjusted p=0.037) with chemotherapy-
induced peripheral neuropathy (CIPN) among 950 lung cancer patients treated with platinum based 
therapy 251. 
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Table 1.3 Summary of SNPs in drug transporter genes associated with response to platinating agents. 
SNP ID Gene symbol 
Gene 
Function 
Cancer 
Type 
Associated  
Phenotype Associated Genotype PubMed ID (s) 
rs10981694 SLC31 Influx transporter NSCLC 
Cisplatin 
ototoxicity 
rs10981694 (A>C) C Variants show 
poor tolerance to ototoxicity 22516052 
rs7851395, 
rs12686377 SLC31 
Influx 
transporter NSCLC 
Platinum 
resistance, 
survival 
AG haplotype of rs7851395 A>G  
and  rs12686377 T>G  contributed 
to longer survival. Patients with GT 
haplotype show increased 
susceptibility to platinum 
resistance 
22725681 
rs2273697 ABCC2 Efflux transporter 
Ovarian 
cancer 
Treatment 
response, 
survival 
1249G>A or Val417Ile 22112610 
rs2231142 ABCG2 Efflux transporter 
Ovarian 
cancer Median PFS C421A or Gln141Lys 22112610 
Lung 
cancer OS  
rs2231142 significantly associated 
with worse OS (HR: 1.60; 95% CI 
1.04-2.47) 
19107936 
rs2725264, 
rs4148149 ABCG2 
Efflux 
transporter NSCLC OS  
rs2725264 vs OS (P=0.041); 
rs4148149 vs OS (P= 0.014) 23689644 
rs8187710, 
rs717620 ABCC2 
Efflux 
transporter NSCLC 
OS , treatment 
response 
rs8187710  vs OS (p=0.036). Allele 
A was associated with adverse OS 
(p=0.009); rs717620 (C-24T),  24CC 
was associated with a better 
treatment response (P=0.032).  
26816351,  
19568750 
 rs3740066 ABCC2 Efflux transporter NSCLC  Toxicity 
 rs3740066 (C3972T) 3972T had 
increased risk of severe 
thrombocytopenia toxicity  
(P=0.034), overall toxicity (P=0.02) 
and hematologic toxicity (P=0.002) 
20943283 
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rs1045642 ABCB1 Efflux transporter 
Lung 
cancer Chemosensitivity 
rs1045642 (C3435T) C/C genotype 
more sensitive to platinum-based 
chemotherapy than patients with 
C/T and T/T.  
 24687344,  
22932088,   
22766400,   
22704851,   
22296372 
rs2032582 ABCB1 Efflux transporter 
Ovarian 
cancer Toxicity 
rs2032582 (G2677T), vs grade 3 or 
4 hematological and 
gastrointestinal toxicities  
 19203783,  
20189873 
rs1128503 ABCB1 Efflux transporter 
Ovarian 
cancer Anemia 
C > T; p = 0.023, OR = 1.71, 95% 
CI = 1.07-2.71 25881102 
rs1729786  ABCC4 Efflux transporter 
Lung 
cancer CIPN 
rs1729786  vs Chemotherapy-
induced peripheral neuropathy 
(p=0.0377) 
25586538 
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1.3.4.1.2 Xenobiotic metabolism genes 
Polymorphisms in GST genes are associated both with cancer susceptibility and anticancer drug 
resistance 252. GSTP1 gene is located on chromosome 11 (11q13.2). This gene has 7 exons along 
with 7 splice variants. Low GSTP1 expression level was found to be associated with better response 
in NSCLC patients (P <0.003) 253. Polymorphisms in GST genes are associated both with cancer 
susceptibility and anticancer drugs resistance 252. Genetic variations in GST genes including rs1695 
(GSTP1 I105V, shown in Figure 1.10) have been shown to be associated both with resistance, 
toxicity and efficacy of platinum-based drugs 247, 252, 254, 255. rs1695 (GSTP1 Ile105Val, A313G) was 
associated with clinical out come in NSCLC patients. GSTP Val/Val exhibited a shorter survival 
time, and had a 1.89-fold greater risk of death than patients with the IIe/IIe genotype. Similar 
association was also reported by several studies 241, 256-263. Additionally, Patients with homozygous 
mutant GSTP1 GG genotype were at risk for severe platinum-associated polyneuropathy (P = 0.01) 
in NSCLC platients 255. rs1695 is also associated with neutropenia in NSCLC patients. Toxicity 
was less for patients with the 105Val allele (p = 0.020) 264. Similarly, rs1695 was also found to be 
associated with PFS (p = 0.004) in ovarian cancer patients 265, 266. rs1695 was also found to be a 
significant risk factor for grade 3 or 4 hematological (adjusted OR, 3.08; 95% CI, 1.12-8.43) and 
gastrointestinal toxicities (adjusted OR, 9.74; 95% CI, and 1.59-15.85) 267. Additionally, high 
expression of GSTP1-1 was significantly associated with a poor DFS and OS (P = 0.047 and P = 
0.033, respectively) 234, as well as poor PFS in ovarian cancer patients 268. Furthermore, the GSTP1-
A-allele was also associated with better prognosis (P = 0.032) and GSTP1-AG genotype was 
associated with necrosis in the tumor's post-chemotherapy histology (P = 0.001) testicular germ 
cell tumor 269.  GSTP1 expression and rs1695 GA/GG was also significant associated with poor OS 
(P=0.004) in gastric cancer in Chinese population 270-272. rs1695 was also found to be contributed 
in colorectal cancer patients treated with oxaliplatin. Patients with Val/Val genotypes significantly 
associated with better and longer survival of colorectal cancer 273, 274. rs1695 was also associated 
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with toxicity for cisplatin based radiochemotherapy (P = 0.005) 275 esophageal cancer. Furthermore, 
rs1695 was also contributed in oxaliplatin-related neuropathy. Patients with homozygous GSTP1 
105Ile allele showed more toxicity than patients homozygous or heterozygous for the GSTP1 
105Val allele (P = 0.02) in gastrointestinal cancer patients treated with oxaliplatin-based 
chemotherapy 276. Another SNP rs1138272 (Ala114Val) was found to be associated with platinum 
based chemotherapy treated NSCLC patients. Genotype (Ala/Val or Val/Val) had significantly 
better survival compared with patients with (Ala/Ala; P = 0.037). Median survival was 16.1 months 
compare to 11.4 months for Ala/Ala 277.  
Glutathione S-Transferase Mu 1(GSTM1) gene is located on chromosome one (1p13.3). The most 
important polymorphism in GSTM1 is a partial gene deletion in GSTM1 gene which is called 
GSTM1 null genotype, resulting in complete absence of GST M1 enzyme activity. 5-year survival 
and time to progression was better for GSTM1-null genotype patients compared with GSTM1-wt 
genotype patients (P = 0.001 and P = 0.013, respectively) in ovarian cancer patients receiving 
platinum based chemotherapy. GSTM1-wt genotype was also important predictors of risk of death 
(P = 0.036) 278. Additionally, thrombocytopenia, anemia and neuropathy were less among patients 
with the GSTM1-null or GSTM3 intron 6 AGG/AGG genotype in ovarian cancer patients receiving 
platinum based therapy 265, 279. GSTM1 null polymorphism was also associated with treatment 
response in testicular germ cell tumors, NSCLC patients and lung cancer patients where GSTM1-
null were superior responders to platinum drugs than GSTM1-wt (P = 0.014)258, 261, 269, 280. 
Glutathione S-Transferase Theta 1 (GSTT1) is located on chromosome 22 (22q11.23) and 8,179 
bases long. GSTT1 overexpression was found to be influenced decreased cisplatin sensitivity in 
lung cancer patients treated with platinum compound (171). Non-null GSTT1 genotype was a poor 
prognostic factor for overall response in ovarian cancer 247, 281 and toxicity 247, 266, 279. Similar 
association was also observed in gastric cancer patients where response rate was higher in GSTT1 
(+) genotype compared with GSTT1 (-) genotype 271. 
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Glutathione S-Transferase Alpha 1 (GSTA1) gene is located on chromosome 6 (6p12.2). The 
GSTA1 promoter region polymorphism rs3957357 (-69 C>T) polymorphism correlated with the 
OS in ovarian cancer patients receiving platinum drugs chemotherapy. Patients with T/T genotype 
survived longer than C/C carriers (P=0.044) 265. GSTA1∗B polymorphism comprise with -52G>A 
(rs3957356), −69C>T (rs3957357) and -567T>G (rs4715332) were also associated with an 
increased OS in patients with different malignancies treated by platinum compound282. 
Glutathione S-Transferase Mu 3 (GSTM3), Glutathione S-Transferase Mu 4 (GSTM4) and 
Glutathione S-Transferase Mu 5 (GSTA5) genes are located on chromosome 1. The GSTM3 SNP 
rs1799735 or GSTM3*B induces high GSTM3 expression and results in beneficial effects in 
cisplatin chemotherapy 265, 266, 283 in ovarian  cancer. Two tag SNPs in GSTA5 (rs4715354) and 
GSTM4 (rs560018) were associated with survival in lung cancer patients treated with platinum 
based drugs. Furthermore, rs560018 was significantly associated with IC50 in lymphoblastoid cell 
lines generated from 100 healthy Caucasian-American subjects (p=0.019) 171. 
SOD1 and SOD2 are also involved in platinum drug xenometabolism. The SOD2 mis-
sense/nonsynonymous coding SNP rs4880 (47T/C or Val16Ala) CT + CC combined genotype was 
shown to be significantly associated with decreased median OS time of 23 months when compared 
to the TT genotype (P=0.002) in gastric cancer patients receiving platinum based combination 
therapy 270. SNP rs4880 was also found to be associated with ototoxicity in cisplatin treated 
pediatric medulloblastoma patients Texas Children's Cancer Center (1987-2010). The rs4880 T > 
C substitution results in a Val > Ala amino acid change at position 16 of the SOD. The C-allele of 
the rs4880 variant was significantly associated with increased SOD2 activity which leads to 
ototoxicity (odds ratio = 3.06, 95% confidence interval: 1.30-7.20) 284. 
Myeloperoxidase (MPO) is another component of the detoxification pathway of platinum drugs. 
The mutant genotypes of the MPO promoter SNP -463G>A was shown associated (A allele) with 
lower carboplatin-induced hematological toxicity in cancer patients 285. Another missense SNP 
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rs1800566 (C609T/Pro187Ser) in the gene NAD(P)H Quinone Dehydrogenase 1 (NQO1) was 
significantly associated with higher prevalence of TT genotype (P < 0.001). TT genotype carriers 
had less chance to response with chemotherapy than compared to CC genotype carriers (P = 0.003) 
in advanced NSCLC receiving platinum-based chemotherapy 286. Table 1.4 lists the salient 
variations in xenobiotic metabolism genes associated with pharmacogenomics of platinum drug-
based chemotherapy.
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Table 1.4 Summary of SNPs in drug metabolism genes associated with Platinum-based chemotherapy. 
SNP ID Gene symbol Cancer Type 
Associated 
Phenotype Associated Genotype PubMed ID (s) 
rs1695 GSTP1 
NSCLC 
Clinical 
outcome, 
polyneuropathy 
rs1695 (GSTP1 Ile105Val, A313G) Val/Val 
exhibited a shorter survival time, and had 
a 1.89-fold greater risk of death than 
patients with the IIe/IIe genotype. 
Patients with GG genotype were at risk for 
severe platinum-associated 
polyneuropathy (P = 0.01) 
 023167352,  24958519,  
24729086,  22761669,  
22009704,  21766492,  
19568750,  17409936,  
11844594,  22031394,  
17409936 
Ovarian cancer PFS, Toxicity 
rs1695 vs PFS (p = 0.004); rs1695 vs grade 
3 or 4 hematological (adjusted OR, 3.08; 
95% CI, 1.12-8.43); vs gastrointestinal 
toxicities (adjusted OR, 9.74; 95% CI, and 
1.59-15.85)  
 22188361,  19786980,  
19203783 
Testicular germ 
cell tumor Prognosis 
A allele was associated with better 
prognosis (P = 0.032) and AG genotype 
was associated with necrosis in the 
tumor's post-chemotherapy histology (P = 
0.001) 
19741569 
 Gastric and 
Colorectal 
cancers 
Tumor 
response, PFS, 
and OS 
Patients with Val/Val genotypes 
significantly associated with better and 
longer survival. 
 27154175,  25901207,  
23020798,  9626464,  
22994779,  19922504, 
Esophageal 
cancer Toxicity 
Rs1695 vs toxicity for cisplatin-based 
radiochemotherapy (P = 0.005) 21286719 
Gastrointestinal 
cancer Neuropathy 
Ile/Ile showed more toxicity than Val/Val 
and Val/Ile genotype (P = 0.02) in patients 
treated with oxaliplatin-based 
chemotherapy  
16707601 
rs1138272 GSTP1 NSCLC Survival 
Genotype (Ala/Val or Val/Val) had 
significantly better survival compared 
with patients with (Ala/Ala) (P = 0.037). 
16342067 
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rs3957357 GSTA1 Ovarian cancer OS 
Patients with rs3957357 (C>T) T/T 
genotype survived longer than C/C 
carriers (P=0.044) .  
19786980 
rs4880 SOD2 Gastric cancer, medulloblastoma OS 
rs4880 CT/CC was significantly associated 
with decreased median OS time 
compared to the TT genotype (P=0.002). 
 25901207,  26400460 
MPO-
463G>A  MPO   Toxicity 
Promoter SNP -463G>A was associated 
with lower carboplatin-induced 
hematological toxicity 
24083736 
rs1800566 NQO1 NSCLC Response 
rs1800566 TT genotype carriers showed 
less response compared to CC genotype 
carriers (P = 0.003) 
24464627 
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Figure 1.10 Genetic variants in GSTP1 associated with survival/outcome and/or toxicity in patients treated with Platinum drug-
based chemotherapy (Green boxes denote coding SNPs). 
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1.3.4.2 Genes involved in DNA damage and repair (PD) pathway and their impact on 
platinating agent response  
Several genes are involved in the drug pharmacodynamics pathway. HMGB and PARP are 
involved in the identification of pt-DNA adducts which is followed by repair of these DNA 
damages (pt-DNA adducts) through NER repair genes, Mismatch repair genes, double strand break 
repair genes and finally translesional replication repair (SOS) pathway genes when all other repair 
pathway fails. Polymorphisms in these DNA repair genes may modulate not only DNA repair 
capacity, but also clinical outcome of treatment with DNA damage-inducing anticancer drugs 
including platinating agents (Tables 1.5 and 1.6).  
1.3.4.2.1 Pt-DNA adduct repair  
The HMGB1 gene is located at chromosome 13q12.3. It is 160,894 bases long including 8 exons 
and 8 splice variants. In epithelial ovarian cancer (EOC) patients treated with platinum based 
therapy HMGB1 expression was an independent predictor for PFS (P = 0.024). High HMGB1 
expression associated significantly with poorer prognosis (PFS) 287. In Chinese lung cancer patients, 
rs1412125 and rs2249825 of HMGB1 were significantly associated with the platinum-based 
chemotherapy response 288. Poly (ADP-Ribose) Polymerase 1 (PARP1) is a 47,410 bases long gene; 
located in chromosome 1q42.12 with 23 exons and 10 splice variants. PARP1 is a 113 kDa protein 
that contains a DNA-binding domain with two zinc fingers and an auto-modification domain. The 
non-synonymous polymorphism in PARP1 rs1805412 (Val762Ala/T2285C) influenced the 
prognosis of advanced NSCLC patients treated with platinum-based chemotherapy. PARP1 
2285CC genotype was a significantly associated with poor PFS (CC vs. CT/TT: adjusted HR = 
1.90, 95 % CI = 1.02-3.52) 289. 
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1.3.4.2.2 Mismatch repair pathway genes 
MSH2 and MSH6 are located at chromosome 2p21 and 2p16.3 respectively, whereas MSH3 is 
located at chromosome 5q14.1. Downregulation of hHSH2 expression has been shown associated 
with improved survival, while high expression was correlated with poor survival in ovarian cancer 
patients following cisplatin treatment 154. Furthermore, MSH2 expression was associated with a 
shorter time to tumor recurrence, resistance to chemotherapy and death in testicular cancer 290. On 
the other hand, human MSH6 (hMSH6) defects result in 1.5-4.8 fold increase in cisplatin resistance 
and 2.5-6 fold increase in replicative bypass of cisplatin adducts 291. MSH6 protein levels were also 
correlated to progression during Platinum-based chemotherapy (P = .0281) in patients with 
malignant pleural mesothelioma (MPM) 292.  
Among the mismatch repair gene polymorphisms evaluated for correlation of with response to 
cisplatin- or carboplatin-based chemotherapy, gIVS12-6T/C (hMSH2) was associated with 
treatment response (p=0.0173) in peripheral lymphocytes from advanced NSCLC patients 
belonging to the Chinese population 293. Significant correlation was found between the MSH3 
5’UTR SNP rs1105524 and PFS. The G/A and A/A genotypes (median survival time: 14.27 
months; 95%CI = 9.80-18.75) showed shorter survival than patients with the G/G genotype (median 
survival time: 26.37 months; 95%CI = 15.03-37.71) (P = 0.04) 293. 
MLH1 is located at chromosome 3p22.2 with 21 exons while MLH3 is located at chromosome 
14q24.3 and it has 14 exons. Decreased hMLH1 expression was significantly correlated with 
improved survival, while high expression was correlated with poor survival in ovarian cancer 
patients following cisplatin treatment 294. A study by Scartozzi et al observed that among 38 patients 
with advanced ovarian cancer treated with cisplatin-based chemotherapy, 19 (56%) showing loss 
of hMLH1 expression with a median survival of 55 months while 15 (44%) showing normal 
hMLH1 expression had a lower median survival of 12 months (P=0.014) 295. MLH1 expression 
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was also significantly associated with PFS (P = .0205) following platinum-based chemotherapy in 
malignant pleural mesothelioma292.  In addition, MLH1 expression was associated with a shorter 
time to tumor recurrence, resistance to chemotherapy and death in testicular cancer 290.  Non-
functional hMLH1 caused 1.5-4.8-fold increased cisplatin resistance and 2.5-6-fold increased 
replicative bypass of cisplatin adducts 291. The non-synonymous coding MLH1 polymorphism 
rs1799977 (Ile219Leu/A655G) was shown associated with OS of diffuse large B-cell lymphoma 
(DLBCL). AG/GG genotype displayed an increased death risk (hazard ratio [HR] = 3.23; P < .001) 
compared with patients carrying the AA genotype 296.  
The PMS1 gene is located on chromosome 2 (2q32.2), while PMS2 is found in clusters on 
chromosome 7 (7p22.1). Deficiency of PMS2 associated with cisplatin resistance in ovarian cancer 
patients 297. 
1.3.4.2.3 Nucleoside excision repair 
XPA is located on chromosome 9 (9q22.33) and it has 10 exons along with 4 transcripts. High XPA 
level predicts a poor prognosis in locally advanced nasopharyngeal carcinoma (NPC) patients 
treated with platinum-based chemo-radiotherapy 298. Malignant ovarian cancer tissues from 13 
patients, whose tumors were clinically resistant to therapy showed greater levels of total XPA 
mRNA and activity (P = 0.011) compared to clinically sensitive individuals to platinum therapy (n 
= 15) 208, 299, 300. XPA expression in effusion tumor cells from metastatic ovarian carcinoma patients 
was shown associated with complete response to chemotherapy (P = 0.03): XPA expressed in 
greater than 25% of tumor cells from recurrent patients showed better PFS (P < 0.001) and OS (P 
= 0.04) 301, 302. XPA rs1800975 (A23G), a promoter polymorphism, is associated with favorable 
prognosis of NSCLC receiving platinum based chemotherapy. XPA23 A/G+G/G genotypes were 
associated with significantly longer progression- free survival (PFS) (P = 0.001) and OS (P = 0.001) 
303, 304. Another important finding was, association between this rs1800975 and prognosis in 250 
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inoperable non-small cell lung cancer (NSCLC) patients treated with platinum-based 
chemotherapy. XPA 23 GA/AA genotypes were associated with poor survival (HR 1.55, p = 0.011 
overall and HR 1.72, p = 0.008) and increased risk of death and progression (HR 1.73, p = 0.013 
and HR 1.65, p = 0.016, respectively) 305. Furthermore, rs1800975 was associated with relative risk 
(RR) of NSCLC patients receiving platinum based therapy. Homozygous G/G genotype showed a 
higher RR than patients with G/A or A/A genotype (74.1% vs 50.0%; OR: 0.09; 95% CI: 0.00–
0.64; p = 0.013) 306. rs1805160, XPA (Arg228Gln) was found significantly associated with 
recurrence from ovarian cancer in 125 Caucasian patients (HR (AA)= 12.06 (95% CI 1.22–118.76); 
HR(AG+GG) =9.11 (95% CI 1.12–73.90)) 307. In addition, the XPA missense polymorphism 
rs104894131 (Cys108Phe) was associated with severe hematological toxicity in 55 NSCLC 
patients treated with platinum compound in combination with vinorelbine. 308. 
XPC is located in chromosome 3 (3p25.1). It is 33,637 bp long and has 18 exons and 7 splice 
variants. XPC intronic variant rs2607755 was significantly associated with OS and disease free 
survival of platinum compound treated African Americans head and neck cancer patients (OS HR 
= 0.62 (0.45, 0.86), DFS HR = 0.51 (0.30, 0.86)) 309. Epithelial ovarian cancer cohort study showed 
that median PFS of patients carrying the Lys/Lys and Lys/Gln+Gln/Gln genotype of the XPC mis-
sense SNP rs2228001 (Lys939Gln/C2704A) polymorphism were 25 and 12 months (P=0.039), OS 
of patients was 31.1 and 27.8 (P=0.048). Additionally, patients with the Gln allele had an increased 
risk of death (HR=1.75; 95% CI=1.06-2.91) compared Lys/Lys genotype 310. This polymorphism 
also showed similar association in NSCLC patients. The heterozygous A/C genotype carriers had 
a poorer response rate than the wild A/A genotype carriers (P = 0.023) 311. Additionally, rs2228001 
was associated with higher toxicity in NSCLC patients treated with platinum based therapy. T allele 
was associated with higher hematological toxicity (OR: 7.50, 95 % CI: 0.89-63.17, p = 0.036) 308. 
rs2228001 CC genotype was also associated with ototoxicity in cisplatin-treated osteosarcoma 
patients (P-value= 0.042) 312. Furthermore, rs2228001 (Lys939Gln) was significantly associated 
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with grade 3 or 4 neutropenia (p = 0.0026) and grade 3 or 4 hematological toxicity in blader cancer 
patients receiving platinum based chemotherapy. Gln/Gln or Lys/Gln + Gln/Gln genotypes of XPC 
had higher toxicity compared with Lys/Lys (OR: 10, p = 0.0070 vs OR: 6.3, p = 0.0069; 
respectively) 313. rs3731108 (AG)/AA genotype versus the GG genotype was associated with 
prolonged a PFS of 21.3 months versus 13.4 months (P = .03) with stage III and IV papillary serous 
ovarian cancer. Similarly, rs1124303 (GT)/GG genotype versus the TT genotype was associated 
with a prolonged PFS of 22.8 months versus 14.9 months (P = .03) in same patient’s cohort 
314(Fleming ND.et al 2014 PMID: 21751198). Another SNP, XPC rs2228000 (Ala499Val) 
significantly associated with lung cancer survival (P = 0.002). Among 185 stages III-IV NSCLC 
patients treated with platinum-based chemotherapy 315.  
XPB/ERCC3 is located at chromosome 2q14.3 with 15 exons and 9 splice variants. XPB/ERCC3 
is also associated with platinum drug response in different cancers. For an example, rs3738948 was 
associated with platinum drug response in NSCLC patients. A/A genotype achieved poor response 
(68.3%) compare to A/G and G/G genotype (100% and 89.3%) (p = 0.008) 306. 
XPD/ERCC2 (chromosome 19q13.32; 24 exons and 12 splice variants missense variant rs13181 
(2251A>C or Lys751Gln) was associated with nephrotoxicty in platinum drug treated NSCLC 
patients 308. G allele and T allele carrier patients showed significantly lower nephrotoxicity (p = 
0.017 and p = 0.029) than in other patients 308. The XPD synonymous SNP Asp312Asp rs1799793 
(G312A), and XPD Lys751Gln (rs13181) were significantly associated with NSCLC patient’s 
response to platinum drugs therapy 316-319. Patients with Lys/Gln genotype was 0.400 times 
chemotherapy sensitivity compare with Lys/Lys genotype (P < 0.05). Furthermore, Lys/Lys vs 
Lys/Gln had significant differences in PFS. Whereas, Asp/Asp vs Asp/Asn genotype also showed 
similar association 316-319. In 93 NSCLC patients significant difference was observed in OS between 
XPD Asp312Asp and Asp312Asn individuals (20.0 vs 12.4 months, P=0.04) 320. Similar result was 
observed in another study in NSCLC patient’s cohort, where median RFS (relapse-free survival 
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duration) CC, CT heterozygous and TT mutant allele genotypes were 28.3 months, 46.9 months 
and 80.1 respectively. Furthermore, median RFS was longer in mutant group (P = 0.018) 321. 
Another study also reported that, XPD 312 C/T+T/T and XPD 711 C/T+T/T (rs1052555) associated 
with poor responses to platinum based chemotherapy in 496 and 375 NSCLC patient’s cohort. 
Furthermore, median PFS and OS of patients of XPD 312 C/T+T/T genotype and XPD 711 
C/T+T/T genotype was significantly lower compare to wild-type homozygous patients 322-324. XPD 
Lys751Gln (A>C) polymorphism was also significantly associated with decreased PFS in Asians 
NSCLC patient’s population treated with platinum based drug (P=0.879) 325. Variant genotypes of 
XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln  formed haplotype and were significantly 
associated with poorer NSCLC survival.  The most common haplotype GCA (Asp(312)Asn, 
Asp(711)Asp and Lys(751)Gln) exhibited significant risk effect on NSCLC survival (P = 0.001). 
ERCC2 Lys751Gln was also associated with survival outcome of metastatic breast cancer patients 
treated with carboplatin-containing chemotherapy 326. These two SNPs were also associated with 
Grade 4 neutropenia and nephrotoxicity in advanced NSCLC, ovarian cancer and advanced gastric 
cancer (AGC) patients treated with platinum based chemotherapy 263, 265, 313, 327.  In 73 metastatic 
colorectal cancers patient cohort, rs13181 Lys/Lys genotype responded well (P = 0.015). The 
median survival for those with the Lys/Lys genotype of rs13181 was 17.4 compare to 12.8 and 3.3 
months for patients with the Lys/Gln and Gln/Gln respectively (P = 0.002). Lys751Lys and the 
Asp312Asp polymorphism are linked and they form a haplotype (P < 0.001)  328, 329. Similar result 
was observed in another study, ERCC2 rs13181T>G, the G allele was associated with reduced 
response and poor PFS and OS in Caucasians 330. There is evidence that, these two polymorphism 
affected response and prognosis of bladder cancer patients treated with platinum based 
chemoradiotherapy 331. XPD 751 A/A also showed a significant longer survival in the squamous 
cell carcinoma (P=0.034) and ovarian cancer treated with platinum based chemotherapy 249, 332. 
These two polymorphisms were associated with event-free survival (EFS) in 130 patients with 
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high-grade osteosarcoma receiving platinum based therapy 333. Similar result was reported from 
another study, where ERCC2 rs13181 G allele was significantly associated with shorter event-free 
survival (P-value=0.021)312. Colorectal cancer patients with XPD751 Lys/lys genotype were 
associated with 3.8-fold increase in failure of chemotherapy compared to Lys/Gln. The median 
time to progression (MTTP) were 11.3 months vs 2.9 months for patients with Lys/Gln and Gln/Gln 
genotypes (P < 0.05)334. Furthermore, XPD Lys751Gln rs13181 (A751C) was significantly 
associated with Event-free survival and OS in patients receiving oxaliplatin. Patients with C allele 
had a shorter median event-free survival and OS (6 months vs 11.6 months p = 0.008, 15.6 vs 25.3 
months p=0.016) 335-337.  In addition, GA+AA genotypes of XPD rs1799793 were associated with 
improved response to platinum chemotherapy of gastric cancer patients and a significantly 
decreased risk of mortality 338. AA genotype of ERCC2 rs1799793 was also associated with a better 
response to chemotherapy, longer OS in gastric cancer patients 339).  A synonymous SNP in XPD 
gene rs238406 Arg(156)Arg (homozygous minor allele) was associated with increased risk of grade 
3 or 4 leukopenia (P=0.005) in non-small cell lung cancer patients in a Chinese population receiving 
platinum based chemotherapy. Further, Arg(156)Arg (rs238406) polymorphism was also 
significantly associated with grade 3 or 4 hematologic toxicity (; P = 0.009), and severe leukopenia 
(P= 0.005) 340, 341. Furthermore, haplotype "CG" of (Arg(156)Arg-Asp(312)Asn) associated with 
grade 3 or 4 hematologic toxicity 340. ERCC2/XPD rs238406 SNPs were poorer DFS and OS of 
572 esophageal squamous cell cancer (ESCC) patient’s treated with platinum drugs. Hazard ratio 
for TT vs. GG+GT for DFS and OS was HR = 1.43, P = 0.020 and HR = 1.52, P = 0.008 342. The 
XPD SNP rs50872 was associated with median survival duration, poor survival and grades 3 and 
4 infections in NSCLC patient’s population receiving platinum based treatment. Median survival 
for G/G, A/G, and A/A genotypes was 35.75, 36.07 and 16.75 months, respectively (p<0.001). 
Additionally, rs238405 and rs238416 was significantly related to OS 233. 
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XPF/ERCC4 is a 32,204 bases long gene located at chromosome 16p13.12. It has 14 exons along 
with 8 splice variants. Low XPF expression in HNSCC patients is associated with better response 
to induction chemo-radiotherapy, while high XPF expression correlates with a worse response 
(p = 0.02) in advanced head and neck cancer receiving platinum therapy 343. The XPF/ERCC4 
(rs12926685) CT+CC genotype versus the TT genotype was associated with a prolonged PFS of 
16.7 months versus 12.4 months (P = .03) in 139 patients with stage III and IV papillary serous 
ovarian cancer treated with platinum based therapy 314.  ERCC6-Q524* and ERCC4-A583T were 
related with favorable response to first-line platinum-based chemotherapy in advanced-stage high-
grade serous EOC. ERCC4-A583T is missense mutation somatic mutation associated with 
heterozygous loss or complete loss of functional ERCC4, while ERCC6-Q524 is a nonsense 
mutation 344. Synonymous SNP, rs1799801 in the ERCC4 gene significantly correlated with the 
relative risk (RR) in advanced NSCLC patients receiving platinum based therapy. Patients with the 
T/T genotype showed a significantly lower RR than compare to T/C or C/C genotype (25.0% vs 
44.7%; OR: 3.30; 95% CI: 1.19–10.00; p = 0.021)306. 
ERCC5/XPG is located on chromosome 13 (13q33) with 15 exons and 8 splice variants. ERCC5 
rs1799977 (His46His), a synonymous polymorphism, were associated with clinical outcomes of 
378 advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based 
chemotherapy regimens. NSCLC patients carrying the ERCC5 46T/T genotype had increased PFS 
and OS, with 0.52 (0.31-0.96) 345, 346. In 228 advanced NSCLC patient’s cohort among three tag-
single nucleotide polymorphisms rs2094258, rs751402, and rs2296147 in the ERCC5 promoter 
region. The rs751402 AA genotype was associated with a better treatment response (AA vs. 
AG+GG: odds ratio (OR)=2.74, 95% confidence interval (CI) 1.04-7.26, P=0.036). Additionally, 
in the subgroup of patients with squamous cell carcinoma rs751402 AA genotype showed stronger 
association (AA vs. GG: OR=6.40, 95% CI 1.15-35.50, P=0.043; AA vs. AG+GG: OR=6.12, 95% 
CI 1.15-32.52, P=0.019). This result also suggested that ERCC5 rs751402 AA genotype increased 
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the chemotherapy response in advanced NSCLC, especially in patients with squamous cell 
carcinoma 347. Furthermore, ERCC5/XPG rs2094258 and rs873601 also showed poorer DFS and 
OS among patients with resected esophageal squamous cell cancer (ESCC) patients. rs2094258, 
CT+TT vs. CC: for DFS hazards ratio = 1.68 and P = 0.012; and for OS hazard ratio = 1.99 and P 
= 0.0001), whereas for rs873601 GA+GG vs. AA, DFS hazard ratio = 1.59 and P = 0.024; OS 
hazard ratio = 1.91 and P = 0.0005 342. Another study reported similar associations where CT+TT 
genotype of rs2296147 had a significantly longer median PFS and OS than CC genotype. Similarly, 
rs2094258 AG+GG genotype had a longer median progression time and OS time than AA genotype 
(348. ERCC5 (D1104H) rs17655 was related with more infection (P = 0.017) in 388 stage IIIB and 
IV NSCLC patients treated with platinum-based chemotherapy 349. Additionally, ERCC5 
(D1104H) rs17655 was associated with OS (P = 0.004) for lung cancer patients and with PFS for 
ovarian cancer receiving platinum-based chemotherapy 350, 351. The polymorphism rs751402 
located in the 5’ UTR of ERCC5 generates a ORF (G= no ORF vs A= ORF) that controls the 
expression of ERCC5. AA expresses a significantly lower level of the uORF that results in higher 
levels of ERCC5 protein. cancer patients who carried the A allele were more resistance platinum 
chemotherapy due to relatively high rates of repair of platinum–DNA adducts within tumors 352. 
Further, platinum drug treated NSCLC patients carrying the 5’ UTR variant rs2296147 TT and the 
3’ UTR variant rs873601 GG genotypes were significantly associated with favorable outcome for 
PFS and OS 353. Furthermore, a significant decreased risk of death was observed among patients 
carrying the rs2296147 TT genotype compared with the CC genotype 354. In addition, patients with 
the rs1057768 (C/T) TT genotype had a significantly lower treatment response, short median PFS 
and OS compared with the rs1057768 CC genotype respectively in NSCLC patient receiving 
platinum based therapy 354. 
The ERCC1 gene is located on chromosome 19 (19q13.32). It is 71,496 bases long gene along with 
14 exons and 17 transcripts or splice variants. Increased ERCC1 expression associated with 
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Platinum drugs resistance in various cancers including ovarian, NSCLC, nasopharyngeal, 
esophageal, cervical, head and neck squamous carcinoma, liver, osteosarcoma, lung 
adenocarcinoma, biliary tract adenocarcinoma, mesothelioma, pulmonary adenocarcinoma, 
bladder cancer, gastric cancer, adrenocortical carcinoma and urothelial carcinoma 208, 211, 213, 267, 299, 
302, 355-373. EOC patients treated with platinum-based chemotherapy were significantly associated 
with time to progression (TTP) and OS. OS was significantly longer with low expression group 
compared with patients showing high expression of ERCC1 protein 374. Another study reported that 
patients with ERCC1-positive tumors had significantly shortened progression-free (p<0.00001) and 
OS (p=0.0006) compared to patients with ERCC1-negative tumors 375-378.  In advanced cervical 
cancer patients with negative ERCC1 expression associated with response to Platinum based 
chemotherapy (p=0.021) as well as disease-free survival for this Patients (p=0.046) 379. ERCC1 
expression also found to be associated with outcome in gastric cancer patients receiving platinum 
drugs. Meta-analysis of twenty-one studies involving 1,628 patients of gastric cancer showed high 
ERCC1 expression was significantly associated with shorter OS and lower response to 
chemotherapy in advanced GC patients receiving platinum based chemotherapy (HR 1.83; 95 % 
CI 1.45-2.31; P < 0.001; RR 0.49; 95 % CI 0.38-0.62; P < 0.001) 380-388. Many studies have 
demonstrated a correlation between low levels of ERCC1 and increased survival in NSCLC patients 
treated with cisplatin 389 as well as carboplatin 390-416. On the other hand, high levels of expression 
of ERCC1 mRNA and protein both found to be associated with resistance to cisplatin in NSCLC 
389. Non-small cell lung cancer (NSCLC) and gastric cancer patients treated with platinum-based 
chemotherapy showed absence or low expression of ERCC1 was associated with longer disease 
free survival DFS (P=0.037, P < 0.0001, P = 0.018) and longer OS (P = 0.007) 417. Low ERCC1 
expression level was correlated with longer OS (HR (95% CI) of NSCLC patients treated with 
platinum based therapy. Additionally, NSCLC patients with ERCC1 low expression also had a 
better PFS (P < 0.05) for platinum based chemotherapy. On the other hand, high expression of 
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ERCC1 was found to be associated with poor prognosis (P<0.001) and decreased survival rates in 
lung cancer patients treated with platinum based chemotherapy 417.  
A multivariate analysis in platinum-based chemotherapy, low expression of ERCC1 was shown to 
be an independent predictive factor for response to chemotherapy (P = 0.018), time to progression 
(P = 0.025), and OS (P = 0.038) 418. As ERCC1 increased, the probability of response decreased 
(P = 0.083), the risk of progression (ERCC1, HR = 1.59, P = 0.002; and death (ERCC1, HR = 1.62, 
P = 0.008) increased 418. Tumor samples from patients enrolled in the International Adjuvant Lung 
Cancer Trial concluded that patients with ERCC1-negative tumors appear to benefit from adjuvant 
cisplatin-based chemotherapy 419-422.  Similarly, for patients treated with carboplatin, ERCC1 
expression was correlated with OS. The median OS for high expressed ERCC1 patient’s vs low 
expressed group was 9.5 months (95% CI 6.7 to 11.8) vs 15.6 months (95% CI 11.6 to 24.8) 423. In 
another study, a NSCLC patient’s group treated with carboplatin and paclitaxel combination 
therapy, the prognosis was significantly better of the ERCC1-negative group compare to ERCC1-
positive group (P= 0.014) 387, 424, 425. Additionally, meta-analysis evaluated the relationship between 
ERCC1 expressions and the clinical outcomes including overall response rate (ORR), OS or PFS 
on 1129 patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy. 
Analysis indicated that positive/high ERCC1 expression was associated with unfavorable OS 
(HR = 1.18, 95%CI = 1.02-1.37) and PFS (HR = 1.46, 95%CI = 1.14-1.88) 426-428. ERCC1 was also a 
predictor of shorter survival in Asians and Caucasians for head and neck squamous cell carcinoma 
(HNSCC) patients treated with platinum-based treatment. High ERCC1 expression was associated 
with unfavorable OS (p = 0.009), PFS (p = 0.000) and ORR (p = 0.044) 429, 430. Furthermore, ERCC1 
was also associated with higher objective response, median PFS, and median OS in patients with 
advanced bladder cancer treated with platinum-based chemotherapy. Patients with ERCC1 
low/negative expression showed significantly prolonged median OS time and the median PFS time 
compared to ERCC1 high/positive expression (hazard ratio 0.69, 95% CI 0.54-0.89, P=0.004, and 
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hazard ratio 0.76, 95% CI 0.66-0.89, P=0.000, respectively) 384, 431, 432. In malignant pleural 
mesothelioma (MPM) patients receiving platinum based chemotherapy, a significant association 
was found between ERCC1 protein levels and OS (P = .032) 292, 433. ERCC1 was also associated 
with clinical outcomes in patients with pulmonary adenocarcinoma treated with 
pemetrexed/cisplatin as first-line chemotherapy. Low ERCC1 expression was significantly 
associated with better relative risk (RR) (p = 0.015) and longer PFS (p = 0.004). Low ERCC1 
expression was also associated with longer OS (p = 0.003) 434. Nasopharyngeal cancer patients 
treated with platinum (cisplatin) based chemotherapy also showed that ERCC1-negative tumors 
had longer disease-free survival (p = .076) and OS (p = .013) than patients with ERCC1-positive 
tumors 435. Similarly, in biliary tract adenocarcinoma (ABTA) patients treated with platinum-based 
chemotherapy median PFS was (4.6 vs. 1.9 months, p = 0.014) and OS was (9.1 vs. 7.9 months, p 
= 0.017) in ERCC1-negative group than in ERCC1-positive group, respectively. Furthermore, 
disease control rate (DCR) was also better in patients with ERCC1 negative than in ERCC1 positive 
patients (p = 0.048) 415. ERCC1 was also found to associated with pancreatic cancer patients treated 
by platinum based chemotherapy Median survival, longer time to progression was significantly 
higher in group with low ERCC1 levels (Median survival, 11.9 versus 9.9 months, p ≤ 0.05) 436. 
Similarly, ERCC1 expression also correlated with lack of response (P=0.006) and poor disease-
specific (P=0.020) and OS (P=0.040) in gastro-esophageal cancer patients receiving platinum-
based chemotherapy 437. Furthermore, ERCC1 expression was strongly correlated with poor 
prognosis and OS in adrenocortical carcinoma (ACC) patients treated with platinum-based 
chemotherapy. OS was eight months in high ERCC1expressed group whereas, 24 months in low 
ERCC1 expressed group (P=0.004) 438, 439.   
Figure 1.11 summarizes the structure of ERCC1 gene along with pharmacogenomically relevant 
polymorphisms that are associated with treatment outcome of platinum based chemotherapy. 
ERCC1 rs3212986 (C8092A), a missense mutation (Gln506Lys), was found to be associated with 
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response to platinum based therapy in gastric cancer patients. AA genotype was associated with 
lower rates of complete remission and partial remission along with higher risk of death in gastric 
cancer patients 440. Similarly, rs3212986, CA and AA genotypes associated with a poorer response 
to chemotherapy compared to the CC genotype (P = 0.04, P = 0.01). Patients with the AA genotype 
associated with longer OS time when compared with the CC genotype (34.91 months vs. 51.19 
months, P = 0.003) in gastric cancer patients receiving platinum based therapy 441, 442. In gastric 
cancer patients another SNP rs11615 was also found with clinical outcome. TC+CC genotypes 
were associated with significantly decreased risk of mortality (hazard ratios = 1.71, 95% CI, 1.06-
2.72) 338. CC genotype of ERCC1 rs11615 was associated with a better response to chemotherapy 
in gastric cancer patients. CC genotype significantly associated with a longer OS of gastric cancer 
330, 339. rs3212986 was also associated with PFS in NSCLC patients. ERCC1 mRNA levels were 
lower in CC homozygous patients compared with the patients carrying the A allele (p = .024)443. 
NSCLC patients with rs3212986 CA genotype significantly contributed to poorer disease-free 
survival (DFS) and OS than those with the CC genotype (p=0.037 and 0.004) 444, 445. rs3212986 
was also found to be associated with a significantly increased risk of grade 3 or 4 gastrointestinal 
toxicity (P = 0.03) in NSCLC patients. Patients with the variant allele of the SNP showed grade 3 
or 4 gastrointestinal toxicity (odds ratio, 2.33; 95% confidence interval, 1.07-5.05)  417. Among 128 
advanced NSCLC patients treated with platinum-based chemotherapy, a statistically significant 
association was observed between the rs3212986 (C8092A) polymorphism and OS (P = 0.006, by 
log-rank test), with median survival times of 22.3 (C/C) and 13.4 (C/A or A/A) months, 
respectively, suggesting that any copies of the A allele were associated with poor outcome 444, 445. 
Furthermore, rs3212986 was found to be associated with survival of platinum chemotherapy treated 
Esophageal squamous cell carcinoma patients (P = 0.01). Homozygous mutant allele (AA) showing 
the most significantly reduced survival (P = 0.04) compared to (CC) 446. ERCC1 polymorphism 
rs3212986 C/A was also associated with PFS and OS of epithelial ovarian cancer (EOC) patients. 
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The CA or AA genotypes could influence OS (HR = 1.28, 95% CI = 1.05-1.56; and HR = 1.55, 95% 
CI = 1.17∼2.05, respectively) 247, 447-449. On the other hand, rs3212986, C/C wild-type genotype 
significantly associated with PFS (P = 0.034) in platinum treated malignant mesothelioma (MM) 
patients 450.  
In NSCLC, the synonymous coding SNP rs11615 (Asn118Asn), was also found to be associated 
with response against platinum based chemotherapy. Patients with C/C showed better response 
compare to C/T + T/T genotype (P = 0.007) 243, 257, 315, 451. Similarly, OS was significantly longer in 
patient’s C/T or T/T allele compare to C/C allele (P=0.014) for rs11615 332, 426, 452. rs11615 was also 
found to be associated with ERCC1 expression and platinum drug treated EOC patient’s outcome. 
TT genotype had a significantly poor response (OR = 6.22, 95%CI:1.12-34.42), shorter PFS (HR 
= 2.19, 95%CI:1.14-4.22, P = 0.009) and OS (HR = 2.22, 95%CI:1.06-4.64, P = 0.021) to platinum-
based chemotherapy 366, 382, 453, 454. On the other hand, rs11615 was also associated with the risk of 
anemia in platinum drug treated ovarian cancer patient. Risk was higher for T allele compare to C 
allele (T > C; p = 0.031, OR = 1.61, 95% CI = 1.04-2.50) 249, 455, 456. In osteosarcoma patient’s 
rs11615, T/T was strongly associated with a higher event free survival compared to C/C genotype 
457. Furthermore, ERCC1 C/C significantly associated with better survival and longer survival of 
colorectal cancer patients treated with platinum based chemotherapy 273, 328, 458, 459. Furthermore, 
rs11615 polymorphism was associated with therapeutic response in Caucasian patients. Meta-
analysis study reported that C allele was found to be associated with better patient response 
platinum based therapy 460. Furthermore, rs11615 TT genotype and T allele and rs3212986 AA and 
A allele were associated with a poor response and higher risk of death from platinum treated 
NSCLC patients 255, 454, 455, 461-471. In a study concerning ovarian cancer patients (n=280) median OS 
was 45, 40 or 30 months for the rs3212986 (C8092A) genotype CC, CA and AA, respectively. 
Patients with CA+AA versus CC in had increased risk of death (p=0.077) 265, 327. rs3212986, 
rs11615 were significantly associated with OS in T4 breast cancer patients treated with 
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chemotherapy containing platinum (p-values = 0.036 and 0.004, respectively). combination of 
these two genotypes found to be played a role as significant prognostic factor in T4 breast cancer 
patients receiving platinum-based chemotherapy (p-values = 0.022 and 0.049, respectively) 472. 
rs11615, the T/T genotype was found to be associated with prolonged median cancer-specific 
survival (p = 0.026) in platinum treated advanced urothelial cancer (UC) 473. Additionally, these 
two SNPs rs11615 and rs3212986 were associated with higher risk of nephrotoxicity in ovarian 
cancer and neurotoxicity in advanced gastric cancer patients 456. Another 2 SNPs in ERCC1 5'-
flanking region, -433T>C and 262G>T was associated with decreased ERCC1 RNA expression. 
262G allele is associated with better drug response and longer survival time compared with the 
262T allele in SCLC patients 474.  
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Figure 1.11 Genetic variants in ERCC1 associated with survival/outcome and/or toxicity in patients treated with platinum drug-based 
chemotherapy (Green box denotes coding SNP; Yellow boxes represent non-coding SNPs). 
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Table 1.5 Summary of SNPs in NER pathway genes associated with Platinum chemotherapy. 
SNP ID Gene symbol Cancer Type 
Associated 
Phenotype Associated Genotype PubMed ID (s) 
rs1800975 XPA  NSCLC 
PFS, OS 
XPA23 (A/G+G/G) were associated with 
significantly longer PFS (P = 0.001) and 
overall survival (OS) (P = 0.001) 
19430706 
Survival, 
Progression, 
Risk 
PA23 (A/G+G/G) was associated with poor 
survival (p = 0.008) and increased risk of 
death(p = 0.013), progression (p = 0.016) 
and relative risk (RR). Homozygous G/G 
genotype showed a higher RR than 
patients with G/A or A/A genotype (p = 
0.013). 
 22511383,  25069034 
rs104894131 XPA  NSCLC Toxicity 
XPA -2166T>C was associated with severe 
hematological toxicity in 55 NSCLC 
patients 
 26193985, 23617284  
rs1805160 XPA  Ovarian cancer Recurrence 
HR (AA)= 12.06 (95% CI 1.22–118.76); 
HR(AG+GG) =9.11 (95% CI 1.12–73.90) in 
125 Caucasian patients  
17825393 
rs2607755  XPC Head and Neck cancer OS, DFS 
rs2607755 vs OS (HR = 0.62 (0.45, 0.86)); 
vs DFS (HR = 0.51 (0.30, 0.86)) in African 
Americans head and neck cancer patients 
24487794 
rs2228001 XPC 
Ovarian 
cancer OS rs2228001 (C/A) vs OS (P=0.048) 23621265 
NSCLC Response, Toxicity 
Heterozygous A/C genotype carriers had a 
poorer response rate and higher 
hematological toxicity (p = 0.036.) than 
the wild A/A genotype  
 19434073,  26193985 
Osteosarcoma Toxicity rs2228001 CC genotype was associated with ototoxicity (P-value= 0.042)  19434073 
Bladder 
cancer Toxicity 
rs2228001 was significantly associated 
with grade 3 or 4 neutropenia (p = 0.0026) 
and grade 3 or 4 hematological toxicity.  
21047201 
rs1124303 XPC Bladder cancer PFS 
 rs1124303 (GT/GG) genotype (PFS= 22.8 
months) vs TT genotype (PFS= 14.9 21751198 
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months) was associated with a prolonged 
PFS(P = .03) 
rs3731108 XPC Ovarian cancer PFS 
rs3731108 (AG/AA) genotype (PFS=21.3 
months) vs GG genotype (PFS=13.4 
months) was associated with prolonged 
progression-free survival (PFS) (P = .03) in 
patients with stage III and IV papillary 
serous ovarian cancer.  
21751198 
rs2228000 XPC NSCLC Survival  rs2228000 vs survival (P = 0.002) among 185 stages III-IV NSCLC patients. 21739480 
rs3738948 XPB/ERCC3 NSCLC Response 
rs3738948 A/A genotype achieved poor 
response (68.3%) compare to A/G and 
G/G genotype (100% and 89.3%) (p = 
0.008) 
25069034 
rs13181 XPD/ERCC2 
NSCLC PFS, RFS, Toxicity 
 Patients with rs13181 Lys/Gln genotype 
was 0.400 times chemotherapy sensitivity 
compare with Lys/Lys genotype (P < 0.05). 
Lys/Lys vs Lys/Gln had significant 
differences in PFS and nephrotoxicity (p = 
0.017) 
 26193985, 26124006,  15173214,  
16351803,  23977265,  25596702,  
24260311 
Colorectal 
cancer 
Response, 
EFS, OS 
 Patients cohort with rs13181 Lys/Lys 
genotype responded well (P = 0.015). 
Median survival: Lys/Lys =17.4 months; 
Lys/Gln=12.8 months; Gln/Gln=3.3 (P = 
0.002)in 73 metastatic colorectal cancers 
patient’s cohort . rs13181 was 
significantly associated with EFS and OS. 
Patients with rs13181 C allele had a 
shorter median EFS and OS in patients 
receiving oxaliplatin. 
 11751380,  26125734,  21278243,  
18085999,  18797464,  19432884,  
22967467  
Gastric cancer Respose, PFS, OS 
rs13181T>G, the G allele was associated 
with reduced response and poor PFS and 
OS in Caucasians gastric and colorectal 
cancer patients. 
21278243 
squamous cell 
carcinoma,   
rs13181 showed a significant longer 
survival in the squamous cell carcinoma 
(P=0.034) and ovarian cancer. 
 21676483, 25881102 
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Ovarian 
cancer 
rs1799793 XPD/ERCC2 
Gastric cancer Response, OS, Risk 
 rs1799793 was associated with improved 
response,  longer overall survival (OS) and 
a significantly decreased risk of mortality.  
 26622786,  25542228 
NSCLC OS 
Significant difference was observed in 
overall survival (OS) between XPD 
rs1799793 Asp312Asp and XPD 
Asp312Asn individuals (P=0.04) 
 26124006,  15173214,  16351803,  
23977265,  24841663,  23534713,   
22374424,   24446315 
 rs13181, 
rs1799793 XPD/ERCC2 
NSCLC, 
Ovarian 
cancer and 
gastric cancer 
toxicity 
Toxicity  rs13181, rs1799793 were associated with Grade 4 neutropenia and nephrotoxicity . 
 16649224,  19786980,  19332728 ,  
21047201 
Bladder 
cancer 
Response, 
Prognosos 
rs13181, rs1799793  affected response 
and prognosis. 16880786 
Osteosarcoma EFS 
 rs13181, rs1799793 were associated with 
event-free survival (EFS) in 130 patients 
with high-grade osteosarcoma receiving 
platinum based therapy  
 21826087,  19434073 
rs150461093 XPD/ERCC2 NSCLC Toxicity  rs150461093 associated with nephrotoxicty. 26193985 
rs1052555 XPD/ERCC2 NSCLC Response, PFS, OS 
rs1052555 XPD 711 C/T+T/T  was 
associated with poor responses in 496 and 
375 NSCLC patient’s cohort. Median PFS 
and OS of patients of XPD 711 C/T+T/T 
genotype was significantly lower compare 
to wild-type homozygous patients.  
 23534713,   22374424,   24446315 
rs238406 XPD/ERCC2 
NSCLC Toxicity 
rs238406 vs grade 3 or 4 hematologic 
toxicity (P = 0.009); vs severe leukopenia 
(P= 0.005) 
 22479369,  19458053,  19458053 
Squamous cell 
cancer OS, DFS 
rs238406 SNPs was associated with  
poorer DFS and OS. 27246611 
rs50871 XPD/ERCC2 Head and Neck cancer OS, DFS 
rs50871  vs OS (HR = 0.80); vs DFS (HR = 
0.67). 24487794 
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rs50872, 
rs238405 ,  
rs238416 
XPD/ERCC2 NSCLC Survival, Toxicity 
 Median survival for rs50872 G/G, A/G, 
and A/A genotypes was 35.75, 36.07 and 
16.75 months, respectively (p<0.001); 
rs50872 was also associated grades 3 and 
4 infections; rs238405 and rs238416 were 
significantly related to OS in NSCLC 
patients  receiving platinum based 
treatment. 
22608006 
rs12926685 XPF/ERCC4 Ovarian cancer PFS 
rs12926685 CT/CC genotypes (PFS=16.7) 
vs TT genotype (PFS= 12.4 months)(P = 
.03) 
21751198 
rs3136038,  
rs3136130 XPF/ERCC4 
Head and 
Neck cancer Survival 
rs3136038 and  rs3136130 were 
associated with survival. 24487794 
rs1799801 XPF/ERCC4 NSCLC Risk 
Patients with the rs1799801 T/T genotype 
showed a significantly lower RR than 
compare to T/C or C/C genotype (p = 
0.021.) 
25069034 
 rs751402 ERCC5/XPG 
Squamous cell 
cancer Response 
 rs751402 AA genotype was associated 
with a better treatment response [AA vs. 
AG+GG: OR=2.74, 95% CI=1.04-7.26, 
P=0.036)  
23211354 
Pediatric 
ependymoma Resistance 
 rs751402 AA patients were more 
resistance platinum chemotherapy due to 
relatively high rates of repair of platinum–
DNA adducts within tumors.  . 
26338418 
 rs2296147 ERCC5/XPG NSCLC PFS, OS 
  rs2296147 CT+TT genotype had a 
significantly longer median PFS and OS 
than CC genotype. 
 23621222, 24615519,  23621222 
 rs2094258,  
rs873601 ERCC5/XPG 
Esophageal 
cancer OS, DFS 
 rs2094258 CT+TT vs. CC: for DFS (HR = 
1.68 and P = 0.012); for OS (HR = 1.99 and 
P = 0.0001). rs873601 GA+GG vs. AA, DFS 
(HR = 1.59 and P = 0.024); OS (HR= 1.91 
and P = 0.0005).  
27246611 
rs2094258 ERCC5/XPG NSCLC Progression, Survival 
rs2094258 AG+GG genotype had a longer 
median progression time and OS time 
than AA genotype. 
24353624 
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 rs873601 ERCC5/XPG NSCLC Outcome 
 rs873601 GG genotype  was significantly 
associated with favorable outcome for 
PFS and OS. 
24615519 
rs17655 ERCC5/XPG 
NSCLC Infection rs17655 was related with more infection 
(P = 0.017). 23118991 
 lung cancer 
patients, 
Ovarian 
cancer 
PFS, OS 
rs17655 was associated with OS (P = 
0.004) for lung cancer patients and  PFS 
for ovarian cancer. 
 17855454,  22158331  
Bladder 
cancer Toxicity 
rs17655 is  associated with grade 3 or 4 
neutropenia. 21047201 
rs1057768 ERCC5/XPG NSCLC Response 
rs1057768 TT genotype had a significantly 
lower treatment response, short median 
PFS and OS compared with the CC 
genotype. 
23621222 
 rs11615 ERCC1 
Urothelial 
cancer Survival 
rs11615, the T/T genotype was found to 
be associated with prolonged median 
cancer-specific survival (p = 0.026). 
23148636 
Pancreatic 
cancer Survival rs11615 was associated with survival.  24403499,  18425336 
Osteosarcoma EFS 
 rs11615, T/T was strongly associated with 
a higher event free survival compared to 
C/C genotype 
23098477 
Colorectal 
cancer Survival 
rs11615, significantly associated with 
longer survival  22994779,  22567180,  16144907 
rs3212986 ERCC1 
Malignant 
Mesothelioma PFS 
rs3212986, C/C wild-type genotype 
significantly associated with progression-
free survival (PFS). 
21765044 
Esophageal 
cancer Survival 
rs3212986 was found to be associated 
with survival. 25191856 
rs3212986, 
rs11615 ERCC1 Gastric cancer 
Remission, 
OS 
rs3212986 and rs11615,  were associated 
with remission, risk of mortality and OS. 
27173253,  26823845,  26722542,  
26622786,  25542228,  21278243 
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NSCLC PFS, DFS, OS, Toxicity 
rs3212986 and  rs11615  were associated 
with PFS, DFS, OS, death risk, 
Nephrotoxicity, gastrointestinal toxicity. 
 25647444,  19361884, 25250341,  
24958519,  22532140,  21739480,  
22932088,  24859833,  23727606,  
22031394,  23226053,   20462983,  
20351547,  20143185,  20070981,  
19362955,  24370899,  24338713,  
24045016,  21676483, 15277258,  
15297394,  15746057, 17222938 
Ovarian 
cancer 
PFS, OS, 
Toxicity 
rs3212986 and rs11615 polymorphism in 
ERCC1 were associated with PFS, OS , 
anemia and nephrotoxicity in epithelial 
ovarian cancer (EOC)  
 24499239,  23632208,  19203783,  
18640939,  24444563,  25881102,  
22329723,  21496891,  19786980,  
19332728, 18024864, 17961161, 
23632208 
Brest cancer OS rs3212986, rs11615 were significantly associated with OS in T4 breast cancer 25253066 
rs2298881 ERCC1 SCLC Response, Survival 
262G allele is associated with better drug 
response and longer survival time 
compared with the 262T allele  
18451256 
71 
 
1.3.4.2.4 Homologous recombination DNA repair (Double strand break) gene 
The XRCC1 gene is located on chromosome 19q13.31 (17 exons, 9 splice variants). XRCC1 
expression is a prognostic marker for survival in different cancer patients receiving platinum 
therapy. Positive XRCC1 was associated with twofold increase risk of death (p = 0.007) and 
progression (p < 0.0001) and progression free survival [p = 0.003], as well as adverse reactions in 
ovarian cancer 217. XRCC1 expression was associated with disease-specific mortality (P=0.024) in 
bladder cancer patients treated with platinum chemotherapy 359.  
The major polymorphisms in this gene associated with platinum based chemotherapy are the 
missense SNPs rs1799782 (Arg194Trp/C580T) and rs25487 (Arg399Gln/G1196A).   
The rs1799782 TT genotype and the CT genotype showed higher efficacy the CC genotype 
whereas, rs25487 GG genotype was found more sensitive to chemotherapy compared with the AG 
genotype 256, 289, 317, 324, 346, 397, 468, 475-482.  
rs25487 399A/A genotype was significantly associated with longer PFS and OS in 378 lung cancer 
patients treated with platinum based chemotherapy260, 345, 483, 484. XRCC1 rs25487 is also associated 
with the clinical outcome of platinum-based chemotherapy in gastric cancer patients. A allele was 
found to be significantly associated with poor OS (HR = 1.40; 95%CI = 1.04-1.90) of gastric cancer 
for platinum-based chemotherapy327, 485, 486. XRCC1 rs25487 was also associated with reduced 
relative risk (RR) to platinum-based chemotherapy in gastric and colorectal cancer patients. Odds 
ratio for A/G + A/A vs G/G was 0.73; 95% CI, 0.55-0.96 487-489. Severe neutropenia was associated 
with rs25487 Arg/Arg genotypes in ovarian cancer patients 265. rs25487 was also shown 
significantly associated with improved cancer-specific survival in bladder cancer patients receiving 
platinum drugs (P=0.009) 331. Ovarian cancer patients bearing the Trp/Trp genotypes of the 
missense mutation rs1799782 had longer survival time than Arg/Arg genotype and rs25487, 
Gln/Gln genotypes had 0.44-fold risk of death than Arg/Arg genotype. The combination of both 
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194 Trp and rs25487 (Arg399Gln) 399 Gln allele was found to be associated with decrease risk of 
death in ovarian cancer patients treated with platinum based drugs 490, 491.  
Furthermore, rs1799782 was also associated with severe hematological toxicity.  The odds ratio 
(OR) of was significantly lower in patients carries T allele (OR = 0.22, 95 % CI: 0.06-0.82, p = 
0.018) in NSCLC patients treated by platinum based drugs 308.  
In addition, rs1799782 (Trp vs. Arg, OR=1.342, 95% CI: 1.176) was shown associated with 
increased risk of cervical cancer and better response to platinum drugs, whereas rs25487 allele A 
was linked with a poor response 492-495. rs25487 was also found to be associated with clinical 
response in platinum drugs treated NSCLC patients. GA or GG genotypes had better response than 
AA genotype P = 0.028). Additionally, Patients carrying CT or TT genotypes of rs1799782 of 
XRCC1 showed more sensitive to platinum-based chemotherapy compared to patients with CC 
genotype (P = 0.002) in NSCLC patients 496. A meta-analysis study that included total of 53 studies 
with 7433 advanced lung cancer patients reported that Trp/Trp and Trp/Arg genotypes of 
rs1799782 was found to be associated to better response rates to platinum-based chemotherapy 
compared to Arg/Arg genotype (TrpTrp+TrpArg vs. ArgArg: odds ratio (OR) = 2.02, 95% CI, 1.66-
2.45) whereas the Gln/Gln and Gln/Arg genotypes of rs25487 were significantly associated with 
the poorer response rates compared with the Arg/Arg genotype (GlnGln +GlnArg vs. ArgArg: 
OR = 0.68, 95% CI, 0.54-0.86)497. In another meta-analysis study also concluded that rs1799782 
(Arg194Trp) was significantly associated with the efficacy of platinum-based chemotherapy in 
NSCLC 498(Fan X. et al PMID: 26458583). In 122 pancreatic cancer stage-III/IV patients’ rs25487 
and rs1799782 were associated with clinical response to platinum drug therapy. Arg399Gln + 
Gln399Gln genotypes had a worse prognosis in pancreatic cancer patients receiving platinum based 
therapy 499.  
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XRCC2 is a 31,387 bases long gene located at chromosome 7q36.1. It has 3 exons and 2 splice 
variants. A 5′ flanking SNP rs6464268 in XRCC2 was associated with toxicity in esophageal 
adenocarcinoma patients, who received cisplatin-based preoperative radio-chemotherapy. Patients 
with AA genotype had grade 3–4 radiation-related toxicity, compared to GG or GA genotypes (P 
= 0.005) 275. Further, the XRCC2 41657T allele of the polymorphism C41657T was associated with 
significantly higher carboplatin and cisplatin sensitivity than lung cancer patients with 41657C/C 
genotype (P = 0.046 and P = 0.039, respectively) 500 
XRCC3 variants (Chromosomal location 14q32.33; 10 exons; 18 Splice variants; length=17,897 
bases) were found to contribute patient outcome in various types of cancers undergoing platinum 
chemotherapy. The missense coding SNP rs861539 (C18067T/Thr241Met) was found associated 
with clinical outcome of 1024 NSCLC patient’s cohort receiving platinum based therapy. CC 
genotype was related to more resistance to platinum-based chemotherapy when compared patients 
with CT or TT genotypes (P = 0.009) 501. Another meta-analysis study also reported that rs861539 
was associated with good response to platinum-based chemotherapy in NSCLC patients. Odds ratio 
(OR) was 1.509 at 95% CI: 1.099-2.072 for ThrMet/MetMet vs. ThrThr. 502. Similar kind of 
association was observed in platinum drug treated ovarian cancer patients, where Thr/ Thr genotype 
associated with increased risk of death compare to Met/Met genotype 491. Another study showed 
that XRCC3 241 Thr/Met or Met/Met allele was associated with longer OS than Thr/Thr allele 
(19.0 m vs. 12.5 m, p=0.081) in NSCLC patients treated with platinum based combination therapy 
322, 503. The XRCC5 polymorphisms rs1051685 and rs6941 were associated with hematologic 
toxicity in lung cancer patient treated with platinum based compound 501.  
1.3.4.2.5 Translesional Replication DNA repair (SOS) genes 
REV1, REV3, and REV7 are involved in translesional DNA repair mechanism in platinum drug 
metabolism pathway. The G/G genotype of rs240966 (as intronic variant) and A allele of rs456865 
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(an intronic variant) were associated with higher grade 3 or 4 gastrointestinal toxicity in patients 
504.  
NSCLC patients (n=663) treated with platinum based therapy reported that rs240969 and 
rs3218573 was significantly associated with the treatment response (P=0.0082 and 0.036, 
respectively). Additionally, patients with G/G genotype of rs240966 or A allele of rs456865were 
found to be associated with grade 3 or 4 gastrointestinal toxicity 504. 
POLB is located in chromosome 8 (8p11.21). It has 16 exons with 17 splice variants. High POLB 
expression had significantly poorer prognosis than patients with low expression (P < 0.05) in 97 
colorectal cancer patients (CRC) (505. The non-synonymous polymorphism in POLB, P242R, was 
associated with OS (P = 0.018) in 456 lung cancer patients treated with platinum-based agents 350. 
is located in chromosome 5 (5q13.3). Finally, rs3213801 within the gene Polymerase (DNA 
Directed) Kappa (POLK; chromosome 5q13.3) was found to be associated with increased risk of 
death in NSCLC patients treated with Platinum-Based Chemotherapy. Patients with AA genotype 
had a shorter survival compared with AG or GG genotype (P= 0.010) 506. 
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Table 1.6 Summary of SNPs in MMR, NHEJ and SOS pathway genes associated with Platinum drug chemotherapy outcome. 
SNP ID 
Gene 
symbo
l 
Gene Function Cancer Type 
Associate
d 
Phenotyp
e 
Associated Genotype PubMed ID (s) 
rs1412125, 
rs2249825 
HMGB
1 
pt-DNA adduct 
recognition 
Lung Cancer Response 
rs1412125 and rs2249825 were 
significantly associated with response 
in Chinese lung cancer patients.  
24684392 
rs1805412  PARP1 NSCLC PFS 
rs1805412 (Va1762Ala) -762 CC 
genotype was significantly associated 
with poor PFS (CC vs. CT/TT: adjusted 
HR = 1.90, 95 % CI = 1.02-3.52)  
23479135 
hMSH2 
gIVS12-
6T/C  
MSH2 
Mismatch 
repair pathway 
NSCLC Response 
hMSH2 gIVS12-6T/C associated with 
response to cisplatin- or carboplatin-
based chemotherapy in peripheral 
lymphocytes from advanced NSCLC 
patients belonging to the Chinese 
population.    
20458443 
rs26279, 
rs1105524 MSH3 NSCLC PFS 
rs26279 (Ala1054Thr) was associated 
with sensitivity to platinum-based 
chemotherapy (P = 0.014).  rs1105524 
G/A and A/A genotypes showed 
shorter PFS than patients with the G/G 
genotype (P = 0.04).  
25966119 
 rs1799977 MLH1 B-cell lymphoma OS, risk 
 rs1799977 was associated with OS. 
AG/GG genotype displayed an 
increased death risk (hazard ratio [HR] 
= 3.23; P < .001) compared with 
patients carrying the AA genotype.  
21156845 
rs5742933 PMS1 NSCLC OS 
rs5742933  was found significantly 
associated with poorer prognosis on 
OS in a case-cohort of 568 NSCLC 
patients  
21739480 
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rs1799782 XRCC1 
Double strand 
break repair 
pathway 
Ovarian 
cancer Risk 
rs1799782 associated with decrease 
risk of death 
 22983827,   
22938418 
Mesothelio
ma OS 
rs1799782 was associated with overall 
survival(OS)  22982660 
rs25487 XRCC1 
Bladder 
cancer Survival 
rs25487 significantly associated with 
improved cancer-specific survival 24649183 
Ovarian 
cancer Toxicity 
rs25487polymorphism was associated 
with neutropenia  19786980 
  OS, risk 
rs25487 (Arg399Gln/G1196A) was 
associated with the OS and risk. A 
allele was found to be significantly 
associated with poor OS.  
24634242, 24465544, 
19332728, 24224851, 
17593927, 11712813 
Esophageal 
cancer 
Response
, Survival 
rs25487 was found to be associated 
with the response and poor survival 16785472 
rs25487 
and 
rs1799782 
XRCC1 NSCLC Response, Toxicity 
rs25487 and  rs1799782 were 
associated with clinical response and 
hematological toxicity. 
 25784983, 
24938464,  
24737519,  
24729390,  
24446315,  
23549037,  
23479135,  
23167352,  
22705987,  
22551904,  
22339849, 20719167, 
19362955, 19157633,  
15173214,  
27248474, 26585370, 
26458583, 26193985,  
24782167,  
21805378, 17504986, 
22009704 
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Cervical 
cancer 
Risk, 
Response 
rs1799782 was associated increased 
risk of cervical cancer and better 
response to platinum drugs. rs25487 A 
allele was linked with a poor response 
23464469, 19563645, 
18851872,  16875718 
Pancreatic 
cancer Response 
rs25487 and rs1799782 was associated 
with clinical response  22026922 
rs6464268 XRCC2 Esophageal cancer Toxicity 
Patients rs6464268 AA genotype had 
grade 3–4 radiation-related toxicity, 
compared to GG or GA genotypes  
21286719 
rs861539 XRCC3 
NSCLC Resistance 
rs861539  CC genotype was related to 
more resistant to platinum-based 
chemotherapy when compared 
patients with CT or TT genotypes (P = 
0.009) 
27248474,  
23940523, 22374424, 
22152690 
Ovarian 
cancer Risk 
rs861539  Thr/ Thr genotype 
associated with increased risk of death 
compare to Met/Met genotype  
22938418 
rs861539, 
rs1799794 
and 
rs861530  
XRCC3 Gastric cancer Survival 
rs861539, rs1799794 and rs861530 
were associated with survival  21347786 
XRCC3 -
316A>G XRCC3 
Mesothelio
ma Toxicity 
XRCC3 -316A>G was found to 
associated with treatment-related 
toxicity. 
22982660 
rs1051685 
and rs6941 XRCC5 Lung cancer Toxicity 
rs1051685 and rs6941 of XRCC5 were 
associated with hematologic toxicity 26358256 
rs240966, 
rs456865, 
rs240969, 
rs3218573 
REV1, 
REV3, 
and 
REV7: 
Translesional 
Repair 
NSCLC Response, Toxicity 
 G/G genotype of rs240966 and 
rs456865 was associated with higher 
grade 3 or 4 gastrointestinal toxicity.  
rs240969 and  rs3218573 were 
significantly associated with the 
treatment responses. 
26278154 
rs3792136 REV1 NSCLC Risk rs3792136 was associated with increased risk of mortality (P=0.030) .  26611653 
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rs3087403,  
rs462779 REV1 
Osteosarcom
a EFS, OS 
rs3087403 had significantly shorter 
EFS and OS (p = 0.004, p < 0.001 
respectively).  rs462779 was also 
significantly associated with shorter 
OS (p<0.001) and shorter EFS (p = 
0.003) of cisplatin-based 
chemotherapy. 
25748439 
POLB 
P242R POLB Lung cancer OS 
POLB P242R was associated with OS (P 
= 0.018) in 456 lung cancer patients 
treated with platinum-based agents.  
17855454 
rs3213801 POLK NSCLC Survival 
Patients with rs3213801 AA genotype 
had a shorter survival compared with 
AG or GG genotype (P= 0.010)  . 
26611653 
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1.3.4.3 Additional genetic variants identified by genome-wide analysis studies (GWAS) 
Genome--wide gene expression or polymorphism analyses studies (GWAS) are approaches to 
rapidly scan the complete genome or transcriptome to identify highly significant and 
actionable genetic variations associated with a target disease or condition 507, 508. 
GWAS studies that have so far identified gene expression patterns and SNPs with sensitivity 
to platinum drugs are listed in Table 1.7 along with major details 509-513. A GWAS study in 
1,244 EOC patients treated with carboplatin and paclitaxel combination therapy identified two 
SNPs (rs7874043 and rs72700653) in TTC39B which were associated with PFS. On the other 
hand, genome-wide association scan in 334 NSCLC patient’s cohort and 375 patients as 
validation cohort identified a SNP rs2838566 located at 21q22.3. Minor A allele was found to 
be significantly associated with increased risk of liver injury. Additionally, rs13014982 at 
2q24.3 and rs9909179 at 17p12 were also found to be associated with myelosuppression in 
NSCLC patients 514, 515. Additionally, another GWAS study explain SNP (rs11138019) 
association with the expression of gene ABCD2 along with carboplatin and cisplatin response 
516. Associations between NSCLC survival and SNPs were identified by GWAS study in 
Chinese populations. Three SNPs rs7629386 at 3p22.1, rs969088 at 5p14.1, and rs3850370 at 
14q24.3 were associated with worse NSCLC survival while two SNPs rs41997 at 7q31.31 and 
rs12000445 at 9p21.3 were associated with better NSCLC survival. Furthermore, rs7629386 
at 3p22.1 (CTNNB1) and rs3850370 at 14q24.3 (SNW1-ALKBH1-NRXN3) were associated 
with survival in Caucasian population 517. Cell-based GWAS approach have been identified 
single nucleotide polymorphisms associated with platinum susceptibility which were then 
evaluated in head and neck cancer patients treated with platinum-based therapy. Two SNPs, 
rs6870861 and rs2551038 were associated significantly with overall response and expression 
of two important organic cation/anion transporters genes (SLC22A5 and SLCO4C1) which 
are involved in platinum uptake and clearance 518. However, these LCLs are derived from 
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normal healthy individuals and therefore do not represent actual variations of cancer patients. 
Therefore, in vitro findings using these cell lines cannot be reliably validated using patient 
data (518.  Similar approach also discovered SNP rs1878022 in the chemokine-like receptor 1 
(CMKLR1) which was associated with poor OS in 327 advanced-stage NSCLC patients who 
received platinum-based chemotherapy519. GWAS study on SCLC patient cohort identified 3 
loci, 20q13.2 (rs4809957G >A), 22q12.2 (rs36600C >T) and 5p15.33 (rs401681C >T) which 
were significantly associated with the survival time of SCLC patients. Hazard ratio (HR) for 
patients with the rs4809957 GA or AA genotype was 0.80 (P = 0.0187) and 0.73 (P = 0.0263) 
compared with the GG genotype and T allele for rs36600 or rs401681 was 0.78 (P = 0.0199) 
and 1.29 (P = 0.0047) respectively compared with the CC genotype 520. Another study in SCLC 
identified association between rs1820453 T>G within the promoter region of YAP1 on 
chromosome 11q220 and rs716274 A>G in the region of downstream of DYNC2H1 (11q22.3) 
with small-cell lung cancer survival. Functional analysis showed that the rs1820453 T>G 
change creates a transcriptional factor binding site and downregulates YAP1 expression 521. 
GWAS in LCLs for cisplatin cytotoxicity identified rs11169748 and rs2440915 SNPs in 
DAPK3 and METTL6 which were also associated with OS in lung cancer patients 522, 523. 
GWAS approach on brain tumor had identified genetic variations in ACYP2 associated with 
cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10-8; hazard ratio = 4.5) in brain tumors in 
children population 524. 
Epstein-Barr Virus (EBV)-transformed human lymphoblastoid cell lines (LCLs) are used as 
model systems to identify germ-line genetic variations and gene expression associated with 
anticancer drug response. Using Epstein-Barr Virus (EBV)-transformed human 
lymphoblastoid cell lines (LCLs) as model system, SNPs in a number of genes have been 
identified as candidates for platinum-drug and paclitaxel response: The International HapMap 
Project is an organization that developed a panel of EBV-transformed LCLs (Hapmap panel) 
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from populations with African, Asian and European ancestry with a goal to create a publicly 
available catalog of common patterns of human genome variations including SNPs and gene 
expression 525. Genome-wide association analysis with carboplatin and cisplatin cytotoxicity 
(IC50) in HapMap LCLs with European (CEU), African (YRI) and Asian ancestries also been 
reported 526. Association of SNPs and gene expression levels with carboplatin-induced 
cytotoxicity among 89 HapMap LCLs belonging to African ancestry (YRI) has been studied 
and results was validated by using 377 ovarian cancer patients receiving at carboplatin-based 
chemotherapy. SNP rs1649942 could be replicated in an independent LCL set and was also 
found significantly associated with decreased PFS in ovarian cancer patients 527. Another 
Genome-wide meta-analysis of SNPs was associated with carboplatin- and cisplatin-induced 
cytotoxicity among 608 LCLs representing world population panels of diverse ancestry. 
Results showed a rs7572081 located in intronic region of the gene NBAS (neuroblastoma 
amplified sequence) and was most significantly associated with carboplatin cytotoxicity 
(P=5.1 × 10-7). Additionally, rs7210837 was significantly associated with cisplatin IC50 and 
rs244903 (located in the first exon of RARS) associated with carboplatin IC50. rs10138824 
(located in an intron of MPP5-membrane protein, palmitoylated 5), rs8008724 (located in an 
intron of EIF2S1- eukaryotic translation initiation factor 2, subunit 1 alpha) and rs10431718 
(located in an intron of FAM71D-family with sequence similarity 71, member D) associated 
with IC50 of both drugs and the expression of BCL2, GSTM1 (glutathione S-transferase mu 
1) respectively. Furthermore, GSTM1, GSTT1, ERCC2 and ERCC6 were found associated 
with platinum drug response. 528.  
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Table 1.7 SNPs found significantly associated with Platinum drug chemotherapy outcome in GWAS studies
SNP ID (Gene symbol) Cancer Type Associated Platinum-drug Phenotype PubMed ID (s) 
rs7874043, rs72700653 (TTC39B) Ovarian cancer PFS 26840454 
rs201023017 (SLC9A9 ), 
rs66696671 (TIAL1), rs10674174 
(PCDH20), rs1525599 (LRP1B), 
rs2748151 (CDH4), rs12025262 
(ZNF731P), rs150303591 (FRAS1) 
Ovarian cancer 
LCLs 
Associated with cytotoxicity in LCLs developed form EOC patients 
receiving carboplatin combination therapy  27047539 
rs1649942 Ovarian cancer PFS 21705454 
rs2838566, rs13014982, 
rs9909179 NSCLC 
 rs2838566 A allele was significantly associated with increased risk of 
liver injury 
 26100964,  
25823687 
rs11138019 (ABCD2)   Gene expression of ABCD2; carboplatin and cisplatin response.  24739237 
rs7629386 (CTNNB1), rs969088, 
rs3850370, rs41997, rs12000445  NSCLC Worse NSCLC survival  22872573 
rs6870861 (SLC22A5), rs2551038 
(SLCO4C1) 
Head and neck 
cancer  
rs6870861 was associated significantly with overall response and 
expression of SLC22A5, which are involved in platinum uptake and 
clearance. 
21497773 
rs1878022 (CMKLR1) NSCLC Associated with poor OS in advanced-stage NSCLC patients who received platinum-based chemotherapy 21483023 
rs4809957, rs36600, rs401681 SCLC 
 rs4809957 GA or (HR=0.80; P = 0.0187) and AA genotype (HR=0.73; 
P = 0.0263) compared with the GG genotype.  
Patients with rs36600 T allele (HR=0.78; P = 0.0199) compared with the 
CC genotype.  
Patients with rs401681 T allele of rs401681 (HR=1.29; P = 0.0047) 
compared to CC genotype.  
25415319 
rs1820453 (YAP1), rs716274 
(DYNC2H1) SCLC 
rs1820453 T>G within the promoter region of YAP1 associated with 
small-cell lung cancer survival. 21118971 
rs11169748 (DAPK3), rs2440915 
(METTL6) Lung cancer Associated with OS in lung cancer patients  21775533 
rs7572081 (NBAS), rs7210837, 
rs10138824 (MPP5), rs8008724 
(EIF2S1), rs10431718 (FAM71D), 
rs244903 (RARS) 
LCLs Associated with carboplatin cytotoxicity in LCLs 21844884 
rs1872328 (ACYP2) Brain tumor rs1872328 associated with cisplatin-related ototoxicity ( P = 3.9 × 10(-8) in brain tumors in children population.  25665007 
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1.4 Paclitaxel chemotherapy 
 Introduction 
Taxol is a microtubule binding, widely used chemotherapeutic agent 46. It was first isolated from 
the bark of the yew tree (Taxus brevifolia) in 1967 by Monroe Wall and Mansukh Wani529. In 1979, 
Peter Schiff and Susan Horwitz discovered that paclitaxel stimulated microtubule polymerization 
530. Major members include paclitaxel and docetaxel. Basic structure of taxanes. Figure 1.12 shows 
the basic structure of Taxanes along with differences in paclitaxel and docetaxel based on the 
moieties attached to the sites marked R1 and R2 in the basic structure 531. paclitaxel (Empirical 
formula: C47H51NO14; Molecular weight: 853.9 g/mol; Average mass: 853.9 Da; Trade names: 
Abraxane, Taxol, Onxol, Nov-Onxol) was approved for clinical use in 1995 and it is now widely 
used to treat various cancers including breast and ovarian cancer, non-small-cell lung cancer and 
Kaposi’s sarcoma 532. paclitaxel is a mitotic inhibitor that stabilizes microtubules. The stabilized 
microtubules interfere with the normal breakdown of microtubules during cell division leading to 
induction of apoptosis 532-538. 
However, the response rate for paclitaxel based therapy is 65%, however tumor recurrence occurs 
in almost all patients approximately after 15 months 46. Drug resistance is the principal cause for 
90% of the deaths among EOC patients 539. Furthermore, side effects such as severe hypersensitivity 
reactions (sHSR), hematological toxicity mainly severe neutropenia and peripheral neuropathy 
(PNP) are the major challenges for this drugs based chemotherapy 531, 540.   
Lack of reliable biomarkers that would enable prediction of response or association with drug 
related toxicity is another challenge for developing paclitaxel individualized therapy. Identification 
of genes and polymorphisms associated with paclitaxel treatment outcome is the major goal for 
developing new therapeutic strategies with maximum drug efficacy along with decreasing drug 
related toxicity. Here we explore how differential expression and/or activity of genes are involved 
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in paclitaxel pathway and presence of SNPs can have an impact on treatment outcome and toxicity 
in cancer patients being treated with paclitaxel.  
Understanding the pharmacogenomics of paclitaxel will provide an opportunity to identify likely 
responders along with poor responders, non-responders and patients with adverse effects which 
will help to provide better treatment.  
 Mechanism of action of paclitaxel 
Paclitaxel is administered (175mg/m2) in combination with carboplatin (AUC 5–7.5) every 3 
weeks for 6 cycles intravenously for EOC and NSCLC patients 43, 45, 58, 541-545. Paclitaxel diffuses 
through the small openings on the microtubule surface or microtubule lattice fluctuations and binds 
to β-tubulin on the inside surface of the microtubule resulting in a conformational change in tubulin 
form (Figure 1.13) 546. This alteration enhances microtubule assembly, inhibits depolymerisation 
and stability followed by mitotic arrest resulting from lack of microtubule bundling which 
eventually leads to apoptotic cell death (Figure 1.13) 532-538. In addition, after entering the body, 
paclitaxel is metabolized by cytochrome enzymes CYP3A and CYP2C 547-550. The major 
metabolites of paclitaxel are 6-α-hydroxypaclitaxel and p-3’-hydroxypaclitaxel which are formed 
by CYP2C8 and CYP3A4/5 metabolism, respectively (Figure 1.12) 551, 552. Taxol metabolism was 
studied using membrane fractions from Hep G2 cells contain several human cytochrome P450 
enzymes. Only P450 2C8 formed 6 alpha-hydroxytaxol and 3A3 and 3A4 was catalyzed Metabolite 
B formation. The correlation between hepatic 2C8 protein content and 6 alpha-hydroxytaxol 
formation was found to be high (r2 = 0.82) (Rahman et al. 1994). The role of individual 
modifications was then investigated by high-pressure liquid chromatography/mass spectrometry 
using human liver microsomes and recombinant P450 expressed in Ad293 cells 547-549, 549, 550. 
Notably, these metabolites do not have appreciable antitumor activity 553.  
Paclitaxel is excreted (70–80%) in bile as metabolites or as the parent drug by adenosine 
triphosphate- (ATP) binding cassette multidrug transporters including P-glycoprotein (P-gp or 
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ABCC1) and multidrug resistance protein 2 (MRP-2 or ABCC2). Renal clearance occurs only 
about 5–10% of drugs 547-550. 
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Figure 1.12 a) Basic structure of taxanes showing differences in paclitaxel and docetaxel (R1 and R2) 531 b) Major metabolites of 
paclitaxel with the enzymes involved 553. 
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Figure 1.13 Mechanism of action of paclitaxel. 
Figure shows a) binding to tubulin and b) overall schema of events leading up to cellular sensitivity to paclitaxel 532 
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 Metabolic (PK/PD) pathway of paclitaxel 
Transporters are involved in the regulation of intracellular drug concentration for effective 
cytotoxic activity of paclitaxel 554. paclitaxel is a substrate for several cell membrane transporting 
enzymes. paclitaxel enters into the cells through OATP1B3 (SLCO1B3) influx transporter. 
Polymorphism in this gene were found to be associated with paclitaxel pharmacokinetics 555, 556. 
Additionally, OAT2 (SLC22A7) is highly expressed in human liver and was found to transport 
paclitaxel in vitro 557. On the other hand, ATP-binding cassette (ABC) transporters, which include 
48 proteins in humans, is involved in paclitaxel transport. Studies has been shown that inhibition 
of ATP-binding cassette sub-family B member 1 (ABCB1) or P-gp is associated with increased 
level of paclitaxel bioavailability 558-560. Furthermore, it has been reported in several studies that 
ABCB1 was overexpressed in platinum resistant ovarian cancer cells, human lung carcinoma clonal 
cell line and also in other paclitaxel-resistant cell lines 539, 561. Non-small cell lung carcinoma 
(NSCLC) patients receiving paclitaxel therapy with no or low expression of MDR-1/P-gp/ABCB1 
showed better response compared to patients with increased MDR-1/P-gp/ABCB1 expression 
(p<0.05) 562. In ovarian cancer, MDR-1/P-gp overexpression was also found to be significantly 
associated with poorer paclitaxel response and survival (p=0.004) 563, 564. The multi-resistance-
associated protein (MRP) family of transport proteins or ABCC (adenosine triphosphate-binding 
cassette C group) transporters is another class of drug efflux pumps which include ABCC1, ABCG2 
and ABCC2 that are involved in paclitaxel transport as well as development of resistance against 
taxanes 168, 550, 565-569. paclitaxel related neurotoxicity was associated with ABCB1, CYP2C8 and 
CYP3A5 polymorphisms 570-573. 
CYP2C8 and CYP3A4 are key enzymes involved in the metabolism of paclitaxel. CYP2C8 
metabolizes paclitaxel to the primary metabolite 6α-hydroxypaclitaxel whereas, two minor 
metabolites 3'-p-hydroxypaclitaxel and 6α, 3'-pdihydroxypaclitaxel are produced by CYP3A4. 
Extensive inter-individual variations in CYP genes influence paclitaxel treatment response 531, 574-
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576. Furthermore, polymorphisms and gene expression changes in pregnane X receptor (PXR), a 
nuclear receptor involved in CYP enzymes induction and molecular regulation of CYP3A, may 
also contribute to drug resistance to chemotherapeutic agents in cancer patients 577.  
Tubulin and its binding capacity with paclitaxel is a major player in paclitaxel drug resistance 578. 
Altered expression levels of microtubule binding proteins (MBPs) are associated with paclitaxel 
drug response 579-582. For example, microtubule-associated protein (MAP) 7 domain-containing 
protein 3 plays an integral role in breast cancer growth and metastasis 583-585. Sub-categories MBPs 
include canonical MBPs, microtubule-destabilizing proteins, microtubule plus end-tracking 
proteins, and noncanonical MBPs. Canonical MBPs are structural MAPs and bind to the side of 
microtubules to stabilize it by promoting the polymerization and formation of microtubule bundles 
through MAP phosphorylation. MAP2 and tau are the member of this family 586. MAP2 promotes 
paclitaxel sensitivity in breast cancer cell lines 587. Knockdown of tau in breast cancer cells 
increases cancer cell sensitivity to paclitaxel 588. Furthermore, studies reported that low 
concentration of tau is associated with increased paclitaxel binding to microtubules compare to the 
presence of higher levels of tau. So, low tau expression was found to be associated with the greater 
response to treatment whereas, high levels of tau was associated with residual tumor and resistance 
to treatment 589-592. Additionally, overexpression of MAP4 increased microtubule polymerization 
and increased taxane binding with microtubule which resulted in increased sensitivity to the drugs 
593, 594. Microtubule-destabilizing proteins are important regulators of microtubule dynamic 
instability by restoring free α/β-tubulin heterodimers into a ternary complex, resulting in 
microtubule de-polymerization which eventually promotes the formation of spindle microtubules 
595, 596. Stathmin is the most important member of this family. Elevated expression of stathmin plays 
a role in cancer susceptibility to paclitaxel treatment 597, 598. Overexpression of stathmin in breast 
cancer cells significantly decreases the binding of paclitaxel to microtubules and causes paclitaxel 
resistance, whereas, functional knockdown of stathmin using siRNA results in increased sensitivity 
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to paclitaxel 599-602, 602. p53 regulates the expression of the MAP4 and statin 593, 594, 603-605.  
Microtubule plus end-tracking proteins (+TIPs) accumulate at the plus ends of growing 
microtubules and modulate microtubule dynamics and functions. Members of the end-binding 
protein (EB) family are master regulators of the dynamic +TIPs network. EB1 regulates paclitaxel-
induced mitotic arrest and apoptosis. Expression of EB1 is found to be associated with response to 
paclitaxel-based chemotherapy in breast cancer patients  606, 607. CLIP-170 is another member of the 
+TIPs family that is found to be associated with breast cancer cell sensitivity to paclitaxel. Another 
member, Mitotic centromere-associated kinesin (MCAK), shows association with paclitaxel 
resistance through microtubule detachment from centrosomes 608, 609.  
Non canonical MBPs are involved in the regulation of cell proliferation and survival and are also 
associated with paclitaxel sensitivity. Parkin is an important member of this sub-category. Higher 
expression of Parkin is associated with a better response to paclitaxel-containing chemotherapy in 
breast cancer 610. Survivin, is another member that locates to the mitotic spindle during mitosis. 
Upregulation of survivin is associated with paclitaxel resistance in head and neck cancer breast 
cancer cells 611, 612. Lower expression of Spindle genes MAD2 and BUBR1 in breast cancer cell 
lines shows resistance to paclitaxel 613. 
Paclitaxel also has important effects on immune cells including macrophages, dendritic cells (DCs), 
natural killer (NK) cells, effector T-cells, regulatory T-cells (Tregs), and B-cells which eventually 
trigger antitumor immune response. paclitaxel stimulates macrophages, which cause cytotoxicity 
against tumor cells and start anti-tumor immune response 614. In addition, paclitaxel also 
downregulates the expression of the anti-apoptotic molecule Bcl-2 in and upregulates expression 
of the pro-apoptotic member Bax, which leads cells towards apoptosis 615. Furthermore, multiple 
translation factors along with gene-related oxidative stress (UGT1A6, MAOA, and CYBA), 
glycolysis (ADH1A, HK1, and ENO3) and glutathione metabolism are mainly responsible for 
paclitaxel resistance 616-618. Figure 1.14 is a modified version of PharmGKB pathway that 
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represents genes involved in metabolism and transport of paclitaxel and docetaxel, and the 
downstream effects of the drugs 619.  
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Figure 1.14 Metabolic pathway of taxanes. 
The pathway was derived from the PharmGKB database 619
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 Pharmacogenomics of paclitaxel (PK/PD) pathway genes 
Differential gene expression and polymorphisms in genes involved in paclitaxel metabolism 
including influx and efflux transporters, pharmacodynamics and therapeutic targets may be 
associated to the inter-individual variability in response and toxicity.  Here we report the relevant 
genetic variations in the paclitaxel-drug pathway and evaluate their association with chemotherapy. 
We performed a thorough and comprehensive study of the literature on the genes involved on 
taxane or paclitaxel-drug based chemotherapy. Our goal was to evaluate all the studies investigating 
association between gene expression changes and genetic polymorphisms in taxane or paclitaxel 
pathway genes and clinical response to paclitaxel therapy One of our criteria for identifying the 
genes to be selected for the study was based on the pathway information available from the 
resources providing information on key pathways, e.g. KEGG (Kyoto Encyclopedia of Genes and 
Genomes), GO (NCBI’s Gene Ontology database), PharmGkb (The Pharmacogenomics 
Knowledgebase) and PGRN’s (Pharmacogenomics Research Network) drug-specific pathway 
information.. Care was taken to ensure uniformity with respect to gene names and SNP IDs based 
on scientifically accepted notations and nomenclatures.  
The following segment presents the salient genes and genetic variations that have been 
demonstrated to be associated with response to paclitaxel chemotherapy, as well as toxicity. 
1.4.4.1 Pharmacogenomics of efflux-influx transporter and drug metabolizing (PK) genes 
The organic anion transporting polypeptide (OATP)1B3 or SLCO1B3 is a key influx transporter 
for paclitaxel 556. Polymorphisms within this gene have been reported with functional consequences 
555. Two polymorphisms in SLCO1B3, rs4149117 (c.334 T>G, Ser112Ala) and rs7311358 (c.699 
G>A, Met233Ile) were associated with grade 3/4 anemia (P=0.002) in NSCLC patients. As shown 
in Table 1.8, rs7311358 (c.699 G>A) was also associated with overexpression of SLCO1B3 
resulting significantly decreased uptake of paclitaxel compared with the wild-type 620. 
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The OS time and disease-free survival (DFS) were higher in patients with lower expression of ATP-
binding cassette subfamily B member 1 (ABCB1) 621-623. ABCB1 polymorphism rs2032582 (c.2677 
T>G/A) was found to be associated with inferior PFS (hazard ratio=1.49, P=0.017) in NSCLC 
patients 620, 624. Other studies also reported that ABCB1 polymorphisms rs1128503 (1236C>T), 
rs2032582 (2677G>T) and rs1045642 (3435C>T) have been found to be associated with paclitaxel 
response in various cancers including ovarian, lung prostate and breast cancer 247, 570, 622, 625-631, 631-
634, 634, 635. ABCB1 polymorphism rs2032582 (c.2677 T>G/A) was also found associated with grade 
3 or 4 hematological and gastrointestinal toxicities in ovarian cancer patients 247. Additionally, the 
2677 GG genotype showed a significant association with paclitaxel resistance (P = 0.04) 636. The 
ABCB1 polymorphism 3435C>T was associated with increasing risk to develop neuropathy 
(p=0.09) 571. Another study in metastatic breast cancer patients treated with paclitaxel monotherapy 
showed that ABCB1 3435 C>T was associated with lower disease (p = 0.025) as well as shorter 
OS (P = 0.026). A study reported that the synonymous coding SNP rs1128503 (ABCB1; 
Gly412Gly; C1236T) was found associated with increased risk of anemia (p = 0.023) 249. Another 
SNP p.Ser894Ala/Thr in ABCB1 was found associated with the risk of disease progression 
(p = 0,010) in ovarian cancer patients receiving paclitaxel/cisplatin chemotherapy 637. The SNP 
rs2229109 (G1199T/A) in the ABCB1 gene was also shown to be associated with paclitaxel 
resistance in ovarian cancer patients treated with paclitaxel and carboplatin 638.  The ABCA1 SNP 
rs4149313 showed significant (p=0.03) association with thrombocytopenia 639. 
Among SNPs in the ABCC2 gene, rs12762549 (ABCC2, C > G) was associated with decrease risk 
of anemia (p = 0.004) in ovarian cancer patients. rs2073337 (ABCC2, A > G) and rs1695 (ABCC1, 
A > G) was associated with colony stimulating factors (CSF) p = 0.039; p = 0.017, respectively), 
while rs2074087 (ABCC1, G > C) was associated with (p = 0.011) use of erythropoiesis stimulating 
agents (ESAs) 249. rs2725264 in ABCG2 was found to be associated with OS in NSCLC receiving 
taxane-based chemotherapy (P=0.041)238, while the non-synonymous variant in ABCG2, 
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rs2231142 (C421A encoding Q141K, Gln141Lys), was associated with longer median PFS 
(p=0.041) and a reduced risk of disease progression (p=0.022) in NSCLC patients 236. 
CYP2C8 polymorphisms were shown associated with reduced metabolizing activity. Two 
Polymorphisms CYP2C8*3 (R139K; K399R) and CYP2C8*4 (I264M) are common 
polymorphisms in Caucasian population and associated with paclitaxel clinical response 640. 
Patients with heterozygous for CYP2C8*3 showed lower clearance of paclitaxel 570, 641, 642. Another 
study reported that two polymorphisms CYP2C8*2 and CYP2C8*3 associated with two-fold 
higher Km due to lower activity and lower intrinsic clearance of paclitaxel 574. One study found the 
genetic variants CYP2C8*3, and CYP3A5*3 to be associated with paclitaxel-induced toxicity. 
CYP2C8-HapC showed association with lower level values of both leukocytes and neutrophils (p 
< 0.05) than patients with the wild-type genotype. Combining the two genotypes CYP3A5*3/*1 
and CYP2C8-HapC (rs1113129 G/C) showed significant correlation with both leukopenia and 
neutropenia (p = 0.01) 643. Furthermore, in a study in Chinese epithelial ovarian cancer patients 
treated with paclitaxel/carboplatin therapy, CYP3A5*3 (rs776746 G/C) was found to be associated 
with paclitaxel toxicities such as myelo-suppression where CYP3A5*3/*1 genotype showed higher 
risk of developing leukopenia (p < .001) and neutropenia (p < .001) 644. One study reported that 
CYP3A4*1B was found to be associated with paclitaxel pharmacokinetics in ovarian cancer 
patients 570. Another CYP3A4 polymorphism rs4986910 (CYP3A4, T > C) was found to be 
associated with increased risk of thrombocytopenia (p = 0.025) 249. Two other CYP3A4 variants, 
rs2740574 (CYP3A4*1B) and rs35599367 (CYP3A4*22), were found associated with a higher 
CYP3A4 activity and clinical response of ovarian cancer patients treated with first-line paclitaxel 
and cisplatin or carboplatin chemotherapy. Patients carrying the CYP3A4*1BG allele showed 
decreased mean survival rate and lower OS when compared to the AA genotype patients (p = 0.010) 
645. Another study reported that polymorphism CYP3A4*16B was associated with both reduced 3'-
p-hydroxylation of paclitaxel and increased levels of 6alpha-hydroxypaclitaxel. CYP3A4*16B 
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showed lower 3'-p-hydroxypaclitaxel metabolites production (P = .04) and a 2.4-fold higher 
production of 6alpha-hydroxypaclitaxel to paclitaxel (P < .001) compaed with wild-type (1/1) 
patients 646. 
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Table 1.8 Summary of SNPs in efflux-influx transporter and drug metabolizing (PK) genes associated with Paclitaxel 
chemotherapy. 
SNP ID Gene symbol Gene function 
Cancer 
Type 
Associate
d 
Phenotyp
e 
Associated Genotype PubMed ID (s) 
rs2032582  ABCB1 Drug transporter 
Ovarian 
cancer Risk 
p.Ser894Ala/Thr associated with on 
the risk of disease progression 
(p = 0.010). 
25591549 
rs4149313  ABCA1 Drug transporter 
Lung 
cancer, 
ovarian 
cancer 
Toxicity rs4149313 was significantly (p=0.03) association with thrombocytopenia. 22759513 
rs1045642 
ABCB1 Drug transporter 
Advanced 
solid 
tumours  
Toxicity 
rs1045642 was ssociated with 
increasing risk to develop neuropathy 
(P=0.09). 
16950614 
ABCB1 Drug transporter 
Breast 
cancer OS 
rs1045642 C>T was associated with 
lower disease (p = 0.025) as well as 
shorter OS (P = 0.026). 
18836089 
rs1128503 ABCB1 Drug transporter 
Ovarian 
cancer Toxicity 
rs1128503 was associated with 
increased risk of anemia (p = 0.023). 25881102 
rs2032582 ABCB1 Drug transporter 
Ovarian 
cancer Toxicity 
rs2032582 was associated with grade 
3 or 4 hematological and 
gastrointestinal toxicities. 
19203783 
rs2032582, 
rs1128503 
and 
rs1045642 
ABCB1 Drug transporter 
Ovarian, 
lung 
prostate 
and 
breast 
cancer 
Response 
rs2032582 was found associated with 
inferior PFS (P=0.017) and  GG 
genotype associated with paclitaxel 
resistance (P = 0.04) in NSCLC 
patients. Also associated with 
paclitaxel response in various cancers 
including ovarian, lung prostate and 
breast cancer. 
23917080, 19203783, 
18765553, 24810093, 
21955855, 21883677, 
21687948, 20944127, 
19401306, 16803472, 
16467099, 15901749 
and 17062699 
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rs2229109 ABCB1 Drug transporter 
Ovarian 
cancer Rsponse 
rs2229109 associated with paclitaxel 
resistance. 17828752 
rs12762549 ABCC2 Drug transporter 
Ovarian 
cancer Toxicity 
rs2725264 was associated with 
decrease risk of anemia (p = 0.004). 25881102 
rs2231142 ABCG2 Drug transporter NSCLC PSF,Risk 
Associated with longer median PFS 
(p=0.041) and a reduced risk of 
disease progression (p=0.022). 
22112610 
rs2725264 ABCG2 Drug transporter NSCLC OS Associated with OS (P=0.041). 23689644 
rs4149117, 
rs7311358 SLCO1B3 
Drug 
transporter NSCLC Toxicity 
 c.334 T>G (Ser112Ala) was associated 
decreased uptake of paclitaxel and 
grade 3/4 anemia (P=0.002).  c.699 
G>A (Met233Ile) was associated with 
grade 3/4 anemia (P=0.002). 
26641474 
CYP3A4*16B  CYP3A4  
Drug 
metabolizing 
enzyme 
NSCLC, 
SCLC, 
breast 
cancer, 
other 
cancers 
PK 
Associated with both reduced 3'-p-
hydroxylation of paclitaxel and 
increased levels of 6-alpha-
hydroxypaclitaxel 
16890579 
rs2740574 
(CYP3A4*1B)  CYP3A4  
Drug 
metabolizing 
enzyme 
Ovarian 
cancer 
PK, 
Response 
Associated with paclitaxel 
pharmacokinetics and clinical 
response of ovarian cancer patients. 
CYP3A4*1BG allele showed decreased 
mean survival rate and lower OS 
when compared to the AA genotype 
patients (p = 0.010)  
23936594, 19143748 
rs35599367 
(CYP3A4*22) CYP3A4  
Drug 
metabolizing 
enzyme 
Ovarian 
cancer 
Activity, 
Response 
Associated with a higher CYP3A4 
activity and clinical response of 
ovarian cancer patients 
23936594 
rs4986910 CYP3A4  
Drug 
metabolizing 
enzyme 
Ovarian 
cancer Toxicity 
Associated with increased risk of 
thrombocytopenia (p = 0.025)  25881102 
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CYP3A5*3  CYP3A5 
Drug 
metabolizing 
enzyme 
Epithelial 
ovarian 
cancer  
Toxicity 
CYP3A5 *3/*1 genotype showed 
higher risk of developing leukopenia 
(p < .001) and neutropenia (p < .001). 
Associated with paclitaxel-induced 
toxicity such as myelo-suppression. 
21702053, 26179145  
CYP2C8*3  CYP2C8 
Drug 
metabolizing 
enzyme 
Ovarian 
cancer Clearance 
Associated with lower clearance of 
paclitaxel  
20368717, 19143748, 
17923851, 11668219 
rs1113129 CYP2C8 
Drug 
metabolizing 
enzyme 
Ovarian 
cancer Toxicity 
rs1113129 G/C association with lower 
level values of both leukocytes and 
neutrophils (p < 0.05). 
21702053 
100 
 
1.4.4.2 Pharmacogenomics of Microtubule binding protein, apoptosis and immune 
response (PD) genes 
Among the genes involved in paclitaxel pharmacodynamics, low/negative class III β-tubulin 
expression was associated with significantly higher response rate for paclitaxel based 
chemotherapy in NSCLC patients (P<0.00001). Median survival time was longer for patients with 
low/negative expression of class III β-tubulin compared with patients with high/positive expression 
(P<0.00001) 647. In addition, significantly increased MAP2 Expression in breast cancer patients 
showed complete response to neoadjuvant paclitaxel 587. TUBB is one of the primary genes 
involved in the encoding of tubulin β subunits. Polymorphism of TUBB gene was found to be 
associated with both poor response and shortened OS to paclitaxel-containing chemotherapy in 
NSCLC patients 648. Promoter polymorphisms -101, -112, and -157 in TUBB2A associated with 
63-fold variation in b-tubulin IIa gene (TUBB2A) mRNA expression. These polymorphisms were 
beneficial, and protected patients from paclitaxel-induced peripheral neuropathy (HR, 0.62; 95% 
confidence interval (CI), 0.42–0.93; P = 0.021). Additionally, these polymorphisms were inversely 
correlated with paclitaxel-induced apoptosis level (P = 0.001) in lymphoblastoid cell lines 
confirming that higher TUBB2A gene expression conferred lower paclitaxel sensitivity 649.  
Most important among the microtubule-destabilizing enzymes, high stathmin (STMN1) expression 
have been shown to be associated with poor prognosis in ovarian cancer patients treated with 
paclitaxel and platinum 602. The promoter polymorphism rs182455 in STMN1 gene is associated 
with taxane outcome (Table 1.9). Patients with TT genotype showed longer PFS and the lower risk 
of early disease progression (p = 0.0154)650. Mitotic arrest deficient 1 (MAD1) is a mitotic spindle 
assembly checkpoint (SAC) protein plays an important role in metaphase arrest. The polymorphism 
rs1801368 (MAD1 1673 G>A) was associated with the therapeutic response of patients with 
ovarian cancer with paclitaxel based therapy. The GG patients showed a higher rate of response 
and cells showed higher percentage of mitotic arrest (p<0.05) 651.  
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Studies concerning TP53 gene reported that the Pro/Pro genotype of rs1042522 (p.Arg72Pro TP53) 
in p53 was associated with better progression free survival (PFS), higher response rate, and OS 
(p = 0,008) among ovarian cancer patients receiving paclitaxel/cisplatin chemotherapy 637, 652-656. 
Polymorphisms in apoptotic genes were also found to be associated with paclitaxel response. These 
include as rs1061624 (TNFRSF1B), rs2279115 (BCL2), rs9904341 (BIRC5), and rs3769818 
(CASP8) were significantly associated with OS in NSCLC patients receiving paclitaxel-cisplatin 
chemotherapy 657.  
A study investigating the role of immune checkpoints genes polymorphisms with paclitaxel-
cisplatin chemotherapy in NSCLC patients identified rs2297136T > C and rs4143815C > G in PD-
L1 was significantly associated with better chemotherapy response, whereas rs2297136T > C was 
also associated with better OS 658, 659.  
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Table 1.9 Summary of SNPs in Microtubule binding, apoptosis and immune response (PD) genes associated with Paclitaxel 
chemotherapy. 
SNP ID Gene symbol 
Gene 
function 
Cancer 
Type 
Associated 
Phenotype Associated Genotype PubMed ID (s) 
rs1801368 MAD1 Microtubule assembly  
Ovarian 
cancer Response 
rs1801368 was associated with 
therapeutic response of paclitaxel 
based therapy. The GG patients 
showed a higher rate of response 
and cells showed higher 
percentage of mitotic arrest 
(P<0.05). 
23407047 
rs182455 STMN1 Microtubule assembly  NSCLC PFS, Risk 
Patients with rs182455 TT 
genotype showed longer PFS and 
the lower risk of early disease 
progression (p = 0.0154) 
26148901 
rs2279115 (BCL2), 
rs9904341 (BIRC5), 
rs3769818 (CASP8), 
rs1061624 (TNFRSF1B)  
  Apoptosis NSCLC OS Significantly associated with OS. 23973201 
rs1042522 TP53 Apoptosis Ovarian cancer PFS, OS 
rs1042522 was associated with 
better PFS, higher response rate, 
and OS (p = 0.008). 
 25591549, 
23574945, 
22331725, 
16739339, 
16364249, 15958617 
rs2297136, rs4143815 PD-L1  
Immune 
checkpoint 
genes  
NSCLC OS, Response 
rs2297136T > C was associated 
with better OS; rs4143815C > G in 
PD-L1 was significantly associated 
with better chemotherapy 
response. 
27181838, 27198292  
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1.4.4.3 Genome-wide association study (GWAS) genes 
Genome-wide association study (GWAS) in 1,244 EOC patients treated with the carboplatin and 
paclitaxel showed two SNPs (rs7874043 and rs72700653) in TTC39B associated with PFS by 
interacting with the promoters of PSIP1, CCDC171 and an alternative promoter of TTC39B 523. 
Another GWAS study in EOC patients treated with paclitaxel/carboplatin standard doses identified 
a number of SNPs rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22) and rs6674079 
were significantly associated (P ≤ 1.0 × 10(-5)) with poorer outcomes 632. Furthermore, a GWAS 
study on advanced NSCLC patients with squamous cell histology showed that tag SNPs rs4151510, 
rs4151465, rs9568036 in RB1 gene was associated with clinical response of first-line platinum-
taxane. The patients with G/G genotype of rs4151510 had longer OS (p=0.018) 660. An extensive 
GWAS study performed in 276 population panel LCLs and validated in 76 small and 798 non-
small cell lung cancer (SCLC, NSCLC) patients treated with paclitaxel found a SNP rs1106697 on 
chromosome 7 to be associated with paclitaxel response in both LCLs and lung cancer patients 
(NSCLC and SCLC) (p = 0.016 and p = 0.007 respectively). The three SNPs rs1778335, rs2662411 
and rs7519667 were associated with SCLC OS (p = < 0.05) 661. Among other GWAS studies, one  
analysis showed association of SNPs in AIPL1 and BCR with sensory neuropathy in cancer patients 
662; rs1656402 in the EIF4E2 gene, rs1209950 in the ETS2 gene and rs9981861 in the DSCAM 
gene was found associated with poor OS in NSCLC patients 663. A study performing analysis of 
single nucleotide polymorphisms (SNPs) located in the miRNA target sites and their role in 
paclitaxel-cisplatin chemotherapy in advanced NSCLC showed ETS2 rs461155A>G was 
significantly associated with decreased ETS2 mRNA expression664. Table 1.10 summarizes the 
SNPs that were found significantly associated with paclitaxel chemotherapy in GWAS studies 
conducted so far. 
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Table 1.10 SNPs found significantly associated with paclitaxel drug chemotherapy outcome in GWAS studies. 
SNP ID (Gene symbol) Cancer/Cell Type Associated Phenotype Associated Genotype PubMed ID (s) 
rs7874043, rs72700653 
(TTC39B) EOC PFS 
rs7874043 and rs72700653 were associated 
with PFS  26840454 
rs4910232, rs2549714, 
rs6674079, rs6674079 EOC Response 
significantly associated (P ≤ 1.0 × 10(-5)) with 
poorer outcomes 26152742 
rs4151510, rs4151465, 
rs9568036 (RB1)  NSCLC Response associated with clinical response  25684524 
rs1106697, rs1778335, 
rs2662411 and rs7519667  NSCLC, SCLC 
Response, 
OS 
rs1106697 was associated with paclitaxel 
response in both LCLs and lung cancer patients 
(NSCLC and SCLC). rs1778335, rs2662411 and 
rs7519667 were associated with SCLC OS (p = 
< 0.05)  
23006423 
rs1656402 (EIF4E2), rs1209950 
(ETS2), rs9981861 (DSCAM) NSCLC OS Associated with poor OS 21079520 
rs461155 (ETS2) LCLs mRNA expression 
rs461155A>G was significantly associated with 
decreased ETS2 mRNA expression 26893365 
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1.5 Research Study Objectives 
 Gaps in literature 
Understanding the pharmacogenomics of response to carboplatin and paclitaxel chemotherapy is a 
pre-requisite to identify reliable genetic signatures of drug response and toxicity. Several studies, 
including GWAS, have investigated the association of differential expression and/or activity of 
genes involved in the PK/PD pathway due to SNPs with platinum drug-based treatment outcome 
and/or toxicity in various cancers and have identified several key pathway genes polymorphisms 
227, 229, 665, 666. However, a comprehensive pharmacogenomics-based evaluation of these genes to 
identify genomic markers predictive of efficacy/sensitivity is still lacking. However, most SNPs 
identified in such studies have not been validated using independent investigation. 
One of the strategies to identify biomarkers associated with cellular sensitivity to carboplatin and/or 
paclitaxel is use of Epstein-Barr Virus (EBV)-transformed human lymphoblastoid cell lines (LCLs) 
as model systems. SNPs associated with sensitivity have been identified by genome wide analysis 
using LCLs that are part of International HapMap project 189, 191, 192, 667. However, one of the biggest 
disadvantages of using these LCLs is that they were derived from normal healthy individuals and 
therefore do not represent variations in cancer patients. Secondly, these cell lines might not reflect 
gene expression profiles of the target patient subject. Furthermore, large-scale association studies 
conducted so far have not provided reliable and clinically applicable biomarkers of 
carboplatin/paclitaxel response in ovarian/lung cancer due to low sample sizes or lack of 
reproducibility 138, 186, 288, 668, 669. Notably, no study so far has focused on the assessment of 
carboplatin + paclitaxel combination treatment response using in vitro model systems. Therefore, 
a systematic and comprehensive genotype-phenotype association study is required to understand 
the association between genetic variants and carboplatin + paclitaxel drug response in cancer 
treatment. 
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 Objectives and Specific Aims 
We hypothesize that we will identify a robust set of genetic variants and gene expression signatures 
significantly associated with drug response and treatment outcomes within in vitro cancer cell lines 
model systems as well as cancer patients undergoing carboplatin and paclitaxel-based 
chemotherapy. Thus, the objectives of this study were to: 1) Use LCLs derived from ovarian cancer 
patients to identify predictive markers of chemo-sensitivity; 2) Comprehensively and 
systematically evaluate association of gene expression and SNPs with treatment outcome in in vitro 
cell line-based models and clinical trials of ovarian and lung cancer patients.   
Our objectives were achieved through the following specific aims: 
Specific Aim 1. To create an in vitro cytotoxicity profile of EBV-transformed LCLs from epithelial 
ovarian cancer patients in response to carboplatin and paclitaxel as single agents and in 
combination. 
Hypothesis: LCLs from ovarian cancer patients demonstrate inter-patient variation in in 
vitro cellular sensitivity to carboplatin and paclitaxel. 
Specific Aim 2. To evaluate gene expression levels and SNPs in key PK and PD pathway genes in 
epithelial ovarian cancer patients and correlate these with cytotoxicity data obtained from Aim1. 
Hypothesis: Variation in gene expression levels and the presence of SNPs in PK/PD 
pathway genes influence treatment outcomes in ovarian cancer patients. 
Specific Aim 3. To determine correlation of cytotoxicity, gene expression and SNPs identified 
using Genome-wide association study with clinical response (progression free and OS) and toxicity 
(myelosuppression, gastrointestinal toxicity) in the ovarian cancer patients from which the LCLs 
are derived. 
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Hypothesis: In vitro cytotoxicity profiles, gene expression and SNPs are correlated with 
clinical outcome and toxicity in cancer patients treated with carboplatin/paclitaxel-
containing chemotherapy. 
Specific Aim 4: To identify genetic variations in platinum drugs and taxane pathway genes as 
predictors of outcome and toxicity in advanced non-small-cell lung cancer (NSCLC) 
Hypothesis: SNPs within the genes involved in the metabolic pathways of taxanes and 
platinating agents are associated with clinical outcome and toxicity in NSCLC patients 
treated with carboplatin/paclitaxel-containing chemotherapy. 
Long term goal: Successful completion of the project will generate a robust panel of genetic 
biomarkers of carboplatin and paclitaxel single-agent and combination treatment response that can 
serve as a first step towards the development of a precision medicine approach to develop 
pharmacogenomics-guided chemotherapy for maximum efficacy and minimum toxicity. 
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CHAPTER 2 PHARMACOGENOMIC MARKERS INFLUENCE THE 
VARIATION OF IN VITRO CHEMOSENSITIVITY TO CARBOPLATIN AND 
PACLITAXEL AS SINGLE AGENTS AND AS COMBINATION: A PATHWAY 
BASED APPROACH 
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2.1 Introduction 
Ovarian cancer is the most lethal gynecologic malignancy in the United States (NCI SEER cancer 
statistics) 1. An estimated 220,000 new ovarian cancer (OC) cases are diagnosed every year 
worldwide while around 140,000 women die from this disease 2. Epithelial ovarian cancer (EOC) 
is the one of the most common gynecological malignancies and the fifth leading cause of cancer 
death among women in the United States 3. EOC occurs primarily in middle aged or older women, 
rarely before puberty 4.  
The standard treatment for 75% of EOC patients with advanced disease is initial debulking surgery 
followed by carboplatin-paclitaxel combination chemotherapy5. carboplatin [cis-diammine (1,1-
cyclobutanedicarboxylato) platinum(II)] or Paraplatin was approved by FDA in 1989 for the 
treatment of advanced ovarian cancer 6. carboplatin forms DNA inter-strand, intra-strand, and 
DNA-protein crosslinks which is attributed to the formation of DNA helix-distorting adducts that 
result in strand breakage followed by activation of DNA repair mechanisms that interfere with cell 
division, which ultimately results in apoptosis 7. Some of the major genes involved in platinum 
pathway are influx and efflux transporters SLC31A1, ABCC2, ATP7; DNA repair genes MSH6, 
MLH1, XRCC1, ERCC1, ERCC2, XPA; and xenobiotic metabolism genes MPO, SOD1, GSTM1, 
NQO1, GSTP1 8-10.  paclitaxel is another chemotherapeutic agent, used generally in combination 
with platinum drugs for various cancers including lung and ovarian cancers 11. Taxanes like 
paclitaxel block cell division by binding to α-tubulin that stabilizes the microtubules resulting in 
cell death 11, 12, a process regulated by microtubule- associated proteins (MAPs) MAPT, MAP2 and 
MAP4 13. paclitaxel is transported into the cell through influx transporter OATP1B3 (SLCO1B3) 
and metabolized by CYP3A4 and CYP2C8 14, 15 while the drug is effluxed out of the cell by ATP 
binding cassette (ABC) multidrug transporters ABCB1, ABCG2, ABCC1 and ABCC2.   
However, despite currently available therapeutic strategies, 5-year overall survival (OS) in EOC 
remains around 44.2% along with wide inter-patient variation in response 16. Response rate is 10–
110 
 
15% and overall survival is ~12 months in resistant patients 17.  90% of the patients relapse after 18 
months of treatment 18. 
Though patients commonly develop resistance to these chemotherapeutic agents, the underlying 
mechanisms still remain unclear. Alterations in expression of key candidate genes involved in drug 
metabolism pathways and/or the presence of candidate SNPs may have a profound impact on 
treatment outcome/resistance and toxicity in ovarian cancer patients. However, there are not many 
reliable prognostic biomarkers for either carboplatin or platinum to help improve clinical response.  
Epstein-Barr virus (EBV)-transformed Lymphoblastoid cell lines (LCLs) are immortalized cell 
lines generated from human normal lymphocytes through the infection of Epstein-Barr virus (EBV) 
19. EBV-transformed LCLs comprising of multi-ethnic panels representing multiple world 
subpopulations, including the International HapMap project 20-22 and 1000 genomes project 23, have 
been extensively used to identify genetic biomarkers for various chemotherapeutic agents using 
both Genome-wide association and candidate gene approaches 20, 24-26. However, since these LCLs 
are derived from ‘normal’ healthy individuals, they do not truly represent the genetic architecture 
of EOC patients.  
In the current study, we created EBV-transformed LCLs from cells derived from EOC patients, 
performed in vitro chemo-sensitivity assays to derive cytotoxicity profiles for carboplatin, 
paclitaxel and combination treatments, and conducted genetic association studies between in vitro 
drug response phenotypes, gene expression levels and genetic variations of drug pharmacokinetic 
(PK) and pharmacodynamics (PD) pathway genes to identify reliable genomic signatures of 
treatment outcomes.  
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2.2 Materials and Methods 
 Creation of EBV-transformed Ovarian cancer LCLs 
Prior to initiation of chemotherapy, blood was collected following informed consent from ovarian 
cancer patients, diagnosed at the Mayo Clinic between 2000 and 2003. Epstein Barr Virus (EBV)-
transformed LCLs were generated from patients and subjected to in vitro drug testing.  All patients 
provided informed consent, including for passive and active follow-up, using protocols approved 
by the appropriate Institutional Review Board at the Mayo Clinic in Rochester, MN.  
 Cell Culture 
All the cell lines were cultured in RPMI1640 media (Gibco) supplemented with 2 mM L-glutamine 
(Gibco) and 15% fetal bovine serum (HyClone) and were maintained in a humidified incubator at 
37°C with 5% CO2. The cells were passaged every 2 to 3 days in order to maintain them in 
logarithmic growth phase. To confirm healthy growth, cell viability was measured using Countess 
Automated Cell Counter (Life Technologies) and cell line with >80% viability was used for further 
experiments. 
 Drugs 
Carboplatin and paclitaxel were procured from Sigma Aldrich (St. Louis, MO). carboplatin was 
freshly prepared in PBS while paclitaxel was prepared in DMSO (Dimethyl sulfoxide) and stored 
in -20°C in aliquots for 8 weeks.  
 In vitro cytotoxicity assays  
MTT (5-diphenyltetrazolium bromide) reagent (Sigma Aldrich, St. Louis, MO) was used to 
perform in vitro cytotoxicity assays on the cell lines treated with single-agent or combination 
regimens. Briefly, LCLs were plated in 96-well plate at seeding density of 2.5×105 cells/ml and 
incubated at 37°C overnight. Following 24 hour incubation, LCLs were treated with increasing 
concentrations of carboplatin and/or paclitaxel (in duplicate). Concentrations were 0, 5, 10, 20, 40, 
80 and 128 uM for carboplatin and 0, 4.5, 7.5, 10, 20, 40 and 80 nM for paclitaxel treated as single 
agents. In combination treatment, individual drug doses were half (0.5) of the doses for each drug 
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used as single agent in increasing concentrations. Cells were incubated at 37C for 48hrs following 
treatment. Cell viability was determined 48hrs post-treatment by incubating the cells with MTT 
reagent followed by measurement of absorbance at 570 nm the using Synergy plate reader (BioTek, 
USA). The percent cell survival at each concentration and IC50 values and area under survival curve 
(AUC) were calculated as described in the statistical analysis sub-section. 
 Caspase-Glo 3/7 activity Assay 
Apoptotic activity within the LCLs was determined 48 hours following treatment with carboplatin, 
paclitaxel, or combination, the using Caspase-Glo® 3/7 Assay (Promega, USA).  Luminescence 
Intensity were determined as measures of caspase activity using Synergy plate reader (BioTek, 
USA). The caspase activity at each concentration was normalized to control. 
 Cell cycle analysis 
Prior to plating for cytotoxicity and apoptosis experiments, an aliquot from each fresh cell line was 
collected to measure %S phase. Briefly, cells were stained with Propidium Iodide (PI) followed by 
assessment of cell cycle phases using BD FACSCalibur Flow Cytometer (BD Biosciences). FlowJo 
software was used to analyze the % of cells in different cell cycle phases (synthesis phase, growth 
phases).  
 SNP Genotyping 
Patient germline DNA was isolated and genotyped on the Illumina Infinium 610K array, as 
previously described 27. Genotypes were predicted by STRUCTURE 28 analysis to have greater 
than 80% European ancestry. The 1000 Genomes Project 23 was used as reference, imputation was 
completed with mach and minimac in a two-step process 29.  SNPs within carboplatin and paclitaxel 
drug pathway genes were extracted by using the web-based SNPNexus software.  
 RNA Isolation and Gene expression assays 
Total RNA was isolated from LCLs before drug treatment using RNeasy Plus Mini Kit (QIAGEN, 
USA) according to manufacturer’s protocol. RNA quantity and concentration were measured using 
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NanoDrop 2000 UV-Vis spectrophotometer (ThermoScientific, USA). The absorbance ratio 
between absorbances at 260 nm and 280 nm (A260/A280) was computed for assessing RNA 
sample purity.  A260/A280 ratio between 1.8-2.1 was considered as highly pure RNA. Further, 
RNA Quality check was performed using Agilent Bioanalyzer (Agilent RNA 6000 Pico kit) and 
estimated by calculating RNA Integrity Number (RIN) with 2100 expert software version B.02.02. 
RIN greater than 7 was considered indicating good quality RNA. The total RNA was reverse 
transcribed to cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
USA) according to manufacturer’s protocol. 
Expression of key pharmacokinetic and pharmacodynamics pathway genes of carboplatin and 
paclitaxel was determined using the TaqMan® Low Density Array (TLDA) cards (Applied 
Biosystems, USA). Briefly, each TLDA card was custom designed with pre-loaded assays for 
measuring the mRNA expression of selected genes that includes influx and efflux transporters, 
DNA repair gene, detoxifying gene for carboplatin and genes for microtubule associated protein, 
transporters for paclitaxel, along with the housekeeping genes GAPDH and Actin β (Table 2.1). 
Each TLDA card consists of eight separate loading ports which can fill into 48 separate wells for 
each sample. 24 different genes can be assayed in duplicates in a total of 384 wells per card. 
Therefore, each card could analyze the expression of 8 different samples. High-quality cDNA and 
equal volume of 2X TaqMan Universal PCR Master Mix was loaded in to the TLDA card along 
with 100 ul of the sample-specific PCR mix. To distribute reaction mix to the reaction wells 
properly, the TLDA cards were then centrifuged twice for 1 minute at 1200 rpm using a Sorvall 
Legend T Centrifuge that has Sorvall Custom Buckets with TLDA card holder. The cards were 
then sealed by the TaqMan Array Micro Fluidic Card Sealer and real-time quantitative polymerase 
chain reaction (qRT-PCR) was performed on microfluidic card thermal cycling block of Applied 
Biosystems 7900HT Fast Real-time PCR System (Applied Biosystems). Thermal cycling 
conditions were: initial denaturation of 10 minutes at 94.5°C followed by 35 cycles of: annealing 
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and extension of 2 minutes at 50°C, and denaturation at 30 seconds at 97°C and finally 1 minute at 
59.7°C for 40 cycles. For every run, Ct (cycle threshold) values or the cycle number required for 
the fluorescent signal to cross the background level were determined for each gene and used for 
further analysis. Average Ct values representing the mRNA expression levels were normalized to 
the housekeeping/control gene (GAPDH). 
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Table 2.1 Genes included in TaqMan Low-Density array (TLDA) card. 
Gene Gene Name Pathway (s) Role 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Paclitaxel Transporter 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Carboplatin, paclitaxel Transporter 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Carboplatin, paclitaxel Transporter 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 Carboplatin, paclitaxel Transporter 
ACTB actin, beta Control House-keeping gene 
ATP7A ATPase, Cu++ transporting, alpha polypeptide Carboplatin Transporter 
ATP7B ATPase, Cu++ transporting, beta polypeptide Carboplatin Transporter 
BIRC5 baculoviral IAP repeat-containing 5 Paclitaxel Anti-apoptotic 
BIVM/ERCC5 basic, immunoglobulin-like variable motif containing Carboplatin DNA repair 
BRCA1 breast cancer 1, early onset Carboplatin, paclitaxel Genomic stability/Tumor suppressor 
CCNB1 cyclin B1 Paclitaxel Cell cycle regulator 
EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) Paclitaxel Cell proliferation 
ERCC1 
excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (includes overlapping antisense 
sequence) 
Carboplatin DNA repair 
ERCC2 excision repair cross-complementing rodent repair deficiency, complementation group 2 Carboplatin DNA repair 
ERCC6 excision repair cross-complementing rodent repair deficiency, complementation group 6 Carboplatin DNA repair 
FOXC2 forkhead box C2 (MFH-1, mesenchyme forkhead 1) Carboplatin, paclitaxel Differetiation 
FOXL1 forkhead box L1 Carboplatin, paclitaxel Differetiation 
GAPDH 
glyceraldehyde-3-phosphate dehydrogenase-like 6; hypothetical 
protein LOC100133042; glyceraldehyde-3-phosphate 
dehydrogenase 
Control House-keeping gene 
GSTM1 glutathione S-transferase mu 1 Carboplatin Xenobiotic metabolism 
GSTM3 glutathione S-transferase mu 3 (brain) Carboplatin Xenobiotic metabolism 
GSTP1 glutathione S-transferase pi 1 Carboplatin Xenobiotic metabolism 
GSTT1 glutathione S-transferase theta 1 Carboplatin Xenobiotic metabolism 
HMGB1 high-mobility group box 1; high-mobility group box 1-like 10 Carboplatin Pt-DNA adduct repair  
KISS1 KiSS-1 metastasis-suppressor Carboplatin Metastasis suppressor gene 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) Paclitaxel Microtubule- associated proteins 
MAP2 microtubule-associated protein 2 Paclitaxel Microtubule- associated proteins 
MAP4 microtubule-associated protein 4 Paclitaxel Microtubule- associated proteins 
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MAPT microtubule-associated protein tau Paclitaxel Microtubule- associated proteins 
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) Carboplatin DNA repair 
MPO myeloperoxidase Carboplatin Xenobiotic metabolism 
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) Carboplatin DNA repair 
MSH6 mutS homolog 6 (E. coli) Carboplatin DNA repair 
NQO1 NAD(P)H dehydrogenase, quinone 1 Carboplatin Xenobiotic metabolism 
NR1I2 nuclear receptor subfamily 1, group I, member 2 Paclitaxel Xenobiotic metabolism 
PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) Carboplatin DNA repair 
POLB polymerase (DNA directed), beta Carboplatin DNA repair 
POLH polymerase (DNA directed), eta Carboplatin DNA repair 
REV3L REV3-like, catalytic subunit of DNA polymerase zeta (yeast) Carboplatin DNA repair 
SLC22A7 solute carrier family 22 (organic anion transporter), member 7 Paclitaxel Transporter 
SLC31A1 solute carrier family 31 (copper transporters), member 1 Carboplatin Transporter 
SOD1 superoxide dismutase 1, soluble Carboplatin Xenobiotic metabolism 
TP53 tumor protein p53 Carboplatin, paclitaxel Tumor suppresor 
XPA xeroderma pigmentosum, complementation group A Carboplatin DNA repair 
XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 Carboplatin DNA repair 
XRCC2 X-ray repair complementing defective repair in Chinese hamster cells 2 Carboplatin DNA repair 
XRCC3 X-ray repair complementing defective repair in Chinese hamster cells 3 Carboplatin DNA repair 
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) Carboplatin DNA repair 
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 Data analysis 
All statistical analyses were performed using GraphPad Prism software version 7.0 and R statistical 
analysis software version 3.3.1, a free software environment as well as a programming language 
for statistical computing and graphics. Drug IC50 (effective dose that inhibits 50% of the cells), 
area under the survival curve (AUC), EC50 (concentration required to induce caspase 3/7 activity 
by 50%) and the area under the relative caspase activity curve (AUC) were also calculated using 
four parameter logistic dose response curves fitting to the in vitro drug response measurements 
(cell survival and caspase3/7 activity assays) 27.  
To cluster cell lines based on cytotoxicity parameters, unsupervised K-means clustering was 
performed using the algorithm of Hartigan and Wong (1979) to identify the most-resistant and 
relatively sensitive subgroups of cell lines 30. 
We used CalcuSyn software version 2.0 (Biosoft) based on Chou-Talalay method for the analysis 
of  drug combination treatment 31. This quantitative analysis of combination drug effects is based 
on the median-effect equation, derived from the mass-action law principle, that estimates the 
following: 1) combination index (CI) as the measure of the effect of each individual drug in 
combination treatment and 2) dose reduction index (DRI) or the reduction in dose requirement of 
a drug in combination treatment compare to single drug treatment and also 3) the required dose to 
achieve IC50 in combination (carboplatin + paclitaxel) treatment for each cell line 31. Combination 
index (CI) is the quantitative measure of interactions between multiple drug effects interactions 
derived from the median-effect equation or Unified theory of the law of Mass-Action, where CI<I 
is defined as synergistic, CI>1 as antagonistic and CI=1 as additive 31. Additionally, DRI or dose 
reduction index (DRI) of an individual drug in combination treatment is a measure of estimated 
reduction of its dose at a given effect level compared to when the drug is administered as a single 
agent. Therefore, higher DRI corresponds to lower dose requirement which implies reduced 
toxicity at the increased effect in synergistic combination 31.  
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The association of SNPs with in vitro drug response phenotypes IC50 or EC50 was evaluated with 
linear models. For annotation of results across gene regions, SNPs were mapped to genes within 
2KB using Biofilter (assembly CRCh37.p10, genome build 104.0) and SNPNexus, a web-based 
application for the selection of functionally relevant Single Nucleotide Polymorphisms (SNP) for 
large-scale genotyping studies 27. 
Gene expression data generated using TaqMan Low Density arrays (TLDA) was analyzed using 
Partek Genomics Suite software v6.6 to perform differential expression analysis and to find 
correlation between drug pathway gene expression signatures with drug chemo-sensitivity 
parameters using Analysis of variance (ANOVA) model. Heatmaps were generated for each set of 
pathway genes (Carboplatin and paclitaxel) using unsupervised hierarchical clustering (HC) 
analysis based on the genes expressed differentially. Gene expression data was standardized: 
shifted to mean=0 and scaled to standard deviation=1 prior to Hierarchical clustering analysis.  
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2.3 Results 
 In vitro profiling of carboplatin and paclitaxel chemo-sensitivity 
A total of 112 EBV-transformed ovarian cancer cell lines were created. Among these, 81 cell lines 
were successfully treated with carboplatin and paclitaxel as single agents and as combination. 
Figure 2.1 demonstrates the quality control (QC) steps undertaken to check for variability or batch 
effects in the data owing to variations of experimental conditions. Briefly, a few cell lines were 
randomly selected and cytotoxicity assays were performed at multiple time points to check for 
consistency. Our results showed there were no batch effects observed for our drug cytotoxicity or 
caspase activity data. Furthermore, we divided the dataset into two subsets and performed statistical 
verification of any batch effect, as previously reported 27.  
 
Figure 2.1 Workflow representing Data QC (quality check) of chemo-sensitivity assay 
results 
Table 2.2 provides a summary of all the in vitro chemo-sensitivity measures assessed for single 
agent and combination treatments, including IC50, AUC, Caspase AUC and Caspase EC50. Results 
from our in vitro chemo-sensitivity analysis showed wide variability in response to carboplatin and 
paclitaxel treatment as single agent among LCLs from ovarian cancer patients. For carboplatin 
cytotoxicity, IC50 and AUC showed fold changes of 8.34 and 3.84 between the lowest (most-
sensitive) and highest (most-resistant) values, respectively whereas the fold changes were 7.72 and 
5.65, respectively for paclitaxel.  
Boxplots in Figure 2.2 represent the distribution of  log transformed drug-sensitivity parameters 
across the LCL panel. Figure 2.3 depicts a scatterplot matrix showing the correlation between the 
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observed drug chemo-sensitivity parameters in EOC-LCLs. We observed a significantly high 
(r>0.5; p<0.0001) correlation between the following: caspase AUC values for combination 
treatment with caspase AUC for carboplatin (r= 0.86) and paclitaxel (r= 0.84) as single agent 
treatment; paclitaxel IC50 vs paclitaxel AUC (r=0.71); paclitaxel IC50 vs Combination AUC 
(r=0.59); Combination AUC vs paclitaxel AUC (r=0.7); Combination AUC vs carboplatin AUC 
(r=0.59); and carboplatin caspase vs paclitaxel caspase (r=0.74) (Figure 2.3). As expected, IC50 
and AUC values were negatively correlated with corresponding caspase AUC values for a treatment 
regimen indicating increase in caspase 3/7 activity and apoptosis in the dying cells. 
Our results demonstrate a wide range of diversity in response to treatment with carboplatin and 
paclitaxel single agent treatment as well as strong correlation with combination treatment. Our 
caspase 3/7 activity data corroborated with cytotoxicity data (data not shown).  
We also performed flow cytometry analysis of the cell lines prior to performing chemosensitivity 
assays to assess cell cycle phases based on quantification of DNA content. Our results showed no 
correlation between cell cycle phases and drug cytotoxicity revealing drug response was not 
influenced by either cell viability or cell cycle phases (Table 2.3). 
Table 2.2 Summary of in vitro phenotype measures in LCLs from EOC patients. 
Drug Phenotype N Mean Minimum Maximum Fold Change (Max/Min) 
Carboplatin IC50 (µM) 77 52.56 13.63 113.24 8.31 
Carboplatin AUC 81 6165.32 2759 10598 3.84 
Carboplatin Caspase_AUC 79 288.23 100 640 6.4 
Carboplatin Caspase_EC50 (µM) 79 27.12 6 96 16 
Paclitaxel IC50 (nM) 76 19.33 5.84 45.12 7.72 
Paclitaxel AUC 81 3159.52 1165 6584 5.65 
Paclitaxel Caspase_AUC 79 173.49 80 330 4.13 
Paclitaxel Caspase_EC50 (µM) 79 10.75 2.9 56 19.31 
Combination AUC 81 2917.99 1262 6568 5.2 
Combination Caspase_AUC 79 139.35 62 270 4.35 
Combination Caspase_EC50 79 10.73 3.7 41 11.08 
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Figure 2.2 Boxplots representing distribution of a) drug cytotoxicity and b) caspase activity 
following treatment. 
Cytotoxicity values were log-transformed (represented in the y-axes) and boxplots were 
generated using the R statistical packages. (Carb = Carboplatin; Pacl = Paclitaxel; Comb = 
Combination; Casp = Caspase) 
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Figure 2.3 Scatterplot matrix representing pairwise  correlations between IC50 and AUC 
estimates of paclitaxel and carboplatin single-agent and combination treatment.  
Cytotoxicity estimates were log-transformed and a scatterplot matrix was generated using the R 
graphing package. Scatterplots, r values and corresponding significance (pvalues) for each pair-
wise correlation are included. Marginal plots on the diagonal axis represent histograms of the 
individual cytotoxicity parameters. Significance levels are associated with the following symbols 
and represent p-values (0.001, 0.01, 0.05, 0.1, 1) <=> symbols (“***”, “**”, “*”, “.”, " “) 
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Table 2.3 Summary of correlation between cell viability & cell cycle phases and drug IC50 
Phenotype Minimum Mean Maximum sd Carboplatin. IC50 
Paclitaxel. 
IC50 
Combination. 
IC50 
Cell viability 
% 80 91.33 97 3.81 r= 0.2156  r = 0.1135  r= 0.1375  
S-Phase % 12.3 24.843 38.36 4.997 r=0.042 r=-0.1049 r=-0.099 
G1- Phase % 41.62 63.072 76.35 6.906 r=-0.126 r=-0.142 r=-0.165 
G2- Phase % 1.01 11.007 34.95 5.654 r=0.051 r=0.254 r=0.218 
 
 K-Means clustering identified resistant subgroups 
K-Means clustering analysis was performed to identify clusters or subgroups based on our based 
on our in vitro cytotoxicity parameters observed in the EOC-LCLs 30. Three (3) distinctly different 
drug response subgroups were identified (Figure 2.4). We then focused on identifying differences 
in response to carboplatin, paclitaxel and combination treatments between the 3 subgroups 
generated using K-Means clustering. Table 2.4 provides numerical summary of the drug response 
parameters for each K-means cluster. Our results showed that cytotoxicity AUC and IC50 for 
carboplatin, paclitaxel and combination were significantly higher (p< 0.0001) in Cluster 2 (resistant 
subgroup) compared to other cell lines. 7 cell lines (Cluster 2) were identified as most resistant to 
the drug treatments. Cluster1 (n= 26) was identified as the most sensitive while cluster 3 (n=84) is 
the intermediate subgroup (Figure 2.4). Pvalues of Kruskal-Wallis test by ranks are also provided 
for each drug response phenotype (Figure 2.5). 
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a) 
 
b) 
 
Figure 2.4 Results from Kmeans clustering of in vitro cytotoxicity data 
a) Heatmap representing Kmeans clusters generated using in vitro cytotoxicity assay data on the LCL panel. K Means clustering (k=3) 
identified 7 cell lines (middle panel) as most resistant to the drug treatments; b) Bar plots showing subgroups of cell lines in the LCL panel 
clustered using Kmeans clustering analysis (k=3) 
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Figure 2.5 Plots showing differences in response to carboplatin, paclitaxel and combination 
treatments between the clusters generated using in vitro cytotoxicity assay data on the LCL 
panel. 
K-Means clustering analysis was performed to identify clusters or subgroups based on our based 
on our in vitro cytotoxicity profiling data in the cell lines. 
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Table 2.4 Summary of drug response phenotypes in subgroups identified by Kmeans 
clustering. 
Drug Phenotype 
Cluster 1 
(n=26) Cluster 2 (n=7) Cluster 3 (n=48) 
P (Kruskal-
Wallis) 
Carboplatin IC50 (µM) 34.99 236.43 99.69 < 0.0001 
Paclitaxel IC50 (nM) 8.98 125.57 16.12 < 0.0001 
Carboplatin AUC 4907.73 8580.43 6494.31 < 0.0001 
Combination AUC 2120.5 4706 3089.21 < 0.0001 
Paclitaxel AUC 2255.88 5191.43 3352.67 < 0.0001 
 
 Analysis of carboplatin-paclitaxel combination treatment using CI theorem 
Furthermore, we investigated the in vitro interactions between the two drugs, carboplatin and 
paclitaxel, in combination compared to use as single agent in our cell line panel of 81 EOC-LCLs 
using Chou-Talalay’s Combination Index-Isobologram Theorem to evaluate synergism, 
antagonism or additive effects 31. We studied the effect of combination (carboplatin + paclitaxel) 
treatment in our cell line panel of 81 EOC-LCLs. Results showed, for either of the drugs, reduced 
dose was required to achieve a similar effect (% kill) in combination treatment compared to single 
agent treatment for majority of the cell lines. We also observed large variability in the IC50 of 
single-agent treatment compared to its IC50 when used in drug combination (Figure 2.6). Our 
observed CI values showed wide variation (0.14-5.51) within the cell line panel. As mentioned in 
the Methods section, where CI<I is defined as synergistic, CI>1 as antagonistic and CI=1 as 
additive 31. We also observed that dose reduction (DRI) for a drug is low in cell lines where the 
combination results in predicted antagonistic drug-drug interaction (high CI value). High DRI 
corresponds to lower dose requirement, as described earlier, which suggests reduced toxicity 
corresponding to increasing synergism in combination treatments 31.We also observed high 
negative correlation between DRI and CI for carboplatin IC50 (r=- 0.732), as well as for paclitaxel 
IC50 (r=-0.641). Figure 2.7 summarizes the CI and DRI values in the diagonal box plots and 
provides pair-wise correlations between CI and DRI values at predicted IC25, IC50 and IC75. Thus, 
our DRI calculations revealed lower dose requirements to achieve similar anti-cancer effects when 
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the drugs were used in combination, compared to single-agent regimens, based on our observations 
from their reduced predicted IC50 and IC75 values in combination treatments (Table 2.5).  
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Figure 2.6 Representation of variation of the relative IC50s of treatment with single agents and drug combination that indicates 
variation across LCL panel. a) carboplatin; b) paclitaxel. 
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Table 2.5 CI and DRI as measures of Synergism and Antagonism of drug combination 
treatment in LCLs from EOC patients. 
  Drug Phenotype Minimum Mean Maximum 
CI IC50 0.14 1.03 5.51 
 DRI Carboplatin IC50 0.57 2.84 14.04 
 DRI Carboplatin IC75 0.00 2.88 11.23 
 DRI Paclitaxel IC50  0.26 2.74 15.26 
 DRI Paclitaxel IC75 0.00 2.14 7.79 
 
Combination Index (CI) and Dose-Reduction Index (DRI) values were calculated using 
Compusyn software program that applies Median-Effect Principle (by Chou) and the 
Combination Index-Isobologram Theorem (by Chou-Talalay). CI < 1, Synergism; CI = 1, 
Additive; CI > 1, Antagonism. 
 
Figure 2.7 Scatterplots showing correlation between combination index (CI) and dose 
reduction index (DRI) values at IC50. 
Diagonal axis shows boxplots of the distribution of each parameter. 
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 SNPs in pathway genes associated with chemo-sensitivity 
Genotype call rates observed for all samples were >95%, and minor allele frequency (MAF) ≥0.01. 
We performed a genotype-phenotype association analysis between SNPs in carboplatin and 
platinum pharmacokinetic and pharmacodynamics pathway genes extracted from our GWAS study 
and our observed in vitro chemo-sensitivity measures. Table 2.6 provides details of the top 15 
pathway SNPs that were found significantly associated with in vitro cytotoxicity phenotypes and 
their predicted functional effects. We identified significant association between pathway genes of 
drugs with response to carboplatin, paclitaxel as single agent and as combination therapy. At 
p<0.01, 85 carboplatin pathway gene mutations were significantly associated with carboplatin IC50, 
50 paclitaxel pathway genes were associated with paclitaxel IC50 while a total of 67 genetic 
variations were significantly associated with combination treatment chemosensitivity.  
Analysis of association between genetic variations in drug PK/PD pathway genes and in vitro 
caspase activity revealed 46, 23, 63 mutations associated with caspase activity in carboplatin single 
agent, paclitaxel single agent and combination treatment, respectively. Table 2.7 lists the top 15 
Pathway SNPs that were found most significantly associated with caspase activity phenotypes and 
their predicted functional effects.  
2.3.4.1 SNPs in genes associated with drug pharmacokinetics 
Top among the SNPs in drug disposition (PK) genes significantly (p<0.05) associated with 
carboplatin cytotoxicity were the SNPs rs186868889 (p=0.001) and rs72659636 (p=0.001) in the 
gene ABCG2 and rs182123265 (ABCC2; p=0.002). Most significant SNP versus paclitaxel single-
agent cytotoxicity association was found among rs1153867 (ABCC1) and rs9472030 (p=0.002).  
On the other hand, cytotoxicity of carboplatin-paclitaxel combination therapy was highly 
significantly associated with the following SNPs: rs183572778, rs17224787, rs62140866, 
rs17224528 (MSH2); rs3887412 (p=0.0034), rs35598 (p=0.0035), rs35599 (p=0.0035) (ABCC1). 
The top PK pathway gene mutations associated with caspase activity following carboplatin 
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treatment include the transporter genes ATP7B and the xenobiotic metabolism gene GSTM1. 
Mutations in the genes MAP4, MAPT, MAP2, were among the top caspase activity-associated PK 
gene variations following paclitaxel single-agent treatment. Finally, genetic variations in ABCC1, 
BIRC5, MAP4, and GSTP1 were highly associated with caspase activity following treatment with 
carboplatin and paclitaxel as combination. 
2.3.4.2  SNPs in genes related to pharmacodynamics response 
The following SNPs in pharmacodynamics (PD) genes were most significantly associated with 
carboplatin cytotoxicity: rs1425118 (p=0.003), rs55911615 (p=0.003), rs6749415 (p=0.003) in 
XRCC5, and rs75475960 (MSH2; p=0.003). On the other hand, significantly high SNP vs paclitaxel 
single-agent cytotoxicity association was found among TP53 SNPs rs17887200, rs17881556 and 
rs17886760 (p<0.001 for all three SNPs), and the EGFR SNPs rs7779645, rs7804688, rs6947594, 
rs6593209 (p<or =0.001 for all three SNPs), The top PD pathway gene mutations associated with 
caspase activity following carboplatin treatment include DNA repair genes XRCC5, XRCC1, 
ERCC2, and ERCC1, as well as REV3L, MSH6 and KISS1. Top PD pathway gene mutations 
associated with caspase activity following carboplatin treatment include: mutations in the genes 
BIVM/ERCC6, EGFR and BRCA1 were among the top caspase activity-associated PD variations 
following paclitaxel single-agent treatment. Whereas, genetic variations in BIRC5, KISS1, and 
EGFR were highly associated with caspase activity following treatment with carboplatin and 
paclitaxel as combination. 
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Table 2.6 Top pathway SNPs found most significantly associated with in vitro cytotoxicity parameters. 
 
Ch
r 
chromPositio
n dbSNP ID Gene/Gene 
Allele
1 
Allele
2 
Directio
n 
P-value   
(SNP vs 
IC50) 
Predicted 
function 
Carboplatin 
IC50                   
 2 217037273   XRCC5 t c -1 0.001   
 
4 88994224 rs186868889 ABCG2 t g -1 0.001   
 
4 88999267 rs72659636 ABCG2/PKD2 c g -1 0.001 3downstream 
 7 6061988   PMS2/EIF2AK1 a g 1 0.001 3utr 
 2 217028174   XRCC5 a g -1 0.002   
 
10 101573872 rs182123265 ABCC2 a g 1 0.002   
 2 216958899 rs1425118 XRCC5 c g 1 0.003   
 2 217028646   XRCC5 t g -1 0.003   
 2 216958412   XRCC5 a g -1 0.003   
 2 216958402 rs6749415 XRCC5 a g 1 0.003   
 
2 216968340 rs55911615 XRCC5/TMEM169 a g 1 0.003 
3downstrea
m 
 2 47616643 rs75475960 MSH2 c g 1 0.003   
 2 216970326   XRCC5 t c -1 0.003   
 2 216972934   XRCC5/XRCC5 a g 1 0.003 5upstream 
          
Paclitaxel IC50          
 17 7571071 rs17887200 TP53 t c -1 <0.001 3downstream 
 17 7567681   TP53 t c 1 <0.001   
 17 7568628   TP53 a g 1 <0.001   
 7 55185302 rs7779645 EGFR a t -1 <0.001   
 7 55190098 rs7804688 EGFR a t -1 <0.001   
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 7 55203297 rs6947594 EGFR a c -1 <0.001   
 7 55203838   EGFR a g 1 <0.001   
 17 7570869 rs17881556 TP53 t c -1 0.001 3downstream 
 17 7570978 rs17886760 TP53 t c -1 0.001 3downstream 
 17 7570823   TP53 c g 1 0.001 3downstream 
 17 7570956   TP53 a g 1 0.001 3downstream 
 16 16203202 rs1153867 ABCC1 t g 1 0.001   
 7 55200625 rs6593209 EGFR a g -1 0.001   
 6 43271237 rs9472030 SLC22A7/CRIP3 t g -1 0.002 3downstream 
 7 55208284   EGFR a c 1 0.002   
Combination          
 2 48010163   MSH6 t c 1 0.0007 5upstream  
 2 47636927 rs183572778 MSH2 a g -1 0.0011   
 16 16173221   ABCC1 t c -1 0.0012 S667S  
 2 47701362 rs17224787 MSH2 a t 1 0.0019   
 2 47682634 rs62140866 MSH2 a c 1 0.0021   
 2 47684043 rs17224528 MSH2 a g 1 0.0022   
 16 16173516   ABCC1 t c -1 0.0034   
 16 16175030 rs3887412 ABCC1 a t 1 0.0034   
 16 16182528   ABCC1 t c -1 0.0034   
 16 16183045   ABCC1 a g -1 0.0034   
 16 16159023 rs35598 ABCC1 a g 1 0.0035   
 16 16159061 rs35599 ABCC1 t c 1 0.0035   
 16 16168608   ABCC1 t c -1 0.0039   
 16 16169465   ABCC1 t g -1 0.0039   
 16 16170771   ABCC1 a g -1 0.0039   
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Table 2.7 Top pathway SNPs found significantly associated with in vitro combination treatment caspase activity. 
 Chr chromPosition dbSNP ID Gene Allele1 Allele2 Direction P-value (SNP vs Caspase) 
Predicted 
function 
Carboplatin                   
 1 110211681 rs428135  GSTM1 C g 1 0.001   
 2 217003152 rs2303400  XRCC5 T c 1 0.002   
 6 111801193    REV3L A g 1 0.003   
 13 52497540    ATP7B A g -1 0.003   
 19 44062781    XRCC1 D r -1 0.003   
 19 45837542    ERCC2 C g 1 0.003   
 19 45841318    ERCC2 A g 1 0.003   
 2 217012092 rs2160981  XRCC5 A g 1 0.004   
 19 44041363    XRCC1 T c -1 0.004 3’ downstream 
 19 45931387 rs28586606  ERCC1 A g 1 0.004   
 19 45936292    ERCC1 T c -1 0.004   
 1 110291406  GSTM3 T c -1 0.005 3’ downstream 
 1 204181317 rs72749759  KISS1 A c -1 0.005   
 2 48012375    MSH6 C g -1 0.005   
 2 48022688 rs111861797  MSH6 T c 1 0.005   
Paclitaxel          
 10 96845842   CYP2C8 D r -1 0.003   
 3 47977447   MAP4 D r 1 0.005   
 17 44072651   MAPT A g 1 0.005   
 17 44090778   MAPT A t 1 0.007   
 17 44090779   MAPT A c 1 0.007   
 2 210512893   MAP2 A g -1 0.008   
 2 210574383   MAP2 A g 1 0.008   
 2 210596950 rs114531804 MAP2 A g 1 0.008 3’ UTR 
 7 55197234 rs79884022 EGFR T c -1 0.008   
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 7 55206022   EGFR A g 1 0.008   
 17 41250221   BRCA1 D r -1 0.008   
 17 41260985   BRCA1 C g -1 0.008   
 2 210534297 rs141068360 MAP2 T g -1 0.009   
 3 47896738   MAP4 A c 1 0.009 Coding (K1087N) 
 3 47918295   MAP4 A g 1 0.009   
Combination          
 17 76238765   BIRC5 T c -1 <0.001 3’ downstream 
 17 76239023 rs7223704 BIRC5 T c 1 <0.001 3’ downstream 
 17 76231842   BIRC5 T c -1 0.002   
 3 48067426 rs184824121 MAP4 T c -1 0.003   
 1 204150976   KISS1 T c 1 0.005   
 7 55124701 rs6593202 EGFR T c -1 0.005   
 11 67362385 rs7108038 GSTP1 A g -1 0.005   
 16 16195257   ABCC1 A g 1 0.005   
 16 16206501 rs45499397 ABCC1 C g -1 0.005   
 17 76230981 rs8064778 BIRC5 C g 1 0.005   
 17 76231434   BIRC5 A t -1 0.005   
 11 67358076   GSTP1 T g 1 0.006   
 11 67359090 rs7939505 GSTP1 C g -1 0.006   
 11 67359718 rs6591259 GSTP1 A g -1 0.006   
 11 67359947 rs7937159 GSTP1 T g -1 0.006   
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 Differential GEP signatures of drug response 
By comparing gene expression versus response phenotype using the Spearman rank-order 
correlation analysis, several key pathway genes were found significantly associated with drug 
chemosensitivity phenotype measure (details provided in Table 2.8).  
Pre-treatment gene expression levels of candidate genes involved in carboplatin and paclitaxel 
PK/PD pathway were assayed using TaqMan Low Density Arrays. Average Ct values for each gene 
were then normalized using average Ct value of the housekeeping/control gene (GAPDH). Data 
was log-transformed and used for analysis of association with phenotype measures. Genes showing 
no expression in >5% cell lines were filtered out prior to analysis. Differential gene expression 
analysis was performed using the remaining genes to identify gene expression changes that were 
highly correlated with drug chemo-sensitivity. Clustering analysis using the most differentially 
expressed genes revealed distinct clusters/subgroups within the LCL panel. Figure 2.8 and 2.9 
show heatmaps that cluster the EOC LCL panel based on most differentially expressed pathway 
genes for carboplatin and paclitaxel, respectively.  
Expression of the following genes were highly correlated with carboplatin cytotoxicity: ERCC2 
(p=0.015); GSTM1 (p=0.0097); GSTT1 (p=0.0086); NQO1 (p=0.0497), while expression levels of 
the following genes were correlated with response to paclitaxel single agent treatment: BIRC5 
(p=003); FOXL1 (p=0.0148); FOXC2 (p=0.0034). When compared to the phenotype measures of 
carboplatin-Paclitaxel combination treatment, CI values at IC50 was correlated with the carboplatin 
pathway genes ATP7A and ATP7B. In addition, DRI values at IC25 were correlated with the 
following carboplatin pathway genes: POLH (p=0.022); ATP7A (p=0.042) and FOXC2 (p=0.032), 
as well as the paclitaxel pathway genes FOXC2 (p=0.0114), BIRC5 (p=0.0237) and EGFR 
(p=0.0458). 
Spearman correlation analysis between caspase activity and pathway gene expression revealed 
trends towards significance for expression of the genes GSTP1 (p=0.08) and NQO1(p=0.096) for 
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carboplatin treatment and FOLXL1 (p=0.07), BIRC5 (p=0.07) and EGFR (p=0.08) for caspase 
activity induced by paclitaxel single agent treatment (Table 2.8). 
Table 2.8 Summary of results from Spearman correlation analysis between TLDA gene 
expression and drug chemo-sensitivity outcomes (p<0.1). 
Drug Phenotype Column ID p-value (correlation) 
Carboplatin 
IC50 ERCC2 0.035 XPA 0.087 
MTT.AUC 
GSTM1 0.010 
ERCC2 0.002 
MSH2 0.040 
TP53 0.083 
GSTP1 0.023 
NQO1 0.032 
MSH6 0.035 
XRCC2 0.037 
SOD1 0.039 
ATP7A 0.039 
POLB 0.043 
FOXL1 0.045 
REV3L 0.082 
XRCC3 0.096 
Caspase.AUC GSTP1 0.085 
Caspase.EC50 NQO1 0.096 
Paclitaxel 
IC50 BIRC5 0.094 
MTT.AUC 
BIRC5 0.002 
FOXC2 0.003 
FOXL1 0.011 
MAD2L1 0.093 
Caspase.EC50 FOXL1 0.070 BIRC5 0.074 
Combination 
MTT.AUC 
GSTM1 0.017 
ERCC6 0.053 
BIRC5 0.039 
FOXC2 0.064 
NQO1 0.085 
FOXL1 0.090 
Casp.AUC GSTP1 0.022 
Casp.EC50 
XPA 0.017 
HMGB1 0.029 
BIRC5 0.050 
ERCC1 0.061 
NQO1 0.064 
FOXC2 0.078 
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a) 
 
b)  
 
Figure 2.8 Heatmap showing hierarchical clustering of the LCL panel based on differentially 
expressed carboplatin pathway genes. a) All pathway genes; b) Pathway genes most 
significantly associated with cytotoxicity (p<0.1). 
Columns represent cell lines; Rows represent carboplatin pathway gene analyzed using TLDA 
arrays. 
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a) 
 
b) 
 
Figure 2.9 Heatmap showing hierarchical clustering of the LCL panel based on differentially 
expressed paclitaxel pathway genes. a) All pathway genes; b) Pathway genes most 
significantly associated with cytotoxicity (p<0.1). 
Columns represent cell lines; Rows represent paclitaxel pathway gene analyzed using TLDA 
arrays. 
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2.4 Discussion and Conclusions 
EOC accounts for 6% of all cancer deaths among women 3. Despite the routine use of carboplatin-
paclitaxel combination treatment, one of the biggest challenges faced by clinicians is wide inter-
patient variation in clinical response, 7, 32 as well as toxicities including myelosuppression and 
gastrointestinal toxicities 7 and drug resistance 32. Approximately 80% ovarian epithelial cancer 
patients relapse after first line based chemotherapy.  
We hypothesized that modelling drug resistance using in vitro model systems will enable 
identification of genetic variants and gene expression signatures significantly associated with drug 
response. These drug response markers derived from in vitro models may then be validated using 
patient data to identify actionable genetic changes that influence drug resistance and treatment 
outcomes. In the current study, we used a panel of 81 LCLs derived from human ovarian cancer 
patients to identify key mutations and gene expression changes associated with carboplatin and 
paclitaxel response, both as single agents and when used as combination.  
Our in vitro chemo-sensitivity assays showed wide variability in response to carboplatin and 
paclitaxel single agent and combination treatment, that mirrors the wide variability in clinical 
response among ovarian cancer patient samples. We also performed caspase activity assays to 
demonstrate that drug cytotoxicity reflected alterations in caspase-3 and caspase-7 activity, key 
effectors involved in cellular apoptosis and programmed cell death 33. 
We then used Chou-Talalay’s Combination index-Isobologram Theorem to understand the 
interactive effects of carboplatin and paclitaxel when used in combination treatment 31. Evaluation 
of combination index, which is a direct measure of synergism, antagonism or additive interaction 
between the drugs revealed more than 25-fold variation across the cell line panel. Similar variation 
was also observed for DRI values, indicating that drug combinations are also variable based on the 
degree of refractoriness of a tumor. To understand the genetic determinants underlying this 
variability, we performed association analysis between the chemo-sensitivity parameters as 
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phenotype measures and mutations in genes involved in the PK/PD pathway of carboplatin and 
paclitaxel. 
We identified significant association between carboplatin single-agent IC50 and genetic variations 
in drug transporter genes ABCG2 and ABCC2, several mutations in the DNA repair gene XRCC5 
as well as mutations in PMS2 and MSH2. Mutations in the following paclitaxel pathway genes were 
highly associated with paclitaxel IC50: TP53, EGFR, and the transporter genes ABCC1 and 
SLC22A7. On the other hand, several of the top genetic mutations associated with combination 
treatment belonged to the ATP-binding cassette transporter gene ABCC1, and the genes MSH2 and 
MSH6. Notable among the associations we found between coding mutations and drug cytotoxicity 
were F150F in TP53 gene and the S667S in ABCC1 that were associated with paclitaxel and 
combination treatment chemosensitivity, respectively. In addition, we also found association 
between caspase activity and the coding variants R704R (ERCC6), R338R and P428P (MSH6) and 
carboplatin single-agent treatment. The genes ABCC2 and ABCG2 are involved in carboplatin 
efflux and multiple studies have shown association of these transporters with survival in ovarian 
cancer patients 9, 34. Additionally, localization of ABCC2 in the nuclear membrane was shown 
associated with cisplatin resistance and clinical outcome in ovarian carcinoma while ABCC2 
overexpression was associated with resistance to cisplatin in melanoma cells 35. Similarly, ABCG2 
overexpression was found associated with poor survival for platinum-containing cancer 
chemotherapy 36. In contrast, high ABCC1 expression was associated with favorable survival 
measures37. Polymorphisms in ABCC2 and ABCG2 have been shown associated with response to 
platinating agents have shown correlated with treatment response and survival in ovarian cancer 
patients 38.  Polymorphisms in DNA repair genes may modulate not only DNA repair capacity, also 
clinical outcome of DNA damage-inducing anticancer drugs. For example, polymorphisms in 
XRCC5, a gene involved in non-homologous end joining repair process 39, have been shown 
associated with hematologic toxicity in cancer patients treated with platinum based compound 40. 
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PMS2, MSH2 and MSH6 are genes involved in DNA mismatch repair pathway that recognize and 
repair single stranded DNA damage due to Pt-DNA adducts 41. We also found a non-synonymous 
coding variant K1087N in the gene MAP4 significantly associated with caspase activity in 
paclitaxel single-agent treatment. Overexpression of MAP4 have earlier been shown to increase 
microtubule polymerization and taxane binding with microtubule resulting in increased 
chemosensitivity 42, 43. Overall, polymorphisms in these genes representing key nodes in the drug 
metabolism pathway that may have considerable impact on gene function and/or activity thereby 
affecting drug response. 
We also performed differential gene expression of carboplatin and paclitaxel pathway genes to 
identify changes in gene expression levels associated with drug response. Significant among the 
differentially expressed carboplatin pathway genes were ERCC2 (p=0.035 for IC50 and p=0.002 
for AUC), GSTM1 (p=0.010) and NQO1 (p=0.032). Notably, earlier studies have shown 
deregulation of GSTM1 enzyme activity influenced treatment response, 5-year survival and time to 
progression in various cancers including NSCLC and ovarian cancer patients 44. Furthermore, 
differential expression of GSTM1 also influences cisplatin sensitivity in cancer patients treated with 
platinum compound 45.  Upregulation of the nucleoside excision repair (NER) pathway genes 
ERCC1 and XPD expression was found significantly associated with higher resistance in platinum-
based chemotherapy in advanced EOC 46, 47. NER genes play significant role in the identification 
and repair of platinum-DNA adducts (1, 2-intrastrand DNA cross-links) 48. 
Expression of the paclitaxel pathway genes that were significantly associated with cytotoxicity 
included FOXC2 (p=0.003), FOXL1 (p=0.011) and BIRC5 (p=0.002). Alterations in the apoptotic 
gene BIRC5 have been earlier shown associated with overall survival in patients receiving 
paclitaxel-cisplatin chemotherapy where OS was observed to decrease with increase in number of 
risk alleles (‘bad genotypes’) within DNA repair genes including BRCA1, XRCC1 and BIRC5 49. 
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Although earlier studies have reported platinum and taxane sensitivity-related changes in DNA and 
gene expression using cell-based models, the modeling in these studies largely involved datasets 
that comprised of publicly available EBV-transformed LCL panels from healthy individuals 
including the Hapmap project 20-22 . Therefore, our study is the largest study so far conducted on 
LCLs modeled using cells derived directly from ovarian cancer patients. 
Use of immortalized LCLs directly derived from patient subjects has several advantages over 
commercially available LCLs since it empowers us to develop in vitro drug response models that 
can be directly correlated with patient clinical responses.  Here we successfully demonstrate that 
the use of candidate-gene based approaches in immortalized LCLs from patient samples can 
provide reliable genetic markers of drug responses/treatment outcomes that may eventually benefit 
clinical decision-making. 
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CHAPTER 3 RESPONSE TO PLATINUM, TAXANE, AND COMBINATION 
THERAPY IN OVARIAN CANCER: IN VITRO PHENOTYPES, INHERITED 
VARIATION, AND DISEASE RECURRENCE 
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3.1. Introduction 
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death among women in the 
United States (6% of cancer deaths); in 2015, it is estimated that 14,180 women will die from the 
disease 1. The standard treatment for patients with advanced disease is initial debulking surgery 
followed by carboplatin-paclitaxel combination chemotherapy 2. Five-year overall survival remains 
around 45% 2, yet there is a wide inter-patient variation in response. Currently there are few reliable 
prognostic biomarkers for the classification of patients and treatment response.  
Platinating agents, such as carboplatin, interfere with DNA via inter-strand, intra-strand, and DNA-
protein crosslinks, thereby causing DNA damage and prevention of cell division and growth, 
resulting in cell-cycle arrest and apoptosis 3. Although platinum-based drugs are widely used in 
cancer treatment, many tumors are completely resistant to these drugs, and no clinical response is 
attained.  Major molecular mechanisms underlying this resistance might involve alteration in 
platinum inactivation or reduced intracellular accumulation by uptake/efflux transporters, increased 
repair of adducts, increased adduct tolerance or failure of apoptotic pathway. Taxane agents, such 
as paclitaxel, are commonly used chemotherapeutic drugs often in combination with platinating 
agents. Taxanes block cell division by binding to α-tubulin, stabilizing the microtubules, thus 
resulting in cell death 4, 5. Although development of taxane resistance is common, the mechanism 
underlying this resistance is unclear. Molecules implicated in taxane metabolism and disposition 
include cytochrome P450s and drug transporters (e.g., ABCB1, ABCG2, ABCC1, ABCC2, and 
SLC01B3) 6, 7.  Inherited variation in many of the genes encoding these molecules has been assessed 
for association with clinical outcome with inconsistent results 8-10; genome-wide searches to date 
have also failed to identify variants associated with outcome after correction for genome-wide 
testing (p<5x10-8). 
Patient-derived cell line based model systems represent a novel way to identify genomic predictors 
of drug response. Although lymphoblastoid cell lines (LCLs) derived from participants in the 
146 
 
international HapMap project have been used to identify genomic predictors of cytotoxic effects of 
various chemotherapeutic agents 11-16, they are limited as they are not derived from the EOC 
population but from healthy individuals. Here, we generated LCLs derived from Mayo Clinic EOC 
patients, conducted in vitro cytotoxic studies, and associated in vitro drug response phenotypes 
with germline genotype. Utilizing patient-derived LCLs, as opposed to commercially available 
LCLs, allows us to screen and directly correlate in vitro phenotypes and clinical responses.  These 
genome-wide association scans (GWAS) should contribute to the identification of predictive 
markers of treatment responses and ultimately improve clinicians’ ability to tailor therapy decisions 
for EOC patients. 
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3.2. Materials and Methods  
3.2.1. Patients, Lymphoblastoid Cell Lines and Cytotoxicity Assays 
Prior to initiation of chemotherapy, ovarian cancer patients diagnosed at the Mayo Clinic between 
2000 and 2003 provided blood for immediate germline DNA extraction and for the creation of 
Epstein Barr Virus (EBV)-transformed LCLs.  Samples from 74 patients were successfully 
transformed and subjected to in vitro drug testing.  All patients provided informed consent, 
including for passive and active follow-up, using protocols approved by the appropriate 
Institutional Review Board.  
In vitro cellular chemo-sensitivity studies of LCLs were performed in two batches (N=33, N=41) 
using identical procedures and assays. Cells were maintained in RPMI1640 media supplemented 
with 2 mM L-glutamine, and 15% fetal bovine serum at 37°C under 5% CO2. Following 24 hour 
incubation, LCLs were treated with increasing concentrations of carboplatin and/or paclitaxel (in 
duplicate).  The concentrations of carboplatin were 0, 5, 10, 20, 40, 80 and 128 uM, while for 
paclitaxel were 0, 4.5, 7.5, 10, 20, 40 and 80 nM when used as single agents. In drug combination 
experiments, we used half of the doses for each drug in increasing doses (i.e. 2.5 uM carboplatin + 
2.25 nM paclitaxel for “dose level 1” and so on). Cell viability 48 hours post-treatment was 
determined using standard MTT assay13, 17, 18. Caspase3/7 (Promega) apoptosis assays were 
performed at the same time in parallel plates 18, 19. A Synergy 3 plate reader (BioTek Instruments) 
was used to read absorbance (cell viability using MTT) or fluorescence (for caspase3/7 activity) 
intensities.  
Four parameter logistic dose response curves were fit to the in vitro drug response measurements 
(cell survival and caspase3/7 activity assays) for each LCL and treatment (paclitaxel, carboplatin, 
and combination): 
Yi = α +  (β - α) ) ⁄ (1 + [Di / θ ] ϕ ) 
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where Yi is the measurement at dose i (Di ),  α is the estimated bottom of the curve (i.e., 
measurement as Di → ∞),  β is the estimated top of the curve (i.e., measurement as Di → 0), ϕ is 
the slope of the curve, and θ is the inflection point of the curve (i.e., concentration giving a response 
half way between the top and bottom of the curve). The estimated inflection point of the curve was 
used as the drug response phenotype. That is, using these dose-response curves, we estimated the 
relative IC50 (effective dose that kills 50% of the cells) for MTT cell viability and the relative EC50 
(concentration required to induce caspase 3/7 activity by 50%) for caspase3/7 activity 20.  For 
simplicity of presentation, we will refer to these quantitative values as the IC50 for the MTT 
cytotoxicity assays and EC50 for the caspase 3/7 assays. We then applied rank-based inverse 
Gaussian transformation (i.e., Van de Waerden rank transformation).  
Summaries of the IC50 and EC50 values for both experimental batches are presented in Table 3.1. 
We observed a high degree of correlation between many of the drug response phenotypes, as 
expected (Figure 3.1).  
Table 3.1 Mean (SD) in vitro phenotype measures collected on LCLs from 74 EOC patients 
and comparison across experimental batch. 
Phenotype Treatment Batch 1 (N=33) Batch 2 (N=41) P* 
MTT IC50 Paclitaxel 14.22 (8.4) 27.66 (55.1) 0.131 
Carboplatin 55.16 (73.9) 105.52 (138.0) 0.049 
Combination 31.10 (37.6) 47.16 (84.8) 0.281 
Caspase 3/7 EC50 Paclitaxel 11.34 (6.7) 9.39 (6.2) 0.865 
Carboplatin 26.00 (13.9) 26.58 (15.3) 0.203 
Combination 10.36 (4.39) 10.28 (5.9) 0.953 
 
*P is result from testing difference in two groups based on a two-sample t-test assuming unequal variances 
(Welch Test) 
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Figure 3.1 Scatterplot matrix of drug response phenotypes by experimental batch. 
Spearman correlations are presented on the upper panel of each plot (log scale). (A) Batch 1 (N = 33), the 
highest correlation being between paclitaxel IC50 and combination IC50 (r = 0.81) and caspase EC50 
measurements for paclitaxel and combination treatments (r = 0.78).  (B) Batch 2 (N = 41), the highest 
correlation was between paclitaxel and combination IC50 measurements (r = 0.39). 
3.2.2. Genotyping and Statistical Methods  
Germline DNA was genotyped on the Illumina Infinium 610K array, as previously described 19, 21, 
22. All samples had genotype call rate >95% and were predicted by STRUCTURE 23 analysis to 
have greater than 80% European ancestry.  SNPs were excluded with call rate < 95%, Hardy-
Weinberg Equilibrium p < 10-4, or no variation in this set.  Using the 1000 Genomes Project 24 as 
reference, imputation was completed with mach and minimac in a two-step process 25, resulting in 
data on more than 30 million SNPs.  Assessment of imputation quality was completed and high 
quality imputed markers (r2≥ 0.30 and MAF≥0.01) were retained (6,243,550 SNPs).  
The association of each SNP with in vitro drug response phenotypes IC50 or EC50 was evaluated 
with linear models 26 using the expected genotype or “dosage” (i.e., additive or dose-response/trend 
model). Thus, a negative effect estimate indicates that the carriers of the minor/rare allele have 
lower IC50 (EC50) values (i.e., were more “sensitive” to treatment).  The two in vitro experimental 
batches were analyzed separately followed by meta-analysis was conducted using metal 27, with 
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weights applied for the number of samples in each group.  We completed the GWAS analyses for 
each individual in vitro drug response phenotype, as opposed to a combined analysis with all 
phenotypes model together, due to the difference in mechanism of action between the drugs (i.e., 
not in the same drug class) 28. For annotation of results across gene regions, SNPs were mapped to 
genes within 2KB using Biofilter (assembly CRCh37.p10, genome build 104.0) 29. Pathway 
analysis used Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, www.ingenuity.com). 
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3.3. Results 
We examined the relationships of in vitro phenotypes with time to recurrence of EOC (40 of 74 
patients had recurred or died).  Of the 74 patients with LCLs included in this study, 51 had available 
information on the first two treatments used:  43 patients were treated with paclitaxel / carboplatin, 
2 treated with paclitaxel / cisplatin, 3 treated with carboplatin / topotecan, and 3 treated with 
carboplatin / other less common agent. paclitaxel in vitro drug response phenotypes were 
moderately associated with time to EOC recurrence (HR = 1.90 per unit increase in MTT IC50, p = 
0.008; HR = 1.84 per unit increase in caspase 3/7 EC50, p = 0.058) (Figure 3.2) (Table 3.2).  
This suggests that patients whose LCLs demonstrated greater sensitivity to the chemotherapeutics 
tested had improved outcome; as Figure 3.2 illustrates, LCLs that were sensitive to paclitaxel (as 
reflected by having low IC50 and low EC50 values) were from patients with longer time to 
progression as compared to patients with LCLs with high values. Although based on a small sample 
size, this provides, for the first time, a link between in vitro chemo-sensitivity testing and clinical 
outcome in EOC. 
Results of genome-wide association analyses for each drug response phenotype are presented in 
Figure 3.3. Regions with p < 10-6 are highlighted and are further displayed in Figure 3.3. Table 
3.3 presents the SNPs associated with the drug response phenotype with p < 10-6.  Overall, we 
found a greater proportion of significant results (e.g., at p < 10-6) for the combination therapy as 
compared to the single agent therapies. In particular, we found strong SNP associations with 
combination therapy in the following gene regions: SLC9A9 (MAF = 0.41, p = 6x10-7), TIAL1 
(MAF = 0.23, p = 7.3x10-7), ZNF731P (MAF = 0.39, p = 6.6x10-7), and PCDH20 (MAF = 0.42, 
p = 8.2x10-7).  None of these regions were found to be moderately associated with single agent 
carboplatin or paclitaxel IC50 in other pharmacogenomic studies involving commercially available 
LCLs, such as those of the International HapMap Consortium (personal communications for 
carboplatin study and paclitaxel study published by Niu et al 30.  
152 
 
Table 3.2 Hazard ratios (p-value) associating in vitro drug phenotypes with time to disease 
recurrence. 
 Caspase 3/7 EC50 MTT IC50 
Paclitaxel 1.84 (0.058) 1.90 (0.008) 
Carboplatin 1.00 (0.991) 1.00 (1.000) 
Combination 1.42 (0.376) 1.01 (0.930) 
 
* P-value determined from a likelihood ratio test; Hazard Ratio > 1 indicates worse outcome for subjects 
with high IC50 ("resistant"); 40 events; bold, p<0.10 
 
 
Figure 3.2 Kaplan-Meier curves for time to progression and paclitaxel in vitro phenotypes. 
The groupings were defined by 3 quartiles representing low, medium or high values for the phenotype 
based (A) MTT assay IC50 or (B) Caspase 3/7 EC50 assay. The p-value presented is from a Cox proportional 
hazards model with the in vitro phenotype modeled as a continuous measurement on the log-scale. 
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Table 3.3 SNPs with p < 10−6 association with a drug response phenotype.  
 
 
*Nearest gene within 2000 gene pairs. 
For regions with multiple SNPs with p < 10−6 , the most significant SNP is presented. A negative estimate indicates that carriers of the minor allele had, on 
average, lower IC50 or EC50 (“sensitive”) while a positive estimate indicates that carriers of the minor allele had, on average, higher IC50 or EC50 
(“resistant”). 
Drug Phenotype 
Nearest 
Gene 
SNP Chr Position MAF 
Meta-
Analysis 
P 
Group 1 (N=33) Group 2 (N=41) 
Estimate P Estimate P 
Paclitaxel MTT IC50 BOD1L1 rs185229225 4 13609129 0.02 2.2E-07 -2.53 8.0E-03 -11.64 4.7E-06 
 
Caspase 3/7 
EC50 
MGC32805
/SNCAIP* 
rs3842595 5 121778606 0.14 2.6E-07 -1.37 1.7E-03 -1.34 4.1E-05 
Carboplatin MTT IC50 FRAS1 rs150303591 4 79009309 0.29 5.9E-07 0.86 2.5E-03 1.02 6.3E-05 
Combination MTT IC50 SLC9A9* rs201023017 3 143103669 0.41 6.0E-07 0.84 5.2E-04 0.70 3.3E-04 
  TIAL1 rs66696671 10 121366953 0.23 7.3E-07 -0.89 2.9E-04 -0.76 6.6E-04 
 
Caspase 3/7 
EC50 
ZNF731P rs12025262 1 247356732 0.39 6.6E-07 -0.84 2.5E-04 -0.71 6.9E-04 
  PCDH20 rs10674174 13 61892075 0.42 8.2E-07 -0.73 5.3E-03 -0.86 3.7E-05 
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Figure 3.3 Manhattan plots of the single SNP meta-analysis genome-wide association results 
based the six in vitro drug response measures among ovarian cancer patient LCLs. 
 (A) carboplatin MTT; (B) paclitaxel MTT; (C) Combination of carboplatin and paclitaxel MTT; (D) carboplatin 
Caspase3/7; (E) paclitaxel Caspase3/7; and (F) Combination of carboplatin and paclitaxel Caspase3/7. Blue 
line indicates p-value = 0.00001; Red line indicates p-value=5x10-8. Highlighted regions (circled) are 
displayed in Figure 3.    
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Figure 3.4 Locus Zoom plots for regions with p < 10-6. 
Note: BOD1L1 region not presented as only one SNP in region with p < 0.001. 
We evaluated potential overlap of loci associated with both phenotypes for a given drug. Only one 
SNP was found to be associated with a p < 10-4 with same direction of the effect for MTT IC50 and 
caspase3/7 EC50 values for paclitaxel, carboplatin, or combination treatment. An intronic SNP 
rs35067965 in COLEC12 (chromosome 18, bp 455396) was associated with response to paclitaxel 
(MTT IC50 p = 2.2 x 10-5, caspase 3/7 EC50 p = 3.8 x 10-5) (Table 3.4).  
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We also examined overlap of associations at the level of genes, considering SNPs within 20kb. 
This showed consistency of IC50 and EC50 results for paclitaxel response and COLEC12 and 
revealed similar IC50 and EC50 associations for carboplatin response in the gene regions of CTIF 
and CDH4.  As presented in Table 3.5, additional regions showed joint associations with response 
to multiple drugs, including variants in protein coding regions of BRE, EML6, CTNNA2, LRP1B, 
EYS, NKAIN2, ANTXRL, COL13A1, and MTCL1 (SNPs in gene regions with p < 0.0001).  
Because of the suggested association between in vitro paclitaxel MTT IC50 response and time to 
EOC recurrence (Table 3.2), we also examined recurrence association with SNPs rs185229225 
(intronic BOD1L1) rs35067965 (intronic COLEC12) and rs1525599 (intronic LRP1B) which were 
associated with paclitaxel MTT IC50 (Table 3.3., Table 3.4. and Table 3.5., respectively). 
However, none of these SNPs were associated with time to recurrence with a nominal p-value < 
0.05 (data not shown). 
Table 3.4 Gene regions with SNPs associated with both phenotypes for a given drug. 
Drug Gene Phenotype SNP* Chr Position P Direction† 
Paclitaxel COLEC12 MTT IC50 rs35067965 18 455396 2.2E-05 -- 
  Caspase 3/7 EC50 rs35067965 18 455396 3.8E-05 -- 
Carboplatin CTIF MTT IC50 rs8091660 18 46087936 8.9E-06 -- 
  Caspase 3/7 EC50 rs113867814 18 46259604 1.2E-05 -- 
 CDH4 MTT IC50 rs2748151 20 60133486 4.7E-05 ++ 
  Caspase 3/7 EC50 rs113594423 20 60379048 2.4E-05 ++ 
 
*Presenting most significant SNP in the region for the giving drug/phenotype. SNP within ± 20 KB of the 
listed gene. †A positive estimate indicates that carriers of the minor/variant allele had, on average, higher 
IC50 or EC50 (“resistant”). 
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Table 3.5 Gene regions with SNPs associated with multiple drugs for any phenotype (p < 
0.0001). 
Gene Drug Phenotype SNP* Chr Position P Direction† 
BRE Carboplatin Caspase 3/7 EC50 rs5830067 2 28537890 1.70E-05 ++ 
  Combination Caspase 3/7 EC50 rs7572644 2 28320033 5.80E-06 -- 
EML6 Paclitaxel Caspase 3/7 EC50 rs75314082 2 55087315 7.90E-05 -- 
  Combination MTT IC50 rs17046344 2 55023600 4.90E-05 ++ 
LINC01122 Paclitaxel Caspase 3/7 EC50 rs72817940 2 58998563 6.40E-05 ++ 
  Carboplatin Caspase 3/7 EC50 rs4233974 2 59295043 2.60E-05 -- 
CTNNA2 Carboplatin MTT IC50 rs17261321 2 80197843 3.60E-05 ++ 
  Combination MTT IC50 rs6719499 2 80193386 6.00E-05 -- 
LRP1B Paclitaxel MTT IC50 rs1525599 2 141778702 8.60E-05 ++ 
  Combination Caspase 3/7 EC50 rs13020675 2 142212928 6.20E-05 -- 
EYS Paclitaxel Caspase 3/7 EC50 rs201083182 6 65736914 2.30E-06 -- 
  Combination Caspase 3/7 EC50 rs2064701 6 65676556 3.60E-05 ++ 
NKAIN2 Paclitaxel Caspase 3/7 EC50 rs550987 6 124905510 4.10E-05 -- 
  Combination Caspase 3/7 EC50 rs670616 6 124885773 7.80E-05 ++ 
C7orf65 Carboplatin Caspase 3/7 EC50 rs10230114 7 47705506 2.40E-05 ++ 
  Combination Caspase 3/7 EC50 rs11771997 7 47712495 2.40E-05 ++ 
ANTXRL Paclitaxel Caspase 3/7 EC50 rs12572446 10 47665906 4.30E-05 ++ 
  Combination Caspase 3/7 EC50 rs10906942 10 47670851 4.90E-05 ++ 
COL13A1 Carboplatin Caspase 3/7 EC50 rs10999018 10 71654602 2.40E-05 ++ 
  Combination Caspase 3/7 EC50 rs77535242 10 71652985 3.50E-05 ++ 
TMEM132D Paclitaxel Caspase 3/7 EC50 rs77438645 12 130304313 7.60E-05 -- 
  Carboplatin Caspase 3/7 EC50 rs1451904 12 130166947 6.50E-05 ++ 
MTCL1 Carboplatin Caspase 3/7 EC50 rs690089 18 8845223 7.80E-05 -- 
  Combination Caspase 3/7 EC50 rs35765215 18 8839469 6.00E-05 -- 
 
*Presenting most significant SNP in the region for the giving drug/phenotype. SNP within ±20 KB of the 
listed gene. †A negative estimate indicates that carriers of the minor/variant allele had,on 
average,lowerIC50 or EC50(“sensitive”) whilea positive estimate indicates that carriers of the minor/variant 
allele had,on average,higher IC50 or EC50(“resistant”). 
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3.4. Discussion and Conclusions 
In this proof of concept study, we explored use of LCLs derived from EOC patients followed for 
clinical response as a model for discovery of pharmacogenomics markers. LCLs were treated with 
varying concentration of the chemotherapeutics agents (carboplatin and paclitaxel and, uniquely, 
their combination) that were used for the treatment and cellular chemo-sensitivity was determined 
by measuring cell viability and activation of caspase activity (as a marker of apoptosis) post drug 
treatment. Genome-wide association studies were performed to identify inherited markers 
associated with these measures of in vitro chemo-sensitivity (i.e., MTT IC50 and caspase 3/7 EC50 
values) and the relationships between in vitro measures and clinical outcome was explored.  
Although the sample size was small limiting the power of the study, some of the implicated 
biologically interesting genes are worthy of discussion. Pathway analysis of genes with SNPs 
showing association with one of the drug response phenotypes (at p < 10-6), both phenotypes for a 
given drug (at p < 10-4), or multiple drugs for any phenotype (at p < 10-4) found enrichment in 
genes related to malignant solid tumor and epithelial cancers (Figure 3.5A). Among the top 
canonical pathways represented by these genes were “Epithelial Adherens Junction Signaling”, 
“Sertoli Cell Junction Signaling”, and “Endometrial Cancer Signaling” (Figure 3.5B). In addition, 
genes such as CTNNA2 and CDH4, both tumor suppressor genes with role in cell adhesion were 
found to be associated with chemo-sensitivity in carboplatin alone or combination treatments. SNPs 
in CTNNA2- catenin (cadherin-associated protein) alpha2, a structural constituent of cytoskeleton 
and cadherin binding was associated with in vitro cytotoxicity to carboplatin alone as well as in 
combination with paclitaxel. CTNNA2 has been shown to be frequently mutated in laryngeal 
carcinomas with mutations predictive of poor prognosis 31.  Additionally, SNPs within CTNNA2 
have recently been implicated in breast cancer 32 and its role in tumor progression and metastasis 
has been suggested for multiple cancers 33. Variants in CTNNA2 have also been implicated in 
schizophrenia 34 and alcohol addiction 35. CTNNA2 SNPs associated with carboplatin and 
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paclitaxel MTT IC50 were both intronic and present functional relevance of these is not known. 
CDH4, codes for cadherin, and has been implicated in nasopharyngeal carcinoma 36 and aberrant 
methylation of CDH4 promoter has been colorectal and gastric cancer 37. Our results identified two 
intronic SNPs (rs2748151 and rs113594423) that were associated with carboplatin resistant as 
measured by cell death (IC50) and apoptosis (caspase 3/7 EC50). Variants in PCDH20, another 
member of cadherin family, were also found to be associated in vitro drug response. PCHD20 codes 
for protocadherin20 and functions as a tumor suppressor by interacting with Wnt/b-catenin 
signaling38, 39.   
Another gene with role in cell adhesion identified in our study was FRAS1, which encodes for an 
extracellular matrix protein and is involved in the regulation of epidermal-basement membrane 
adhesion and organogenesis during development. Inherited mutations in FRAS1, and FREM2, have 
been associated with development of Fraser syndrome. FRAS1 has also been implicated in ERK 
signaling and influence migration and invasion of lung cancer cell line by influencing FAK 
signaling 40, suggesting its role in tumorigenesis and metastasis of lung cancer. Although the genes 
described above are involved cell adhesion/cell migration, the functional significance of the 
intronic SNPs identified in this study is not known and would require further investigation.  
Two intronic variants within BRE were found to be associated with caspase 3/7 levels for 
carboplatin and combination therapy (indel rs5830067 and rs7572664). BRE encodes for Brain and 
reproductive Organ-Expressed (TNFRSF1A modulator) and is a component of BRCA1-A DNA 
damage repair complex that recognizes Lys 62linked ubiquitinated H2A and H2Ax at DNA lesions, 
resulting in recruitment of BRCA1-BARD1 to double strand DNA breaks 41. BRE expression has 
been shown to be predictive of disease free survival in non-familial breast cancer patients 42 and 
recent studies show its involvement in both intrinsic and extrinsic apoptotic pathways by 
influencing XIAP 43. Variation within EML6, which is involved assembly dynamics of 
microtubules, was found to be associated with platinum-sensitivity which was of interest since 
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paclitaxel’s mechanism of action involved disruption of microtubules; however no evidence exists 
in the literature on functional relevance of these particular SNPs within EML6. No other genes 
involved in microtubule protein were identified with respect to paclitaxel chemo-sensitivity.  
Lastly, two intronic variants within LRP1B (low density lipoprotein related protein 1B) were 
associated with paclitaxel and combination therapy drug response phenotypes. LRP1B is a tumor 
suppressor with decreased expression in several primary cancers and is among ten most 
significantly deleted genes across 3312 cancer samples 44-47. In renal cell cancer, down-regulation 
of LRP1B has been shown to regulate cell motility and actin cytoskeleton reorganization 48. 
Germline SNPs/ haplotype in LRP1B have been associated with aging without cognitive decline 
49; however, associations of germline SNPs with incidence/progression of cancer and 
pharmacogenomics have yet to be reported. 
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Figure 3.5 Pathway analysis of genes with SNPs that demonstrated significant association with 
LCL chemosensitivity with carboplatin or paclitaxel alone or in combination. 
A) Significant number of genes mapped to malignant solid tumor or epithelial cancer; B) Top canonical 
pathways and interaction network among the pathways represented by significantly associated genes. 
In summary, using a patient-derived cell-based model system to generate several in vitro drug 
response phenotypes on a clinically followed set of EOC cases we have identified genetic loci 
associated with response to platinum-taxane therapies. Overall our results identified germ-line 
SNPs in multiple cell adhesion molecules and several tumor suppressor genes (PCDH20, LRP1B, 
CDH4, and CTNNA2). However, none of the most associated SNPs were reported by Huang et al 
15 or associated with mRNA gene expression in lymphoblastoid cell lines 
(http://www.ncbi.nlm.nih.gov/projects/gap/eqtl/index.cgi).  Further studies are needed to 
determine if these SNPs are truly associated with drug response or if they represent false-positive 
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findings. Similar to other studies comparing in vitro chemo-sensitivity with clinical outcomes 15, 50, 
our findings suggest that in vitro response to paclitaxel correlates with time to disease recurrence 
indicating that this model may have utility in several types of future studies.  On possible 
explanation for the observation that paclitaxel correlates with recurrence and not carboplatin may 
be the fact that the majority of EOC patients eventually develop platinum resistant tumors and the 
main factor related to future response maybe attributed to response to taxane therapy. Further 
research is needed to understand the mechanism by which genomic loci impact clinical response in 
ovarian cancer patients to the most common regimen used in the treatment of ovarian cancer 
following surgery.  
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CHAPTER 4 GENETIC VARIATION IN PLATINATING AGENT AND 
TAXANE PATHWAY GENES AS PREDICTORS OF OUTCOME AND TOXICITY 
IN ADVANCED NON-SMALL-CELL LUNG CANCER 
 
 
(Published in Pharmacogenomics (2014), 15(12):1565-74) 
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4.1 Introduction 
Lung carcinoma is the most common malignancy worldwide, and the leading cause of cancer 
deaths. According to the most recent estimates, the global incidence of lung cancer is more than 
1.6 million cases/year, resulting in more than 1.3 million deaths/year (>18% of all cancer deaths) 
1. In the USA, the incidence of lung cancer was estimated to be 228,000 cases in 2013, leading to 
nearly 160,000 deaths (27.5% of all cancer deaths) 2. Histologically, the majority (approximately 
80%) of lung cancers are non-small-cell carcinomas (NSCLCs). The 5-year relative survival of 
patients with advanced NSCLC remains dismal at approximately 4% 2. Indeed, the median survival 
of unselected patients diagnosed with metastatic NSCLC is only 4 months 3. Platinating agent-
based combination chemotherapy is the standard treatment for patients with advanced NSCLC who 
have adequate organ function and performance status, and whose tumor does not have a driver 
mutation amenable to treatment with a specific inhibitor. However, combination chemotherapy 
achieves objective response in only approximately 26% of patients, improves survival modestly, 
and is associated with diverse side effects 4. Interpatient variation in response and toxicity, which 
cannot be predicted for individual patients, precludes the selection and tailoring of chemotherapy 
that might improve outcomes and minimize adverse events. Although clinical factors including age, 
performance status and stage influence the likelihood of benefit from and tolerability of 
chemotherapy, the genetic profile of individual patients may contribute significantly to the marked 
variation in response and toxicity.  
Adverse effects associated with platinating agent-based combination chemotherapy include 
gastrointestinal toxicity, myelosuppression, nephrotoxicity, peripheral neuropathy and ototoxicity 
5.Platinating drugs such as cisplatin and carboplatin act by forming platinum–DNA adducts, which 
lead to cell cycle arrest and apoptosis. Several genes are involved in the carboplatin drug pathway 
(platinating agents pathway PharmGKB: (Figure 4.1) Intracellular levels of carboplatin are 
regulated by drug transporters SLC31A1 (CTR1), ABCC2 (MRP2), ATP7A and ATP7B 6, as well 
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as drug-metabolizing enzymes including MPO, SOD1, GSTM1, NQO1, GSTP1 and MT, which 
are implicated in the development of cellular resistance to these drugs 7-10. Genes of 
pharmacodynamic significance include HMGB1, which is involved in recognition and cellular 
response to platinum–DNA, adducts and DNA repair genes including mismatch repair genes 
MSH6and MLH1, and nucleotide excision repair genes XRCC1, ERCC1, ERCC2and XPA 11, 12. 
Genetic variation in these genes of importance to pharmacokinetic and pharmacodynamics 
pathways of platinating agents may thus contribute to interpatient variation in response and 
tolerability 13. 
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Figure 4.1 Platinum pharmacokinetics/pharmacodynamics pathway 
Representation of the candidate genes involved in the metabolism of platinum containing drugs 14. 
 
Taxanes are routinely given in combination with platinating agents, genes involved in efflux 
(ABCC1, ABCC2, ABCG2 and ABCB1) and metabolism of taxane (CYP3A4 and CYP2C8) are 
critical for its therapeutic efficacy (taxane pathway: PharmGKB)  (Figure 4.2). Although the role 
of genetic variation in taxane response is unclear at this time, some studies have found no 
significant association between SNPs and treatment outcome 15, whereas others have found 
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significant associations between ABCB1SNPs and response to paclitaxel 16, and gastro intestinal 
toxicity in patients treated with taxane and platinum combination therapy 17. In the present study, 
we evaluated SNPs in genes of relevance to the pharmacokinetic/pharmacodynamics pathways of 
platinating agents and taxanes in patients diagnosed with advanced NSCLC and treated primarily 
with carboplatin-based doublet chemotherapy, and determined the association of individual SNPs 
with outcomes and toxicity. We identified specific SNPs that were predictive of progression-free 
survival (PFS) and multiple adverse effects, after adjusting for known clinical prognostic factors in 
multivariate models. Results of our proof-of-concept study provides evidence that in real world 
clinical settings the association of genetics with clinical outcome is evaluable and although 
validation in larger cohorts is required, genetic information can be utilized to develop to more 
effective treatment strategies. 
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Figure 4.2 Taxane pharmacokinetics pathway 
Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the 
downstream effects of the drugs 18. 
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4.2 Materials and methods 
4.2.1 Patients cohort  
 
A total of 635 patients diagnosed with stage IIIB or IV NSCLC between December 1998 and 
December 2008 were identified by the institutional tumor registry (Figure 4.3). Of these, 90 
patients met the following eligibility criteria: histological or cytological confirmation of NSCLC, 
presence of measurable disease, performance status Eastern Cooperative Oncology Group (ECOG) 
0–2, no neoadjuvant or concurrent radiation therapy or surgery, no second malignancies, 
availability of adequate diagnostic tumor tissue, treatment with first-line platinating-agent based 
doublet chemotherapy and complete follow-up at the Minneapolis VA Health Care System (MN, 
USA). The study was approved by the institutional human subjects committee.  
 
Figure 4.3 Patient selection and Study design. 
NSCLC: Non-Small-Cell lung carcinoma, MAF: Minor allele frequency, XRT: Radiotherapy 
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4.2.2 Treatment schedules, dose & toxicity assessments 
Of the 90 patients identified, 87 received carboplatin, two received cisplatin, and two received 
cisplatin and carboplatin as first-line chemotherapy. Patients were evaluated every 2–3 cycles using 
the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. We assessed the following 
hematologic toxicities: anemia, neutropenia, febrile neutropenia and thrombo-cytopenia. 
Nonhematologic toxicities assessed included nausea, vomiting, diarrhea, mucositis, sensory and 
motor neuropathy, renal dysfunction (increase in creat-inine), and liver dysfunction (abnormal liver 
function tests). Grading of toxicities was performed using the National Cancer Institute Common 
Toxicity Criteria Version 4.0.Clinical evaluation and blood tests were performed prior to the first 
cycle of chemotherapy and before each subsequent cycle. Baseline CT scans were obtained before 
the start of treatment, and repeated every 2–3cycles to evaluate treatment response. Patients had 
open access to the oncology clinic for reporting any side effects or concerns during treatment.  
4.2.3 SNP analysis: 
4.2.4 DNA isolation 
Genomic DNA was isolated from formalin-fixed paraffin-embedded specimens (n=86 NSCLC 
patients) using Qiagen DNA isolation from formalin-fixed paraffin-embedded tissues kit (Qiagen, 
Valencia, CA, USA) as per manufacturer’s instructions.  
4.2.5 Genotyping 
Genes of importance to platinating agents and paclitaxel as well as potentially significant SNPs 
within them were selected from PharmGKB 19 and literature search from PubMed. Overall, 63 
SNPs within 29 genes in 86 subjects with detailed clinical information were genotyped using the 
Sequenome platform at the University of Minnesota Genomics Center (MN, USA). Only include 
SNPs with MAF>0.1(Figure: 4.4, Table 4.1). 
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Six samples were removed from further statistical analyses owing to low call rates (<90%). There 
was no significant difference in age, performance status and survival between patients excluded 
versus included in study (p>0.05). Quality control of the SNP data resulted in one SNP being 
removed with a call rate <90%, with no SNPs removed owing to deviations from Hardy–Weinberg 
equilibrium. 
 
Figure 4.4 SNP selection process. 
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Table 4.1 Summary of SNPs genotyped in the NSCLC patients. 
 
SNP Chr Position Gene 
Major 
Allele 
Minor 
Allele MAF 
Call 
rate HWE 
rs1695 11 67352689 GSTP1/missense A G 0.336 0.95 0.8 
rs7483 1 110279701 GSTM3 G A 0.342 1 0.802 
rs11615 19 45923653 ERCC1/cds-synon T C 0.386 0.9875 1 
rs13181 19 45854919 KLC3/nearGene-3 T G 0.431 1 0.821 
rs25487 19 44055726 XRCC1/missense G A 0.27 0.95 0.151 
rs25489 19 44056412 XRCC1/missense G A 0.05 1 0.168 
rs35592 16 16141823 ABCC1/intron T C 0.201 0.9625 0.722 
rs119774 16 16086833 ABCC1/intron G A 0.069 1 1 
rs246240 16 16119024 ABCC1/intron A G 0.131 1 0.614 
rs316019 6 160670282 SLC22A2/missense G T 0.125 1 0.094 
rs447978 3 120491086 GTF2E1/intron A G 0.312 1 0.117 
rs520227 1 190569312  C G 0.307 0.8875 0.001 
rs744154 16 14015081 ERCC4/intron C G 0.312 1 1 
rs851974 6 151971687 ESR (7 kb 5') T C 0.436 1 0.357 
rs1042522 17 7579472 
TP53/nearGene-
5,TP53/missense G C 0.291 0.9875 0.584 
rs1045385 6 10398116 TFAP2A/UTR-3 A NA NA 0.9875 NA 
rs1045642 7 87138645 ABCB1 T C 0.456 1 0.366 
rs1047768 13 103504517 ERCC5/cds-synon C T 0.342 0.9875 0.624 
rs1058930 10 96818119 CYP2C8/missense C G 0.069 1 0.308 
rs1128503 7 87179601 ABCB1 C T 0.456 1 0.652 
rs1138272 11 67353579 GSTP1/missense C T 0.094 1 0.515 
rs1347851 12 90566978  A G 0.244 1 0.542 
rs1625895 17 7578115 TP53/intron G A 0.144 1 0.193 
rs1799735 1 110280254 GSTM3 - TCC  1 NA 
rs1799793 19 45867259 ERCC2/missense G A 0.383 0.9625 0.81 
rs1800566 16 69745145 NQO1/missense C T 0.222 0.9875 0.512 
rs1801244 13 52544805 ATP7B/missense C G 0.481 0.975 0.82 
rs1801247 13 52520471 ATP7B/cds-synon G A 0.051 0.9875 1 
rs1944118 11 111352032 BTG4/intron G A 0.35 1 0.466 
rs2031920 10 135339845 CYP2E1/nearGene-5 C T 0.013 0.95 1 
rs2032582* 7 87160618 ABCB1    0.9875 NA 
rs2228001 3 14187449 XPC/missense A C 0.344 1 0.806 
rs2229109 7 87179809 ABCB1 G A 0.038 1 1 
rs2230671** 16 16228242 ABCC1/cds-synon A G NA 0.9875 NA 
rs2231142 4 89052323 ABCG2/missense C A 0.081 1 0.411 
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rs2235015 7 87199564 ABCB1 G T 0.131 1 0.614 
rs2238476 16 16213872 ABCC1/intron C T 0.062 1 0.259 
rs2273697 10 101563815 ABCC2/missense G A 0.2 0.9375 1 
rs2798389 14 83051150  A G 0.262 1 0.775 
rs3212948 19 45924362 ERCC1/intron C G 0.369 1 0.811 
rs3212986 19 45912736 
CD3EAP/missense,ERCC1/UTR-
3 G T 0.269 0.975 1 
rs3740066 10 101604207 ABCC2/cds-synon G A 0.308 0.975 1 
rs3957357 6 52668687 GSTA1/nearGene-5 G A 0.394 1 0.35 
rs4128317 2 29659854 ALK/intron A C 0.419 1 0.818 
rs4148396 10 101591944 ABCC2/intron C T 0.342 0.95 0.8 
rs6863960 5 114995781  G A 0.469 0.9375 1 
rs7255865 19 21804968  A G 0.412 1 1 
rs8187710 10 101611294 ABCC2/missense G A 0.056 0.9875 1 
rs9282564 7 87229440 ABCB1 A G 0.088 0.975 0.463 
rs9312960 5 204082 CCDC127/5'UTR C A 0.294 1 0.282 
rs10158985 1 226050609 TMEM63A/intron C A 0.247 0.9625 1 
rs11572080 10 96827030 CYP2C8/missense G A 0.106 1 0.589 
rs12188653 5 101383803  G C 0.257 0.95 0.005 
rs13120400 4 89033527 ABCG2/intron T C 0.288 1 0.272 
rs17098912 14 100104329  G A 0.206 1 1 
rs17222723 10 101595996 ABCC2/missense T A 0.051 0.9875 1 
rs17718902 11 17784707 KCNC1/intron A G 0.388 1 0.642 
rs17731538 4 89055379 ABCG2/intron G A 0.2 1 0.725 
rs28364006 16 16228249 ABCC1/missense A G 0.012 1 0.006 
rs28730837 17 56355397 MPO/missense C T 0.025 1 1 
rs45511401 16 16173232 ABCC1/missense G T 0.014 1 1 
rs72552784 7 87145914 ABCB1 C NA NA 1 NA 
 (MAF= minor allele frequency; HWE= Hardy Weinberg equilibrium) 
4.2.6 Statistical methods 
All analyses were restricted to subjects with self-reported race of white or ‘unknown’. Association 
of each clinical feature with clinical outcomes of PFS and overall survival (OS) was assessed using 
Cox-proportion hazards models. Associations of each SNP genotype with clinical outcomes were 
examined using Cox-proportion hazards models, where the SNP genotyped was coded under a 
dominant, codominant or additive genetic model. Models were fit with and without adjustment for 
clinical features associated with clinical outcomes. For analysis of PFS, we included covariates of 
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stage and performance status. For OS, we included performance status as a covariate. For analyses 
with clinical features, stage was treated as a categorical variable and performance status was treated 
as a continuous variable. Age at diagnosis was categorized into four levels based on the 25, 50 and 
75% percentiles of the distribution. All statistical analyses were completed using R (version 2.15.3). 
Adjustment for multiple testing was carried out using Bonferroni correction. 
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4.3 Results 
4.3.1 Demographic features and clinical characteristics 
Demographic and clinical features of the 90 evaluable patients at diagnosis are shown in Table 4.2. 
The median age was 66 years (range: 45–81). All the patients were males, a reflection of the patient 
population at a VA Medical Center. The majority (93%) of patients was white; 81% of patients had 
stage IV disease. Adeno-carcinoma was the most common histological subtype (42% of patients) 
of NSCLC, followed by squamous cell (20%) and large cell (16%) carcinoma. The median 
performance status (ECOG scale) was 1 (range: 0–2). 
Table 4.2 Patient demographics and clinical characteristics (n = 90). 
 n(%) p-value (PFS) p-value (OS) 
Age at diagnosis (years)       
Median  66 0.95 0.25 
Range  45-81     
Race       
White  84 (93.3)     
African–American  1 (1.1)     
American Indian/Alaska Native  2 (2.2)     
Unknown  3 (3.3)     
Stage       
IIIB   17 (19) 0.02 0.48 
IV  73 (81)     
Histology       
Adenocarcinoma  40 (44.4)     
Adenocarcinoma, mucinous  2 (2.2)     
Squamous cell  18 (20)     
Large cell  12 (13.3)     
Large cell neuroendocrine  2 (2.2)     
Non-small-cell carcinoma, NOS  16 (17.8)     
Brain metastasis  12 (13.3)     
Performance status (ECOG)       
Median  1 0.03 0.02 
Range  0-2     
 
ECOG: Eastern Cooperatve Oncology Group; NOS: Not otherwise specified; OS: Overall survival; PFS: 
Progression-free survival.  
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4.3.2 Treatment, response and outcomes 
 
Chemotherapy regimens administered, including the number of cycles and average dose 
intensities of each agent, are shown in Table 4.3. The overall response rate was 19%, with a 
median duration of response of 182days, median PFS of 148 days and median OS of 288 days. 
No patient achieved a complete response.  
Hematological and non-hematological toxicities selected for further analyses are shown in Table 
4.4. No patients developed treatment-related abnormalities in liver function tests, or experienced 
CTCAE grade5 (fatal) toxicity. 
Table 4.3 Chemotherapy regimens, dose intensity, response and survival. 
Regimen  
Number 
of 
patients  
Number 
of 
cycles, 
mean 
(range)  
Dose intensity 
(mg/m2/week)†, mean 
± SE  
Response 
rate, n (%)  
Median 
duration 
of 
response 
(days)  
Median 
PFS 
(days)  
Median 
OS 
(days)  Platinum‡  Second drug    
C + T  77 3.3 (1–6)  1.8 ± 0.3  60.0 ± 10.0  14 (18)  163 148 292 
C + G  9 3.2 (1–5)  1.4 ± 0.4  
455.1 ± 
169.1  3 (33)  185 211 465 
C + E  2 3 (1–3)  1.9 ± 0.5  84.9 ± 19.0  0 (0)  0 NE  NE  
Cis + E  2 1.5 (1–2)  21.8 ± 4.2  75.0 ± 0.0  0 (0)  0 NE  NE  
Total  90 3.2 (1–6)  –  –  17 (19)  182 148 288 
 
None of the patients had a complete response.  
The median PFS and OS were calculated from the Kaplan–Meier estimates.  
†The target dose intensities for each agent were: C AUC 2/week; Cis, 27 mg/m2/week; T, 67 
mg/m2/week; G, 667 mg/m2/week and E, 100 mg/m2/week (with C) and 80 mg/m2/week (with Cis).  
‡Dose of C is expressed as AUC.  
AUC: Area under the concentration–time curve; C: carboplatin; Cis: Cisplatin; E: Etoposide; G: 
Gemcitabine; NE: Not evaluable; OS: Overall survival; PFS: Progression-free survival; SE: Standard error; T: 
paclitaxel.  
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Table 4.4 Hematological and non-hematological toxicities. 
Toxicity and grade†  Chemotherapy regimen  
 C + T, n (%)  C + G, n (%)  C + E, n (%)  Cis + E, n (%)  
Neutropenia          
1–2  10 (12)  5 (56)  0 (0)  0 (0)  
3–4  19 (25)  2 (22)  1 (50)  0 (0)  
Febrile neutropenia          
1–2  0 (0)  0 (0)  0 (0)  0 (0)  
3–4  3 (4)  0 (0)  0 (0)  1 (50)  
Anemia          
1–2  72 (94)  7 (78)  2 (100)  0 (0)  
3–4  2 (3)  2 (22)  0 (0)  1 (50)  
Thrombocytopenia          
1–2  18 (23)  4 (44)  0 (0)  1 (50)  
3–4  3 (4)  2 (22)  0 (0)  1 (50)  
Nausea          
1–2  28 (36)  3 (33)  0 (0)  2 (100)  
3–4  5 (7)  0 (0)  0 (0)  0 (0)  
Vomiting          
1–2  4 (5)  1 (11)  0 (0)  0 (0)  
3–4  4 (5)  0 (0)  0 (0)  0 (0)  
Diarrhea          
1–2  15 (20)  2 (22)  0 (0)  0 (0)  
3–4  7 (10)  0 (0)  1 (50)  1 (50)  
Mucositis          
1–2  1 (1)  1 (11)  0 (0)  0 (0)  
3–4  0 (0)  0 (0)  0 (0)  0 (0)  
Sensory neuropathy          
1–2  24 (31)  3 (33)  0 (0)  0 (0)  
3–4  5 (7)  0 (0)  0 (0)  0 (0)  
Motor neuropathy          
1–2  0 (0)  0 (0)  0 (0)  0 (0)  
3–4  2 (3)  0 (0)  0 (0)  0 (0)  
Increased creatinine          
1–2  2 (3)  1 (11)  0 (0)  0 (0)  
 
†Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 
4.0. None of the patients developed abnormal liver function tests or experienced grade 5 toxicity. The 
number of patients who received each chemotherapy regimen was: C + T = 77, C + G = 9, C + E = 2 and Cis 
+ E = 2. C: carboplatin; Cis: Cisplatin; E: Etoposide; G: Gemcitabine; T: paclitaxel.  
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4.3.3 Pharmacogenetics 
 
We first examined the association of known clinical prognostic factors (covariates) with clinical 
outcomes. Stage (p=0.02) and performance status (p=0.03) were predictive of PFS, and 
performance status (p=0.02) was associated with OS. Therefore, we adjusted for these covariates 
when analyzing the association between SNPs and outcomes. In the analysis of toxicity, we 
adjusted for the total number of cycles received, since the cumulative dose of chemotherapeutic 
agents received would be expected to increase the risk of toxicities such as peripheral neuropathy. 
For genetic association testing, 86 patients had both clinical and genotype data. Of these 86 patients 
we included patients with white ancestry (n=80) for further analysis. Of 58 SNPs with a minimum 
allele frequency of >0.05, one SNP was excluded due to call rate of <0.90. Although number of 
chemotherapy cycles were associated with OS, we decided not to adjust for them as genetic factors 
might be influencing number of cycle and if we adjust for cycles, we might mask some of the 
effects due to patient genetics (as it might be ‘surrogate’ for length of survival[depends on time; 
changes over time]).PFS was associated with SNPs in drug efflux transporters ABCC1 (intronic 
SNPs: rs246240 and rs2238476) and ABCB1 (coding synonymous SNP, rs1128503); a Quinone 
reductase NQO1 (missense  
SNP, rs1800566); TMEM63A (rs10158985); and other genes such as KCNC1 (rs17718902) and 
CCDC127 (rs9312960; summarized in Table 4.5). SNPs within ABCB1 (rs1045642; p=0.04), 
ABCC1 (rs2238476; p=0.03), ABCG2 (rs17731538; p=0.04) and TMEM63A (rs10158985; 
p=0.03) were also associated with OS.  
We also evaluated association of SNPs with major hematological and non-hematological toxicities. 
Toxicities were not associated with the initial performances status (p>0.05) but were associated 
with age and number of treatment cycles. After adjusting for age and number of treatment cycles, 
we found associations of ABCB1SNP with thrombocytopenia (rs2235015; p=0.04), and ABCG2 
179 
 
(rs2231142; p=0.045) and ATP7B (rs1801244; p=0.027) SNPs with nausea (Table 4.6), and 
ABCG2SNP (rs13120400, p=0.027) with sensory neuropathy, respectively. Interestingly, SNPs in 
the DNA repair pathway genes ERCC4 (rs744154; p=0.04) and XPC (rs2228001; p=0.045) 
demonstrated associations with neutropenia and sensory neuropathy, respectively (Table 4.6). 
Additionally, we observed SNPs in TP53 (rs165895; p=0.02), CYP2C8 (rs11572080; p=0.017) and 
CCDC127 (rs9312960; p=0.019) to be associated with diarrhea. rs447978, an intronic SNP in 
transcription factor GTF2E1, was associated with both neutropenia (p=0.024) and nausea 
(p=0.027). After adjustment for multiple testing (Bonferroni) the above indicated associations were 
not significant and the results need to be validated in a larger study. 
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Table 4.5 Association of SNPs with progression-free survival after adjusting for covariates (performance status and stage). 
SNP Gene Drug Chr Major Allele 
Minor 
Allele MAF 
P value    PFS         
Additive Model 
(Dominant Model)  
Hazard Ratio PFS     
Additive Model 
(Dominant Model)  
95% CI, additive model 
(dominant model) 
rs1800566 
(missense) NQO  
platinating 
agents 16 C T 0.222 0.02 (0.037) 1.615 (1.689) 0.089 to 0.870 (0.040 to 1.009) 
rs10158985 
(intron) TMEM63A
# platinating agents 1 C A 0.247 0.032 (0.025) 0.655 (0.592) -0.821 to -0.025 
rs246240 
(intron) ABCC1 Taxane 16 A G 0.131 0.037 (0.072) 0.640 (0.617) 0.409 to 1.001 
rs2238476 
(intron) ABCC1  Taxane 16 C T 0.062 0.045 (0.037) 1.972 (2.32) -0.894 to 0.001 
rs1128503 
(synonymous ) ABCB1  Taxane 7 C T 0.456 0.066 (0.019) 0.730 (0.541) -0.652 to 0.022 
rs17718902 
(intron) KCNC1
# platinating agents 11 A G 0.388 0.069 (0.035) 1.353 (1.717) -0.017 to 0.623 
rs9312960 CCDC1278# platinating agents 5       0.059 (0.042) 1.378 (1.620) -0.003 to 0.645 
 
Data are presented as: values from additive model, three group analysis (values from dominant model, variant carrier vs noncarrier).  
MAF: Minimum allele frequency.  
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Table 4.6 Association of SNPs with toxicity after adjusting for covariates (age as categorical variable and total number of cycles). 
Toxicity Gene SNP 
P value, log  
Additive Model 
(Dominant Model)  
Odds Ratio 
Additive Model 
(Dominant 
Model)  
95% CI, log-additive model (dominant 
model) 
Nausea 
ABCG2  rs2231142_CA (missense) 0.045(0.045) 3.938 (4.052) 0.033 to 2.708 (0.031 to 2.768) 
GTF2E1  rs447978_AG (intron) 0.024 (0.004) 0.409 (0.223) -1.672 to -0.117 (-2.520 to -0.488) 
ATP7B  rs1801244_CG (missense) 0.078 (0.027) 1.977 (4.626) -0.073 to 1.384(0.178 to 2.885) 
Neutropenia 
GTF2E1# rs447978 (intron) 0.027 (0.039) 0.444 (0.345) -1.531 to -0.093(-2.01 to -0.053) 
TMEM63A  rs10158985    0.031 (0.09) 2.557 (2.307) 0.035 to 1.52(0.308 to 2.307) 
ERCC4  rs744154 (intron) 0.04 (0.01) 2.176 (3.697) 0.087 to 1.79(-0.158 to 1.83) 
Sensory 
Neuropathy 
# rs1347851_AG 0.016 (0.023) 0.235 (0.225) -2.625 to -0.27(-2.773 to -0.208) 
ABCG2  rs13120400 (Intron)  0.027 (0.055)  0.271 (0.295) -2.467 to -0.146(-2.465 to 0.024) 
KLC3# rs13181_TG 0.073 (0.021) 2.27 (5.893) -0.076 to 1.715 (0.273 to 3.274) 
XPC  rs2228001_AC (missense) 0.096 (0.045) 0.456 (0.296) -1.71 to 0.14(-2.406 to -0.03) 
Diarrhea 
CCDC127  rs9312960_CA (5'UTR) 0.019 (0.09) 2.429 (2.434) 0.149 to 1.626 (-0.138 to 1.918) 
CYP2C8  rs11572080_GA (missense) 0.017 (0.017) 4.396 (4.396) 0.26 to 2.702 (0.26 to 2.702) 
TP53 rs1625895_GA  (intron) 0.02 (0.023) 3.004 (3.633) 0.174 to 2.026 (0.179 to 2.401) 
Thrombocytopenia 
ABCB1 rs2235015_GT 0.074 (0.04) 2.605 (3.467) -0.093 to 2.004 (0.058 to 2.428) 
# rs17098912_GA 0.072 (0.027) 2.212 (3.115) -0.071 to 1.659 (0.131 to 2.142) 
 
Data are presented as: values from additive model, three group analysis (values from dominant model, variant carrier vs non-carrier). 
†SNPs not in a gene, these were selected from genome-wide association study. 
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4.4 Discussion 
This comprehensive analysis identified pharmacogenomics variants of clinical significance within 
key genes (n=29) in the platinating agents pathway and taxane pathway in NSCLC patients treated 
with a combination of carboplatin and paclitaxel. We found significant associations of drug 
transporter (ABCC1and ABCB1) SNPs with PFS. Although we did not observe significant 
association of ABCB1rs1045642 with outcome/toxicity, ABCB1SNPs rs1128503 (occurring in 
partial linkage disequilibrium with rs1045642) and rs2235015 were associated with PFS and 
thrombocytopenia, respectively. The functional consequence of the three most commonly studied 
SNPs (rs1128503, rs1045642 and rs2032582 also occurring in linkage disequilibrium) in ABCB1is 
still not completely understood. Associations of these SNPs with mRNA/protein expression have 
been shown in some studies but not all the studies. rs1045642, a synonymous SNP (3435C>T; 
Ile1145Ile) has also been indicated to influence protein conformation and substrate specificity 20. 
Previous studies have identified association of ABCB1SNPs (especially rs1045642) with survival 
in osteosarcoma patients treated with cisplatin containing chemotherapy 21. In esophageal cancer 
patients treated with platinating agents, presence of the T allele for rs1045642 is associated with 
significantly longer survival and reduced risk of recurrence 22. Together, these findings suggest that 
drug transporter SNPs that might influence outcomes in several malignancies by altering 
intracellular drug concentrations.NQO1 belongs to the Quinone dehydrogenase family of proteins 
and has been implicated in metabolizing platinum agents. A missense SNP rs1800566 (NQO1*2: 
Pro187Ser) is in the active site of the enzyme and has been associated with reduced NQO1 activity. 
The NQO1 isoform with Ser (NQO1*2) undergoes rapid degradation 23, 24. A recent study reported 
association of the NQO1*2SNP with shorter OS in NSCLC patients treated with adjuvant radiation 
therapy with or without platinating agent based chemotherapy 25. Our results are in concordance 
with these previous observations, with presence of NQO1*2associated with poor PFS (Table 
4.5).Toxicity due to platinating agent and taxane-based chemotherapy remains a major challenge 
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faced by clinicians and patients. There are no well-established biomarkers that can predict such 
toxicities in individual patients. In our efforts to identify SNPs predictive of major hematological 
and non-hematological toxicities, we observed that a missense SNP in CYP2C8, a drug-
metabolizing enzyme involved in the metabolism of taxanes, was significantly associated with 
higher incidence of diarrhea (OR: 4.396; p=0.017). Previous results in breast cancer patients 
receiving paclitaxel have shown significant association of CYP2C8*3(which denotes two highly 
linked SNPs rs11572080 and rs10509681) with better response and a trend towards greater risk of 
peripheral neuropathy 26. CYP2C8*3 is associated with lower paclitaxel-α hydroxylation activity, 
and hence carriers of this SNP have lower clearance of paclitaxel, which can contribute to better 
response but also greater risk of toxicity to normal cells 27, 28 In addition to drug-metabolizing 
enzymes, several SNPs in drug transporters (ABCG2 and ABCB1) were associated with nausea 
and thrombocytopenia, respectively. These drug transporters have been implicated in efflux of 
either platinating agents or taxanes. The ABCG2missense SNP rs2231142 results in a Gln141Lys 
change; which has been associated with lower expression 29 as well as with reduced drug efflux 
capacity of ABCG2 30. Cell lines that are resistant to cisplatin have been shown to express higher 
levels of the copper transporters ATP7Aand ATP7B 5. ATP7A has been implicated in sequestering 
both carboplatin and cisplatin in vesicles. Since SNPs in these transporters have not been evaluated 
for potential clinical impact, we performed an exploratory evaluation of SNPs in ATP7Aand 
ATP7Band found that rs1801244 (valine to leucine change) in ATP7B is associated with nausea. 
The functional effect of the valine to leucine change resulting from this SNP remains to be 
determined. Since platinating agents such as cisplatin and carboplatin form platinum–DNA adducts 
that are repaired by the nucleotide excision repair pathway, interpatient variation in DNA repair 
mechanism due to presence of SNPs in DNA damage/repair pathway genes may influence 
treatment outcome. Although none of the SNPs in the DNA repair pathway genes were associated 
with PFS or OS, significant correlations were observed with toxicities. A 3 ́-UTR SNP (rs3212986) 
184 
 
and a coding SNP in ERCC1( rs11615 ; Asn118Asn) have been associated with reduced ERCC1 
mRNA/protein-expression levels, and lower ERCC1 levels have been associated with better 
outcomes in NSCLC patients receiving platinating agent based chemotherapy 31, 32. Nevertheless, 
while multiple studies have evaluated these two ERCC1SNPs, results have been quite variable and 
remain inconclusive. A recent meta-analysis of 39 previously published studies on these two 
ERCC1SNPs in lung cancer patients demonstrated that the rs11615 SNP might be a potential 
biomarker for risk of developing lung cancer as well as a prognostic marker in NSCLC patients 
treated with platinating agents 33. In our dataset we did not observe significant association of these 
SNPs with toxicity of survival. We did observe a marginally increased risk of neutropenia with 
ERCC4intronic SNP and reduced risk of sensory neuropathy with XPC missense SNP rs2228001 
(C>A; Gln939Lys). Though not extensively studied, rs2228001 has been shown to have a trend 
towards higher risk of ototoxicity in osteosarcoma patients treated with cisplatin 34.Finally, in 
addition to candidate genes in drug pathways; we tested selected genes that have been identified by 
genome-wide association study (GWAS). GWAS analysis in colorectal cancer patients treated with 
5-fluorouracil with or without oxaliplatin identified SNPs in KCNC1 (rs17718902), GTF2E1 
(rs447978), CCDC127rs9312960) or TMEM63A (rs10158985) to be associated with nausea, 
vomiting and drug-induced neuropathy 35. In our study, an intronic SNP (rs447978) in the 
transcription factor GTF2E1 was associated with reduced risk of nausea and neutropenia and an 
intronic SNP in TMEM63 (rs10158985) was associated with neutropenia. Furthermore, SNPs in 
KCL3and CCDC127were associated with increased risk of sensory neuropathy and diarrhea, 
respectively. Although the functional relevance of these genes/SNPs is not known, future studies 
on functional characterization as well as validation of these SNPs are needed to confirm the results 
of the GWAS analysis. 
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4.5 Conclusion 
In conclusion, we identified SNPs within key candidate drug pathway genes that are independently 
predictive of PFS and/or major hematological and non-hematological toxicities in patients with 
advanced NSCLC treated with platinating agent based chemotherapy. There is a paucity of 
predictive markers that can be used to guide clinical decisions for such patients. Our results confirm 
some previously reported associations, but more importantly identify several new candidates that 
warrant testing in prospective studies, that could contribute towards the development of 
personalized medicine. Indeed, a recent Phase II trial demonstrated that response rates are higher 
when chemotherapy is selected based on SNPs in ERCC1and RR M1in patients with advanced 
NSCLC 36, suggesting that incorporation of pharmacogenomics biomarkers into clinical decision 
making has considerable potential for improving therapeutic outcomes. 
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4.6 Summary 
Lung carcinoma is the most common malignancy and the leading cause of cancer deaths worldwide. 
The genetic makeup of individual patients in addition to other clinical factors can influence the 
likelihood of benefit from and tolerability of chemotherapy. We evaluated SNPs in candidate genes 
of relevance to platinating agents and paclitaxel for association with survival and toxicity in non-
small-cell lung cancer patients. After adjusting for covariates, SNPs in drug transporters and NQO1 
were associated with progression-free survival and SNPs in drug transporters as well as in the in 
the DNA repair pathway genes ERCC4 and XPC were associated with toxicity. Comprehensive 
evaluation of the genetic variants in conjunction with known prognostic factors may help optimize 
therapeutic decisions to maximize benefit and minimize toxicity in non-small-cell lung cancer 
patients. 
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CHAPTER 5 SUMMARY 
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Platinum drugs are currently used as standard-of-care chemotherapy for various cancers including 
solid tumors like lung cancer, the most common malignancy in the world, and ovarian cancer, the 
most lethal gynecological malignancy in the United States. Platinating agents including carboplatin 
form DNA helix-distorting DNA adducts that lead to strand breakage activating DNA repair 
mechanisms that ultimately resulting in apoptotic death of cancer cells. Taxanes are another widely 
used class of chemotherapy drug to treat various cancers including ovarian and lung cancers, 
primarily in combination with platinating agents. paclitaxel, a taxane, is a mitotic inhibitor that 
stabilizes microtubules and interferes with cell division leading to induction of apoptosis. 
However, despite considerable improvements in therapeutic approaches, the overall response rate 
of carboplatin/paclitaxel based combination chemotherapy is far from desirable. Drug resistance, 
interpatient variation in response and toxicity are major causes of concern. Furthermore, a large 
bulk of the cancer patients who do respond eventually undergo relapse after first line based 
chemotherapy. Inter-patient variability in treatment response is therefore a commonly observed 
phenomenon in this drug resistance. However, the complete mechanism governing this spectrum 
of sensitivity to chemotherapeutic agents still remains largely unclear. 
Genetic factors like differential expression and/or activity of genes involved in drug metabolism 
pathway and the presence of single nucleotide polymorphisms may have an impact on treatment 
outcome and toxicity in cancer patients being treated with Platinum/Paclitaxel combination. 
Genetic variation in these key pharmacokinetic and pharmacodynamics pathway genes may 
therefore contribute to interpatient variation in response and toxicity.  
Our approach was to use cell line models derived from epithelial ovarian cancer (EOC) patients to 
identify genetic polymorphisms and differential gene expression associated with chemo-sensitivity 
and response to carboplatin and paclitaxel single agent and combination treatments followed by the 
evaluation of these predictive pharmacogenomics markers in epithelial ovarian cancer and NSCLC 
patients undergoing Carbplatin/Paclitaxel combination chemotherapy. For the purpose of cell-
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based modeling of ovarian cancer, we generated immortalized Lymphoblastoid cell lines (LCLs) 
from human lymphocytes from Epithelial ovarian cancer (EOC) patients through the infection of 
Epstein-Barr virus (EBV). Then, we performed a comprehensive profiling in vitro chemo-
sensitivity phenotypes in our panel of ~100 Epstein-Barr virus (EBV) transformed EOC LCLs 
following treatment with carboplatin, paclitaxel as single agent and in combination. We 
demonstrated extensive inter-individual variation in drug response as was evident from the drug 
IC50 and area under survival curve (AUC) values. Fold changes between the lowest (most-sensitive) 
and highest (most-resistant) IC50 and AUC values were 8.34 & 3.84, respectively for carboplatin, 
and 7.72 & 5.65, respectively for paclitaxel. Our drug cytotoxicity values corroborated with the 
caspase activity assay results demonstrating that drug cytotoxicity indeed reflected alterations in 
cellular apoptosis and programmed cell death. Furthermore, using Chou-Talalay’s Combination 
index-Isobologram Theorem we also observed, based on Combination index values, wide inter-
individual variations in effects of carboplatin and paclitaxel when used in combination treatment.  
The wide range of dose reduction index values indicated variability in impact of the dose of one 
drug on another in combination treatment based on the cell line used for the study. 
To understand the pharmacogenomics of the inter-individual variation in chemo-sensitivity 
parameters, we performed a pathway based identification of polymorphisms within the PK/PD 
pathway of carboplatin and paclitaxel as well as analysis of gene expression of these pathway genes 
in the EOC LCLs using TaqMan Low Density Arrays (TLDA), followed by genotype-phenotype 
association analysis. 
Our analysis revealed significant association between drug chemosensitivity measures and genetic 
variations in several key candidate genes involved in carboplatin and paclitaxel pathway. 
Genetic variations in drug transporter genes ABCG2 and ABCC2, several mutations in the DNA 
repair gene ERCC6 and XRCC5 as well as mutations in PMS2 and MSH2 and MSH6 were found 
associated with carboplatin cytotoxicity whereas. Mutations in microtubule associated protein 
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MAP4, the transporter genes ABCC1 and SLC22A7, as well as TP53 and EGFR were associated 
with paclitaxel response. Top among the mutations associated with combination treatment were 
SNPs within the genes ABCC1, MSH2 and MSH6. Remarkably, we found a number of coding 
variants associated with drug response. These include K1087N (MAP4; paclitaxel), F150F (TP53; 
paclitaxel) and S667S (ABCC1; combination), R704R (ERCC6; carboplatin), R338R and P428P 
(MSH6; carboplatin). Our gene expression analysis revealed changes in expression levels of the 
following pathway genes were associated with drug response phenotypes: ERCC2 (carboplatin), 
GSTM1 (carboplatin) and NQO1 (carboplatin); FOXC2 (paclitaxel), FOXL1 (paclitaxel) and 
BIRC5 (paclitaxel). NER genes have been shown to play significant roles in the identification and 
repair of platinum-DNA adducts. Earlier studies have shown upregulation of expression of the NER 
pathway genes ERCC1 and XPD was significantly associated with higher resistance in platinum-
based chemotherapy in advanced EOC. Our results thus corroborate with this earlier finding and 
identifies the NER genes associated with platinum drug resistance. 
Subsequently, we performed a comprehensive genome-wide association scans (GWAS) of 
germline genotype of these patient-derived LCLs to discover predictive pharmacogenomics 
markers of treatment response within the human genome. At p < 10-4, we found genes related to 
malignant solid tumor and epithelial cancers that were significantly associated with our drug 
chemosensitivity measures. Notably, the top canonical pathways represented by these genes 
included Epithelial Adherens Junction Signaling, Sertoli Cell Junction Signaling and Endometrial 
Cancer Signaling, which seems reasonable as the cells were derived from ovarian cancer patients. 
We also found mutations in several relevant genes associated with drug response including the 
tumor suppressor genes CTNNA2, CDH4 and LRP1B; FRAS1, a gene supposedly involved in 
tumorigenesis and metastasis; and the DNA repair gene BRE.  
Subsequently, to understand the impact of genetic variation within the 
pharmacokinetic/pharmacodynamics pathways of platinating agents and taxanes in NSCLC, we 
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performed a genotype-phenotype correlation analysis on in advanced NSCLC patients treated 
primarily with carboplatin/paclitaxel-based combination chemotherapy. Our results showed a 
number of pathway SNPs associated with treatment outcomes and toxicity including progression-
free survival (PFS) and multiple adverse effects, following adjusting for clinical prognostic factors 
in multivariate models. Our results showed SNPs in key pathway genes were associated with 
treatment outcome (PFS) including ABCC1, ABCB1 (rs1045642/ Ile1145Ile, rs1128503, 
rs2235015), NQO1 (NQO1*2: Pro187Ser). Whereas, SNPs in the following genes were also 
associated with hematological and/or non-hematological toxicities: CYP2C8 (diarrhea); ABCG2 
and ABCB1 (thrombocytopenia); (ATP7B rs1801244; nausea); ERCC4 (neutropenia); XPC 
missense SNP rs2228001 (C>A; Gln939Lys). Among other SNPs associated with toxicities 
included rs447978 (GTF2E1; nausea and neutropenia, rs10158985 (TMEM63; neutropenia), as 
wells as SNPs in KCL3 (neuropathy) and CCDC127 (diarrhea). The nonsynonymous coding SNP 
in NQO1, rs1800566 (NQO1*2: Pro187Ser), is in the active site of the NQO1 enzyme and has been 
associated with reduced NQO1 activity since the NQO1 isoform with Ser (NQO1*2) undergoes 
rapid degradation.  
Most remarkably, the expression of NQO1 was also shown to be associated with our in vitro 
profiling of carboplatin chemosensitivity in EBV-transformed ovarian cancer LCLs. Similarly, 
SNPs in a number of other pathway genes that were found relevant with regard to the treatment 
response and/or toxicities resulting from treatment with platinating agents/ taxane-containing 
chemotherapy regimens in NSCLC patients were also shown associated with in vitro 
chemosensitivity in our EOC LCL panel-based model system of drug resistance. For example, the 
ABCC1 intronic SNPs rs246240 and rs2238476 were associated with PFS in NSCLC patients after 
adjusting for covariates, while ABCC1 SNPs were also found significantly correlated with in vitro 
paclitaxel and combination cytotoxicity as well as caspase activity following combination 
treatment. The ABCG2 missense SNP rs2231142 was associated with nausea, and the intronic SNP 
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rs13120400 with Sensory neuropathy in NSCLC; ABCG2 SNPs were also associated with in vitro 
carboplatin cytotoxicity. In addition, SNPs in CYP2C8 and TP53 were associated with diarrhea in 
NSCLC patients as well as response to paclitaxel in vitro. Also, ERCC2 SNPs were associated with 
caspase 3/7 activity following carboplatin treatment in vitro, while the ERCC2/KLC3 missense 
SNP rs13181 that was found significantly associated with sensory neuropathy in NSCLC patients 
after adjusting for covariates. 
Thus, using immortalized LCLs directly derived from patient subjects we could successfully 
develop in vitro drug response models that could be directly correlated with patient clinical 
responses.  Furthermore, we have effectively demonstrated by using candidate-gene based and 
genome-wide approaches in these immortalized LCLs from patient samples we could identify key 
pharmacogenomics changes associated with drug response, treatment outcome and toxicity. 
Finally, we identified genetic variation within the pharmacokinetic/pharmacodynamics pathways 
of platinating agents and taxanes in real world clinical settings in advanced NSCLC patients 
undergoing carboplatin-based chemotherapy.  
However, although we found a number of genetic variations significantly associated with treatment 
outcome and toxicities, the functional relevance of most of these SNPs vis-à-vis activity of target 
genes is still largely unknown. Therefore, for a comprehensive understanding of the role of these 
variations, we propose future studies focusing on the characterization of the significant SNPs using 
functional genetic/genomic approaches. 
Therefore, results from our study provide an actionable panel of reliable genetic biomarkers of 
carboplatin and paclitaxel single-agent and combination treatment response as clinically applicable 
signatures of drug response and toxicity which has the potential to be used in precision medicine 
approaches following further validation to develop pharmacogenomics-guided treatment 
approaches to achieve maximum efficacy and minimum toxicity.  
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